@Immutep outlines clinical development priorities and plans for 2027. CEO Marc Voigt discusses the next steps for efti and IMP761, including potential Phase II trials & upcoming clinical milestones. Watch the full interview below:
www.sharecafe.com.au/2026/10/14/immutep-outlines-clinical…
#biotech #clinicaltrials
Immutep
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. More on Wikipedia
-
Immutep reposted
Sharecafe
@sharecafetweets
-
Immutep reposted
Finance News Network
@Finnewsnetwork
@Immutep outlines clinical development priorities and plans for 2027. CEO Marc Voigt discusses the next steps for efti and IMP761, including potential Phase II trials & upcoming clinical milestones. Watch the full interview below:
www.sharecafe.com.au/2026/10/14/immutep-outlines-clinical…
#biotech #clinicaltrials -
Immutep
@Immutep
Immutep CEO Marc Voigt joined @sharecafetweets Rachael Jones to discuss the company's next phase of clinical development, including its focus on head and neck cancer and soft tissue sarcoma, progress with IMP761, and key milestones planned for 2027. www.sharecafe.com.au/2026/10/14/immutep-outlines-clinical…
-
Immutep
@Immutep
Immutep has an abstract accepted at #esmo2026 in Madrid (23–27 Oct).
The ePoster presents HRQoL data from the EFTISARC-NEO Phase II trial of efti + pembrolizumab + radiotherapy in soft tissue sarcoma.
More details here: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#lag3 #immunotherapy #oncology -
Immutep reposted
Finance News Network
@Finnewsnetwork
ShareCafe's Rachael Jones speaks with @Immutep CEO & ED Marc Voigt about the latest INSIGHT-003 survival data, the ongoing TACTI-004 review, recent patent progress and what's next for the company.
Watch the full interview here:
www.sharecafe.com.au/2026/07/15/immutep-highlights-encour…
#biotech #oncology -
Immutep
@Immutep
Immutep is pleased to announce the grant of a fourth U.S. patent covering eftilagimod alfa (efti) in combination with anti-PD-1/PD-L1 therapies for cancer treatment.
This patent strengthens our IP portfolio and supports future opportunities for efti. www.immutep.com/immutep-secures-fourth-united-states-pate… -
Immutep
@Immutep
Immutep announces a positive update from the INSIGHT-003 Phase I trial, with mature data showing median overall survival of 30.9 months in 1L non-squamous NSCLC.
The Company also provided a TACTI-004 update, with further analysis expected in Q3 CY2026. cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Immutep
@Immutep
Immutep Limited CEO and Executive Director, Marc Voigt, spoke with @sharecafetweets to discuss the Company's next steps following the discontinuation of the TACTI-004 trial.
In the interview, Marc confirms the Company remains well funded with cash runway extending into the first half of 2028 and provides an update on the ongoing root cause analysis across clinical, analytical and manufacturing areas to determine the future pathway for eftilagimod alpha.
Marc also highlights the continued advancement of Immutep's broader pipeline, including the IMP761 autoimmune program, with first Phase I data expected to be presented at the EULAR conference in London on 4 June and upcoming milestones including an ASCO poster presentation in Chicago and completion of the root cause analysis, guided for Q3.
Watch the full interview here: www.sharecafe.com.au/2026/05/18/immutep-advances-autoimmu… -
Immutep
@Immutep
@Immutep is pleased to announce that the U.S FDA has granted Orphan Drug Designation (ODD) for efti for the treatment of Soft Tissue Sarcoma (STS), a rare cancer with significant unmet medical need.
This designation supports development in a rare cancer with significant unmet need and is backed by Phase II EFTISARC-NEO data showing encouraging tumour response and a favourable safety profile in combination with radiotherapy and KEYTRUDA.
CEO of Immutep, Marc Voigt said: “We are pleased that the FDA has recognised the potential of efti for patients with soft tissue sarcoma, a rare and difficult to treat cancer. As previously communicated, the Company is currently undertaking a comprehensive review and analysis following the discontinuation of its Phase III TACTI-004 trial and the outcome will influence the decision regarding any potential future clinical trial with efti. The FDA’s designation, based on very encouraging data from the EFTISARC-NEO trial, provides us with a potential direct step forward into a late-stage study in the neoadjuvant setting for STS.”
#biotech #oncology #clinicaltrials #raredisease #immunotherapy #fda -
Immutep
@Immutep
@Immutep has provided an investor update following the recent discontinuation of the TACTI‑004 Phase III trial in first‑line non‑small cell lung cancer.
A thorough root cause analysis is underway to understand factors contributing to the trial’s futility outcome. This work is essential not only for interpreting TACTI‑004, but also for guiding future development decisions across the broader efti pipeline.
Immutep's portfolio continues to include multiple differentiated assets, including IMP761 with upcoming data in early June.
Read the full update here: www.immutep.com/dw/uploads/2026/04/Immutep-Investor-Updat… -
Immutep
@Immutep
Immutep CEO & Executive Director, Marc Voigt, appeared on FNN to discuss the Phase III TACTI-004 trial update following the interim futility analysis, and the decision to discontinue the study.
In the interview Marc outlines the Company’s next steps, including a detailed review of the data and ongoing strategic planning, and highlights continued progress across Immutep’s broader clinical pipeline, with multiple programs advancing and further key milestones ahead.
Link to the full video here: www.youtube.com/watch?v=ry-BoIUTr5A -
Immutep
@Immutep
@Immutep announces today that the TACTI-004 trial in first line non-small cell lung cancer has enrolled 378 patients, representing 50% of the trial's target enrolment.
Marc Voigt, CEO of Immutep, said, “The excellent pace of enrolment globally in the TACTI-004 trial speaks to the promise of efti and the need for more efficacious therapies in the first line setting for patients with advanced/metastatic non-small cell lung cancer."
The futility analysis and completion of patient enrolment remain on track for the first quarter and third quarter of CY2026, respectively.
Announcement here: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#lungcancer #immutep #nsclc -
Immutep
@Immutep
@Immutep today announces positive update on IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases, from Phase I study.
Updates include:
- Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levels
- Substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseases
Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026.
Announcement here: www.immutep.com/immutep-announces-positive-update-on-imp7…
#autoimmune #immutep #autoimmunediseases -
Immutep
@Immutep
@Immutep today reports strong operational progress in the global TACTI-004 Phase III trial evaluating efti in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, and chemotherapy as first-line therapy for advanced/metastatic non-small cell lung cancer.
Updates include:
- The TACTI-004 trial has enrolled 289 patients globally, representing over 38% of targeted enrolment
- Global progress continues, with more than 120 activated clinical sites and 27 countries having received full regulatory approvals, including the United States
Read the full announcement here: www.immutep.com/immutep-announces-strong-operational-prog…
#nsclc #oncology #immunotherapy #immutep -
Immutep
@Immutep
Great to be mentioned in @australian today off the back of announcing our collaboration with Dr. Reddy's on Monday.
Scott Power, Senior Research Analyst at Morgans said:
"That was a pretty big deal that Immutep announced with Dr.Reddy's and is providing them with important funding from an upfront payment and depending on clinical success there will be more milestone payments come through."
"The deal has put Immutep in a solid position and the share price has responded positively." Thanks to Nadine McGrath & Scott Power for the mention.
Full article here: www.theaustralian.com.au/business/stockhead/news/scott-po… -
Immutep
@Immutep
@Immutep is pleased to announce a new strategic collaboration and exclusive licensing agreement with @drreddys for the development and commercialisation of efti in all countries outside North America, Europe, Japan, and Greater China.
Marc Voigt, CEO of Immutep said: “The license agreement with Dr. Reddy’s is a major commercial milestone for Immutep and further validates the significant potential of efti, our first-in-class cancer immunotherapy.”
“Dr. Reddy’s is a global pharmaceutical company with proven capabilities in the markets they have licensed for efti. This makes them an ideal partner for us to maximise the commercial benefits from efti outside of North America, Europe, Japan and China. Having recently launched Zytorvi® (toripalimab) as the first and only immunotherapy for nasopharyngeal cancer in Australia, Dr. Reddy’s has a strong track record of bringing cancer therapies to patients.”
“In addition to the upfront payment, we stand to earn substantive future milestone and royalty payments. Importantly, we preserve full commercial rights in the world’s largest pharmaceutical markets so we are very well-positioned for future value creation while also maintaining full control of efti’s manufacturing globally, including to Dr. Reddy’s.”
Full announcement here: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#immutep #efti #oncology #immunotherapy #collaboration #drreddys -
Immutep
@Immutep
Immutep has announced positive data from the EFTISARC-NEO Phase II trial evaluating efti in combination with radiotherapy and pembrolizumab for resectable soft tissue sarcoma (STS).
The novel combination achieved a significant 51.5% median tumour hyalinization/fibrosis across multiple STS subtypes, including rare and aggressive tumours with poor prognosis.
The promising results warrant further investigation of this novel combination in registrational settings.
Click here to see the ASX: www.immutep.com/translational-data-and-significant-pathol… -
Immutep
@Immutep
@Immutep is pleased to share that the EFTISARC-NEO clinical trial evaluating neoadjuvant efti in soft tissue sarcomas has been awarded second place in the distinguished Golden Scalpel Award competition.
This competition recognises the most innovative solutions in Polish medicine and is presented by independent experts to initiatives that set new standards in advancing healthcare.
This year, EFTISARC-NEO was the only oncology project to receive this accolade, underscoring its leadership and breakthrough potential in cancer treatment.
To learn more visit: pulsmedycyny.pl/wydarzenia/zloty-skalpel/owa-nadzieja-w-w…
Immutep extends its gratitude to the patients and dedicated team at MSCNRIO whose efforts made this achievement possible. -
Immutep
@Immutep
@Immutep is pleased to share positive clinical data presented at the @myESMO Congress 2025.
Key highlights:
- EFTISARC-NEO Phase II: Met primary endpoint, with the novel combination including efti achieving 51.5% tumour hyalinization/fibrosis in soft tissue sarcoma (p < 0.001). www.immutep.com/primary-endpoint-met-in-eftisarc-neo-phas…
- INSIGHT-003 trial: Generated strong response rates across all PD-L1 expression levels 1L NSCLC, including 61.7% in low & no PD-L1 (TPS <50%), outperforming historical controls (40.8%). www.immutep.com/two-posters-at-esmo-congress-2025-highlig…
- A trial-in-progress ePoster for TACTI-004 Phase III trial in 1L NSCLC was also presented. www.immutep.com/two-posters-at-esmo-congress-2025-highlig…
#esmo25 -
Immutep
@Immutep
@Immutep is pleased to complete another productive meeting with the FDA regarding the eftilagimod alfa (efti) program. We welcome the positive feedback and the agreement on efti's optimal biological dose is another important building block for future potential BLA filings.
Announcement here: www.immutep.com/immutep-announces-successful-completion-o… -
Immutep
@Immutep
@Immutep announces update for pivotal TACTI-004 Phase III in 1L NSCLC.
Immutep has now enrolled & randomised over 170 patients, an important milestone as this is above the # required to conduct the futility analysis, which remains on track for Q1 2026.
Additionally, the # of activated clinical sites continues to expand at a strong pace, now exceeding 100 across 24 countries.
Read more here: www.immutep.com/immutep-announces-update-for-tacti-004-ke…
#clinicaltrials #oncology #immunotherapy #lungcancer #biotech #immutep -
Immutep
@Immutep
We’re pleased to share that George Washington University Cancer Center, will launch an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER2-neg breast cancer patients. The trial is led by Dr. Pavani Chalasani, MD, MPH, Division Director of Hematology and Medical Oncology and aims to assess pathological complete response (pCR) following neoadjuvant efti and chemotherapy treatment.
Read more here www.immutep.com/immutep-announces-research-collaboration-…
#immunotherapy #breastcancerresearch #oncology #efti -
Immutep
@Immutep
@Immutep CEO Marc Voigt recently joined @sharecafetweets Lauren Hays to share an updated company presentation and discuss Immutep's latest developments.
Marc spoke about:
- Progress of the pivotal TACTI-004 Phase 3 trial in first-line non-small cell lung cancer, run in collaboration with Merck/MSD
- The company’s broader oncology and autoimmune pipeline, including the IMP761 program
- Key milestones and catalysts to watch for the remainder of 2025 and beyond
Watch the full discussion here: www.sharecafe.com.au/2025/09/12/immutep-advances-phase-ii…
#nsclc #biotech #sharecafe #sipandlearn #oncology -
Immutep
@Immutep
@Immutep CEO Marc Voigt will be joining the ShareCafe- Sip and Learn webinar this Thursday, 11 September at 12:30pm AEST.
Marc will deliver a company presentation and take part in the Q&A session.
Use this link to register if you'd like to join in! us02web.zoom.us/webinar/register/WN_ZGjemjjGT-eOUhsK18F8EQ -
Immutep
@Immutep
@Immutep is pleased to announce an abstract for the EFTISARC-NEO Phase II investigator-initiated trial has been accepted for oral presentation at the @ctosociety 2025 Annual Meeting taking place 12-15 November 2025, in Boca Raton, Florida.
For more details see www.immutep.com/investors-media/whats-new.html
#immunotherapy #eftilagimodalpha #pembrolizumab #radiotherapy -
Immutep
@Immutep
Immutep is pleased to share its 2025 Annual Report today. Read the full report here: www.immutep.com/dw/uploads/2025/08/Appendix-4E-2025-Full-…
Chairman Dr Russell Howard said:
"FY26 promises to be another year of meaningful progress. You can expect continued momentum for TACTI-004, updates from AIPAC-003, INSIGHT-003, and EFTISARC-NEO, as well as further advancement in our autoimmune portfolio with IMP761.
Our team remains focused on developing innovative immunotherapies that offer new hope to patients with cancer and autoimmune diseases."
The Immutep team is grateful for the continued support of our shareholders and looks forward to keeping them informed of key milestones along the way. -
Immutep
@Immutep
@Immutep's CEO Marc Voigt joined @Ausbiz's Nadine Blayney for a discussion covering a variety of topics including progress on the registrational TACTI-004 Phase 3 trial in non-small cell lung cancer, recent FDA feedback on late-stage clinical development of efti in head & neck cancer (CPS <1), upcoming presentations at #esmo25 for clinical trials using efti, and operational updates.
Watch the full discussion here: ausbiz.com.au/media/big-year-ahead-with-phase-3-progress-…
#oncology #immunotherapy #nsclc #hnscc #ausbiz -
Immutep
@Immutep
@Immutep's CEO, Marc Voigt spoke with @7News Perth as Immutep's pivotal Tacti-004 Phase III trial opens to patients in Western Australia.
Globally the Phase III trial will recruit over 750 patients across more than 150 clinical sites. This final stage of testing is focused on advanced and metastatic non-small cell lung cancer (#nsclc) as a first-line treatment option after diagnosis.
For more information on the trial visit: immutep-lungcancer-trial.comThis media couldn't be displayed. See it on the original post. -
Immutep
@Immutep
@Immutep's CEO Marc Voigt recently joined the @ausbiztv Investor Connect session where he provided an update on the company’s pivotal TACTI-004 Phase 3 trial in first line #nsclc, its clinical-stage IMP761 immunotherapy for autoimmune diseases, upcoming milestones, and more.
Watch the full video here: ausbiz.com.au/media/immutep-asx-imm-investor-presentation…
#oncology #immunotherapy #ausbiz -
Immutep
@Immutep
We’re pleased to announce @Immutep CEO Marc Voigt will join the Ausbiz Investor Connect session on 19 Aug at 1pm AEST.
Join us for an insightful conversation and opportunity to learn more about Immutep’s progress & strategy.
Register here: info.ausbiz.com.au/ausbiz-capital-event-aug-2025
#immutep #biotech #investorconnect #ausbiz -
Immutep
@Immutep
@Immutep has received positive and constructive feedback from the US FDA regarding potential late stage clinical development of eftilagimod alfa for first line treatment of head and neck squamous cell carcinoma patients with PD-L1 expression below 1 (CPS <1).
Read more here: www.immutep.com/immutep-receives-positive-feedback-from-f…
#biotech #oncology #hnscc -
Immutep
@Immutep
@Immutep is pleased to provide an update on its activities for the quarter ended 30 June 2025 (Q4 FY25). Highlights include:
- TACTI-004 Phase III trial in first-line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at multiple sites globally.
- In the investigator-initiated INSIGHT-003 trial in non-squamous 1L NSCLC, efti in combination with KEYTRUDA® and chemotherapy achieved a high 60.8% response rate and 90.2% disease control rate (N=51). In patients with TPS <50% (N=47) who represent a high unmet need and over two-thirds of the 1L NSCLC population, the triple combination with efti achieved a 59.6% response rate as compared to historical control of 40.8%.
-Investigator-initiated EFTISARC-NEO Phase II trial, evaluating efti with radiotherapy plus KEYTRUDA in neoadjuvant setting for resectable soft tissue sarcoma (STS), met its primary endpoint
- Phase I study of IMP761 shows significant T cell suppression and a favourable safety profile
-Strong cash position of A$129.69 million, providing an expected cash reach to the end of CY2026.
Read the full ASX announcement here: www.immutep.com/detail/immutep-quarterly-activities-repor…
#immunotherapy #biotechnology #oncology #lag3 -
Immutep
@Immutep
@Immutep today announces an upcoming poster presentation for the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial at the @IASLC 2025 World Conference on Lung Cancer (WCLC), taking place in Barcelona, Spain, from the 6th - 9th of September 2025.
The poster presentation will include an overview and study design of the TACTI-004 Phase III trial evaluating efti in combination with @MSD’s KEYTRUDA® (pembrolizumab) and chemotherapy as first line therapy for patients with advanced or metastatic non-small cell lung cancer.
The poster will be available on the Posters & Publications section of Immutep’s website following the presentation.
Find more details to the presentations here: www.immutep.com/detail/immutep-to-present-pivotal-tacti-0…
#efti #oncology #clinicaltrial -
Immutep
@Immutep
@Immutep is pleased to share that three abstracts for clinical trials evaluating its first-in-class MHC Class II agonist, efti, have been accepted for presentation at the @myESMO Congress 2025 taking place from the 17th - 21st of October in Berlin, Germany.
Details of the presentations are as follows:
- An abstract on the Company’s pivotal TACTI-004 Phase III in 1L NSCLC has been accepted for a Trials in Progress ePoster
- A Proffered Paper oral presentation detailing results from EFTISARC-NEO, a Phase II investigator-initiated trial in resectable soft tissue sarcoma,
- A poster presentation detailing data from the INSIGHT-003 Phase I investigator-initiated trial in first-line non-small cell lung cancer (1L NSCLC)
Abstracts will be made available on the ESMO website on 13 October 2025.
Find more details to the presentations here: www.immutep.com/detail/immutep-announces-abstracts-accept…
#efti #oncology #esmo -
Immutep
@Immutep
@Immutep’s CEO Marc Voigt appeared on @ShareCafe’s latest episode of Table for Two, where he shared clinical trial updates across Immutep’s oncology and autoimmune programs.
Marc discusses the results from the TACTI-003 and INSIGHT-003 trials in head & neck cancer and in non-small cell lung cancer, as well as exciting progress on IMP761 - a first-in-class LAG-3 agonist antibody targeting autoimmune diseases. Additionally, he highlights TACTI-004, Immutep's pivotal Phase 3 trial in non-small cell lung cancer, and outlines key upcoming milestones for the Company through year end 2025 and beyond.
Watch the full episode here: www.sharecafe.com.au/2025/07/14/inside-immuteps-latest-tr… -
Immutep
@Immutep
@Immutep announces positive initial efficacy data & continued favourable safety from first-in-human Phase I evaluating IMP761, a first-in-class #lag3 agonist antibody. The substantial reduction in T cell activity at 0.9mg/kg dosing level highlights the potential efficacy of IMP761 in treating #autoimmunedisease.
Dosing will continue at 2.5mg/kg and higher levels, with additional data to follow in 2H’CY2025.
Read more: www.immutep.com/detail/immutep-announces-positive-update-… -
Immutep
@Immutep
@Immutep is participating in the upcoming @Jefferies Global Healthcare Conference in NYC. CEO Marc Voigt will present a company overview on Thurs, June 5th at 11:40am ET (US).
A live webcast and replay of the presentation will be available here: wsw.com/webcast/jeff319/immp/1860168
#jefferieshealthcare #oncology -
Immutep
@Immutep
@Immutep is pleased to report the investigator-initiated EFTISARC-NEO Phase II trial evaluating efti with #radiotherapy and KEYTRUDA in #softtissuesarcoma (STS) has met its primary endpoint. STS is an orphan disease with high unmet medical need.
Detailed study results are planned for presentation at a medical conference later this year from the trial’s investigators at the Maria Sklodowska-Curie National Research Institute of Oncology.
Read more here www.immutep.com/detail/immutep-s-efti-with-radiotherapy-k…
#immunooncology #orphandisease #rarecancer -
Immutep
@Immutep
@Immutep has reported excellent survival data from the investigator-initiated INSIGHT-003 trial aimed at treating advanced non-small cell lung cancer (NSCLC).
The trial reported a 60.8% response rate and 90.2% disease control rate in patients, according to RECIST 1.1. This data demonstrates significant improvement in response rate compared to historical controls and safety continues to be favorable.
Additional data from INSIGHT-003 is expected to be presented at a medical conference in 2025 and beyond.
The INSIGHT-003 trial is an investigator-initiated study being conducted by the Frankfurt Institute of Clinical Cancer Research IKF.
Read more: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#efti #keytruda #chemotherapy #lcsm #immunotherapy -
Immutep
@Immutep
@Immutep’s Efti + KEYTRUDA® has achieved an excellent median overall survival of 17.6-months in head & neck cancer patients with PD-L1 CPS <1, who represent a high unmet medical need and have no treatment options without chemotherapy
Read more: www.immutep.com/detail/immutep-s-efti-in-combination-with…
#hncsm -
Immutep
@Immutep
@Immutep is pleased to provide Q3 update. Highlights incl 1st patient dosed in pivotal TACTI-004 study in #nsclc, completion of enrolment in INSIGHT-003 & EFTISARC-NEO w/ updates expected in CY’25, and strong cash position of A$146.25 million.
Read more: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Immutep
@Immutep
@Immutep is pleased to share its latest investor update, highlighting the significant milestone of successfully dosing the first patient in the pivotal TACTI-004 Phase III trial in 1L #nsclc
Read the newsletter: app.sharelinktechnologies.com/announcement/asx/9be095e492…
#biotechnology #oncology #lag3 -
Immutep
@Immutep
In the latest episode of @sharecafetweets' six-part series on #immunotherapy, @Immutep CEO Marc Voigt delves into the mechanisms behind immune checkpoints & their transformative impact on cancer treatment.
#lag3, #oncology, #efti, #keytruda, #nsclc
Watch: www.sharecafe.com.au/2025/03/17/how-immunotherapy-works-u… -
Immutep reposted
CURE Today
@cure_today
First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell #lungcancer @Immutep www.curetoday.com/view/first-patient-dosed-with-efti-in-p…
-
Immutep
@Immutep
The first patient in our TACTI-004 lung cancer trial has been safely dosed in Australia, marking a significant milestone for the team at @Immutep!
Read the announcement: app.sharelinktechnologies.com/announcement/asx/8362254961…
#efti #oncology #clinicaltrial #nsclc
$IMM $IMMP -
Immutep
@Immutep
We are pleased to share that our pivotal TACTI-004 Phase III trial has been selected for an upcoming poster presentation at the European Lung Cancer Congress (ELCC) 2025, taking place in Paris, France, from 26-29 March 2025.
Read more: app.sharelinktechnologies.com/announcement/asx/9327a9c3ba…
#efti #oncology -
Immutep
@Immutep
In episode three of the six-part series with @sharecafetweets, @Immutep CEO Marc Voigt explores the complexities of treating autoimmune diseases and how Immutep’s #imp761 targets the root cause by regulating overactive T-cells.
Watch: www.sharecafe.com.au/2025/03/10/immunotherapy-and-autoimm…
#immunotherapy -
Immutep
@Immutep
Last week in Australia, @Immutep CEO Marc Voigt joined @sharecafetweets to talk about Immutep's upcoming milestones and latest advancements in its phase III clinical trial in lung cancer, which is expected to dose its first patient this month.
Watch: www.sharecafe.com.au/2025/03/10/immuteps-pipeline-progres… -
Immutep
@Immutep
Ep 2 with @sharecafetweets: @Immutep CEO Marc Voigt explores cancer treatment and the expanding role of immuno-oncology. With a strong safety profile, Immutep’s lead candidate shows promise in combination therapies, driving progress in cancer care.
Watch: www.sharecafe.com.au/2025/03/03/immuno-oncology-challenge… -
Immutep
@Immutep
In the 1st episode of a 6 part series with @sharecafetweets, @Immutep CEO Marc Voigt discusses immunotherapy and its impact on cancer treatment. With a Phase 3 lead candidate and key partnerships, Immutep is driving innovation in this $189B market.
Watch: www.sharecafe.com.au/2025/02/24/the-future-of-immunothera… -
Immutep
@Immutep
@Immutep reports strong progress and encouraging clinical results for the half-year ended 31 Dec 2024. With TACTI-004 underway, it is now a Phase III-stage biotech company.
Read: app.sharelinktechnologies.com/announcement/asx/14fa7ee4e1…
#biotechnology #oncology #lag3 $IMM $IMMP -
Immutep
@Immutep
CEO Marc Voigt recently caught up with @sharecafetweets to discuss @Immutep's encouraging progress with #efti.
Listen here: www.sharecafe.com.au/2025/02/19/immuteps-therapies-move-t…
#nsclc #biotechnology #oncology -
Immutep reposted
Sharecafe
@sharecafetweets
Sip&Learn Webinar: Immutep's therapies move towards late-stage development
@Immutep $IMM $IMMP
www.sharecafe.com.au/2025/02/19/immuteps-therapies-move-t… -
Immutep reposted
Sharecafe
@sharecafetweets
Register now at us02web.zoom.us/webinar/register/WN_vMyffVQ_SNStBtroJv0AbQ for the next Sip & Learn webinar discussing biotech and resources, featuring Alterity Therapeutics $ATH Nico Resources $NC1 and Immutep $IMM
@Immutep @NicoResources @AlterityT -
Immutep reposted
Sharecafe
@sharecafetweets
Register now at us02web.zoom.us/webinar/register/WN_vMyffVQ_SNStBtroJv0AbQ for the next Sip & Learn webinar discussing biotech and resources, featuring Immutep $IMM and Nico Resources $NC1
@Immutep @NicoResources -
Immutep
@Immutep
We’re pleased to provide our shareholders with a summary of a busy quarter in Q2 FY25, such as our transition to becoming a #phaseiii biotech.
Read the update: app.sharelinktechnologies.com/announcement/asx/89f7899a44…
#biotechnology #lag3 #immunotherapy -
Immutep
@Immutep
Patient enrolment has been completed for the PhII EFTISARC-NEO trial of efti in #softtissuesarcoma being conducted by the Maria Sklodowska-Curie National Research Institute of Oncology.
Further data is expected in 2025.
#immunooncology #lag3
ASX: www.immutep.com/detail/patient-enrolment-completed-for-ef… -
Immutep
@Immutep
Thank you to everyone who took the time to meet with @Immutep last week at the 43ʳᵈ Annual J.P. Morgan Healthcare Conference.
It was a busy week for our team!
#jpm25 #jpm2025 #lifesciences #healthcare -
Immutep
@Immutep
ICYMI, catch Marc Voigt’s short presentation at @ausbiztv's Investor Connect event at the end of last year. Marc gives a quick snapshot of how @Immutep's lead product candidate fights cancer and how our late-stage clinical trials are tracking.
Watch: ausbiz.com.au/media/partner-content?videoId=39161 -
Immutep
@Immutep
Marc Voigt, CEO of @Immutep, was delighted to join @ausbiztv's Investor Event to discuss its recent advancements in cancer treatment and its promising outlook following encouraging trial results.
Watch the short CEO interview: ausbiz.com.au/media/ausbiz-capital-presenting-partner?vid…
#biotechnology #lag3 -
Immutep
@Immutep
@Immutep announces the completion of patient enrolment for the INSIGHT-003 trial. This investigator-initiated study evaluates efti in combo with KEYTRUDA and doublet #chemotherapy as a first-line treatment for advanced/metastatic non-squamous #nsclc.
app.sharelinktechnologies.com/announcement/asx/af62403513… -
Immutep
@Immutep
ICYMI: Tune in to replay of fireside chat with Dr. Martin Forster of the @ucl Cancer Institute and @Immutep CEO Marc Voigt for an overview of recent data in 1L HNSCC patients with PD-L1 CPS <1 and insights into TACTI-004 Phase 3 in #lungcancer
Replay: goto.webcasts.com/starthere.jsp?ei=1700112&tp_key=1586a126b2 -
Immutep
@Immutep
Join Marc Voigt, CEO of @Immutep, and Professor Martin Forster, M.D., Ph.D., from the @ucl Cancer Institute and UCL Hospital NHS Foundation, London, UK, for an insightful fireside chat hosted by @rwbaird.
Thurs 19 Dec at 10:15 AM ET
Register goto.webcasts.com/starthere.jsp?ei=1700112&tp_key=1586a126b2
#oncology -
Immutep
@Immutep
@Immutep is pleased to announce favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating #imp761.
Read more: app.sharelinktechnologies.com/announcement/asx/567616e642…
#biotechnology #autoimmunedisease #lag3 #immunotherapy -
Immutep
@Immutep
@Immutep in collab with @RossjohnLab first to publish structure of LAG-3/HLA-II complex & resolve how human LAG-3 binds to its main ligand, providing better foundation for development of blocking #lag3 therapeutics incl its own small molecule program.
app.sharelinktechnologies.com/announcement/asx/36eed4d754… -
Immutep
@Immutep
@Immutep is proud to report new positive results from efti in combination with KEYTRUDA® at #esmoio2024 in first line #hnscc patients with PD-L1 expression below 1 (CPS <1). Data shows strong overall & progression-free survival and durability.
Read more: app.sharelinktechnologies.com/announcement/asx/4f2657d1a9… -
Immutep
@Immutep
@Immutep is thrilled to announce the initiation of the TACTI-004 Phase III for 1L metastatic #nsclc that represents a major step towards a potential new standard of care. The first patient is expected to be enrolled in Q1 2025.
Read: app.sharelinktechnologies.com/announcement/asx/fe9462c7ed…
#biotechnology -
Immutep
@Immutep
@Immutep CEO, Marc Voigt, will join @ausbiztv tomorrow for their Investor Connection session at 1pm, discussing advancements in immunotherapy and cancer research.
Register for free to watch: info.ausbiz.com.au/ausbizcapital
#biotechnology #oncology #lag3 -
Immutep
@Immutep
CEO Marc Voigt joined the Frazis Capital Podcast to discuss #lungcancer challenges, the rise of #immunotherapy & Immutep’s innovative work. Hear about clinical trials, autoimmune research & the Company’s vision: www.youtube.com/watch?v=FXUItIkGmU4
#oncology #autoimmunediseases #lag3 -
Immutep reposted
OncLive.com
@OncLive
Eftilagimod alpha plus pembrolizumb and chemotherapy generated favorable survival data in nonsquamous NSCLC. #lcsm #meded
Read here: www.onclive.com/view/eftilagimod-alpha-plus-pembrolizumab… -
Immutep reposted
Targeted Onc
@TargetedOnc
In the phase 1 INSIGHT-003 trial, the combination of eftilagimod alpha, pembrolizumab, and chemotherapy showed promising results in terms of overall survival & progression-free survival in metastatic nonsquamous #nsclc. #lcsm
www.targetedonc.com/view/eftilagimod-alpha-combo-shows-pr… -
Immutep reposted
Finance News Network
@Finnewsnetwork
Immutep (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck.
www.finnewsnetwork.com.au/archives/finance_news_network49…
$IMM @Immutep -
Immutep
@Immutep
@Immutep is pleased to share an Investor Update discussing the upcoming TACTI-004 trial & becoming a Phase 3 biotech. The potential for efti combined with KEYTRUDA & chemo is to set a new standard-of-care in #nsclc
Read more here: app.sharelinktechnologies.com/announcement/asx/292707e10c…
#lungcancerawarenessmonth -
Immutep reposted
Small Caps
@SmallCapsASX
Immutep’s (#asx: $IMM) efti combination therapies show strong efficacy in soft tissue sarcoma and lung cancer trials
smallcaps.com.au/immutep-efti-therapies-strong-efficacy-s… @Immutep -
Immutep
@Immutep
@Immutep shares positive survival data from INSIGHT-003 in 1L #nsclc. With a median overall survival of 32.9 months and progression-free survival at 12.7 months, these results demonstrate significant improvement of ORR compared to historical controls.
app.sharelinktechnologies.com/announcement/asx/efc39c096a… -
Immutep
@Immutep
@Immutep shares promising results from EFTISARC-NEO (Phase II) for soft tissue sarcoma at CTOS 2024. The efti-pembrolizumab-radiotherapy combination shows over three-fold increase in tumour hyalinization compared to radiotherapy alone.
Read: app.sharelinktechnologies.com/announcement/asx/0f6d1c8144…
#biotech -
Immutep
@Immutep
@Immutep is pleased to present its Quarterly Report highlighting robust progress in clinical trials, key regulatory milestones, and a solid cash position.
Read: app.sharelinktechnologies.com/announcement/asx/17b24af5b6…
#lag3 #biotechnology #immunotherapy #oncology $IMM $IMMP -
Immutep
@Immutep
@Immutep will present new data from Cohort B of the TACTI-003 Phase IIb trial in PD-L1 Negative (CPS <1) #headandneckcancer at the @myESMO I-O Congress in December.
Read: app.sharelinktechnologies.com/announcement/asx/e050e436bf…
#biotechnology #lag3 #oncology #hnscc -
Immutep
@Immutep
@Immutep is pleased to share its Annual Report for 2024.
Dr Russell Howard said, "Our confidence in efti and its potential to make meaningful positive change in the treatment landscape for cancer patients is as strong as ever."
Read here: app.sharelinktechnologies.com/announcement/asx/bdead58cab…
#biotechnology -
Immutep
@Immutep
@Immutep announces the first part of the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761 has been fully recruited and the drug has been administered with no safety issues.
Read: app.sharelinktechnologies.com/announcement/asx/e88f1f7ace…
#lag3 #autoimmunedisease -
Immutep
@Immutep
Thank you, @ausbiztv, for hosting CEO Marc Voigt to talk about Immutep’s progress in its #metastaticbreastcancer trial, called AIPAC-003, which has just completed patient enrollment.
Watch: ausbiz.com.au/media/immuteps-clinical-trial-advancement-?… -
Immutep
@Immutep
@Immutep today announces completion of patient enrolment in the randomised Phase II portion of the AIPAC-003 trial in #metastaticbreastcancer patients who’ve exhausted endocrine therapy.
Read more here: app.sharelinktechnologies.com/announcement/asx/7eac6a291d… -
Immutep
@Immutep
Thank you @Finnewsnetwork for hosting Marc Voigt to share his insights on @Immutep’s positive results in #headandneckcancer and an update on the TACTI-004 trial for #lungcancer.
Listen here: www.finnewsnetwork.com.au/archives/finance_news_network47…
#biotech #oncology #immunotherapy -
Immutep
@Immutep
@Immutep is pleased to announce it has received a A$3.6M R&D tax incentive payment from the French Government. Funds will be used to support the ongoing and planned global #clinicaldevelopment of efti and IMP761.
Read more here: www.immutep.com/detail/immutep-receives-a-3-6-million-r-d… -
Immutep
@Immutep
@Immutep announces new data from EFTISARC-NEO, a Phase II investigator-initiated trial of efti in combination with radiotherapy plus KEYTRUDA® for patients with STS, will be presented at the @ctosociety 2024 Annual Meeting on 13-16 November 2024.
Read: app.sharelinktechnologies.com/announcement/asx/268871fa44… -
Immutep
@Immutep
Yesterday at @myESMO Congress 2024, @Immutep presented positive efficacy results with favourable safety in first line head and neck cancer from its TACTI-003 Phase IIb trial of efti in combination with @Merck's KEYTRUDA®.
Read here: app.sharelinktechnologies.com/announcement/asx/b3cf6428a8…
#biotechnology #lag3 -
Immutep
@Immutep
@Immutep is delighted to be joining the esteemed S&P/ASX 300 Index.
Many thanks to our fantastic team and shareholders who share our excitement for the journey ahead for our LAG-3 therapeutics in cancer and autoimmune disease.
#lag3 #biotechnology $IMM $IMMP -
Immutep
@Immutep
@Immutep is pleased to share its 2024 Annual Report, read here: app.sharelinktechnologies.com/announcement/asx/c1a70b0380…
Chairman Dr. Russell Howard said “Our confidence in efti and its potential to make meaningful positive change in the treatment landscape for cancer patients is as strong as ever.”
#lag3 $IMM -
Immutep
@Immutep
@Immutep is excited to announce a late-breaking abstract has been accepted and selected as a Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress on 15 September in Barcelona.
#hncsm #lag3 $IMM $IMMP #esmo
www.immutep.com/detail/immutep-announces-late-breaking-ab… -
Immutep reposted
Sharecafe
@sharecafetweets
Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of autoimmune diseases.
www.finnewsnetwork.com.au/archives/finance_news_network47…
$IMM @Immutep -
Immutep
@Immutep
@Immutep's CEO Marc Voigt talks to @Finnewsnetwork after the first patient was dosed in its first trial of IMP761, designed to address the underlying cause of autoimmune diseases.
Safety data anticipated by year-end
#lag3 #autoimmunedisease $IMM $IMMP
youtu.be/fIASpRg3F7c -
Immutep
@Immutep
@Immutep today announces that the first participant has been successfully dosed in the Phase I Study of IMP761, a first in class agonist LAG-3 antibody.
Read the ASX announcement: app.sharelinktechnologies.com/announcement/asx/ba56fa85a4…
#lag3 #biotechnology #oncology #immunology $IMM $IMMP -
Immutep
@Immutep
Thank you, @ausbiztv for hosting @Immutep CEO Marc Voigt last week to talk about our recent progress in lung cancer, head and neck cancer and autoimmune disease.
Watch the interview here: ausbiz.com.au/media/immutep-gets-fda-boost?videoId=37003
#lag3 #biotechnology #oncology $IMM $IMMP -
Immutep
@Immutep
Thank you, @Finnewsnetwork for hosting CEO Marc Voigt to discuss @Immutep’s Phase III design for a trial in non-small cell lung cancer, our positive results in head and neck cancer, and clearance for a Phase I study in autoimmune diseases.
Watch: www.finnewsnetwork.com.au/archives/finance_news_network47…
$IMM -
Immutep reposted
Multiple Sclerosis News Today
@MSNewsToday
Learn more about the upcoming trial, which will use a “unique challenge model” to study how the antibody therapy affects early T-cell responses. multiplesclerosisnewstoday.com/news-posts/2024/07/25/pote…
#ms #multiplesclerosis #msresearch #msnews #mstreatment -
Immutep
@Immutep
Immutep is pleased to provide an update on its activities for the quarter ended 30 June 2024.
Read the ASX announcement: app.sharelinktechnologies.com/announcement/asx/406bc9ab12…
#lag3 #immunotherapy #biotechnology #oncology $IMM $IMMP -
Immutep reposted
Multiple Sclerosis News Today
@MSNewsToday
Immutep will soon start a Phase 1 trial in the Netherlands to test IMP761, its experimental therapy for MS, in healthy volunteers. multiplesclerosisnewstoday.com/news-posts/2024/07/25/pote… #news
-
Immutep reposted
m3.com編集部
@m3com_editors
PD-L1陰性の再発または転移性頭頸部扁平上皮がんに対するキイトルーダ+eftilagimod alpha、良好な奏効率を示す
www.m3.com/clinical/news/1223410?tw=true -
Immutep reposted
Targeted Onc
@TargetedOnc
The soluble LAG-3 fusion protein efti + pembrolizumab showed positive efficacy and disease control findings in patients with recurrent or metastatic #hnscc with negative PD-L1 expression.
www.targetedonc.com/view/new-immunotherapy-combination-ef… -
Immutep reposted
CancerNetwork®
@CancerNetwrk
Investigators of TACTI-004 plan to enroll approximately 750 patients regardless of PD-L1 expression in their assessment of the efti-based combination. #nsclc
www.cancernetwork.com/view/fda-gives-positive-feedback-on… -
Immutep reposted
-
Immutep
@Immutep
@Immutep announces successful meeting with @US_FDA on Phase III trial design to evaluate efti in combination with KEYTRUDA® and standard chemotherapy in first-line non-small cell lung cancer.
Read here: www.immutep.com/detail/immutep-announces-successful-meeti…
#lag3 #biotechnology $IMM $IMMP -
Immutep reposted
Targeted Onc
@TargetedOnc
Eftilagimod alpha + pembrolizumab led to positive efficacy and disease control findings in patients with recurrent or metastatic head and neck squamous cell carcinoma with negative PD-L1 expression. #hancsm | @TheChristieNHS
www.targetedonc.com/view/new-immunotherapy-combination-ef… -
Immutep reposted
CancerNetwork®
@CancerNetwrk
Eftilagimod alfa, plus pembrolizumab, achieved high efficacy and a favorable safety profile for patients with recurrent or metastatic HNSCC with negative PD-L1 expression. #hncsm | @RobertLMetcalf
www.cancernetwork.com/view/eftilagimod-alfa-combo-appears… -
Immutep reposted
OncLive.com
@OncLive
First-line Eftilagimod Alpha Plus Pembrolizumab Generates Favorable ORR in PD-L1–Negative HNSCC @RobertLMetcalf @TheChristieNHS @myESMO #esmovirtualplenary #medtwitter #oncology www.onclive.com/view/first-line-eftilagimod-alpha-plus-pe…
-
Immutep reposted
ESMO - Eur. Oncology
@myESMO
👉 Check the on-demand resources for the #esmovirtualplenary presenting clinically meaningful ORR in 1st line head and neck squamous cell carcinoma. Open to everyone, everywhere:
🔗 oncologypro.esmo.org/meeting-resources/esmo-virtual-plena… -
Immutep
@Immutep
@Immutep has received regulatory clearance to initiate the first-in-human Phase I study of IMP761.
IMP761 is for the treatment of autoimmune disease.
First participants expected during Q3 CY2024.
Read: app.sharelinktechnologies.com/announcement/asx/9e31eb4c7a…
#lag3 #autoimmunediseases $IMM $IMMP -
Immutep reposted
-
Immutep
@Immutep
Immutep announced positive results from Cohort B of the TACTI-003 Phase IIb trial evaluating efti in combination with KEYTRUDA, achieving a 35.5% response rate in evaluable patients, presented by Dr. Robert Metcalf at the @myESMO Virtual Plenary session.
www.immutep.com/detail/immutep-reports-positive-results-i… -
Immutep
@Immutep
Immutep will present at @myESMO Virtual Plenary session next week, announcing new clinical data in patients with negative PD-L1 expression in the TACTI-003 Phase IIb trial.
Register for the investor webcast here: us02web.zoom.us/webinar/register/WN_4BGck5tfRRqi4Fjf7MxoOA
#lag3 #biotechnology $IMM $IMMP -
Immutep
@Immutep
Thanks @BioWorld for featuring our TACTI-003 results.
"Efti continues to engage both the adaptive and innate immune systems, and is showing efficacy across hot, tepid and cold tumors across all PD-L1 expressions." - CEO Marc Voigt
Read here: www.bioworld.com/articles/710151-immuteps-eftilagimod-pha…
#lag3 -
Immutep
@Immutep
Immutep today reported its positive topline results from TACTI-003. The webcast reply is now available to listen to via the link: www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.a…
#lag3 #biotechnology $IMM $IMMP -
Immutep
@Immutep
@Immutep is excited to report positive topline results from its TACTI-003 Phase IIb trial in first line head and neck cancer today.
Read the ASX: app.sharelinktechnologies.com/announcement/asx/01c5467c4a…
#lag3 $IMM $IMMP -
Immutep
@Immutep
Immutep today announces a License Agreement with @cardiffuni granting the Company exclusive rights to develop and commercialise anti-LAG-3 small molecules.
#lag3 #biotechnology $IMM $IMMP
www.immutep.com/detail/immutep-signs-exclusive-license-ag… -
Immutep
@Immutep
Thank you, Rory Hunter from @SGHiscockandCo Medical Technology Fund for highlighting @Immutep as an exciting biotech with compelling data!
#immunotherapy #lag3
www.afr.com/markets/equity-markets/is-the-asx-on-the-cusp… -
Immutep
@Immutep
@Immutep is delighted to be featured in The @Australian article by Cameron England following the announcement of our new collaboration with MSD (Merck) on a pivotal Phase III trial for lung cancer treatment.
Please see article here: www.theaustralian.com.au/business/companies/immutep-will-…
#immutep $IMM $IMMP -
Immutep
@Immutep
@Immutep announces a collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) through a subsidiary, for the first-line treatment of metastatic non-small cell lung cancer in a pivotal Phase III trial.
cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research…
#immutep $IMM $IMMP -
Immutep
@Immutep
@Immutep is delighted to be featured in @australian today by Eddy Sunarto. The article delves deep into our recent clinical results and ongoing trials with a focus on our next milestones.
#lag3
#immunotherapy
$IMM $IMMP
www.theaustralian.com.au/business/stockhead/immuteps-anti… -
Immutep
@Immutep
@Immutep is excited to be quoted as a biotech pioneer with 'significant growth potential' by Andy Gracey, portfolio manager, @austethical in @FinancialReview article entitled "Healthcare opportunities amid market challenges".
$IMM $IMMP #lag3
www.afr.com/technology/healthcare-opportunities-amid-mark… -
Immutep
@Immutep
@Immutep announces encouraging efficacy, safety, and pharmacodynamic data from the safety lead-in of the AIPAC-003 Phase II/III trial presented at the ESMO - European Society for Medical Oncology Breast Cancer 2024 Congress.
app.sharelinktechnologies.com/announcement/asx/9eb3278d9e…
#lag3
#esmobreast24 -
Immutep reposted
OncLive.com
@OncLive
Eftilagimod Alpha Novel Triplet Combination is Well Tolerated, Generates CRs in Soft Tissue Sarcoma. #oncology #sarcoma
www.onclive.com/view/eftilagimod-alpha-novel-triplet-comb… -
Immutep
@Immutep
Thank you to Eddy Sunarto for taking a close look at our recent trial results in soft tissue sarcoma for The @australian.
#lag3 #immunotherapy
www.theaustralian.com.au/business/stockhead/asx-health-st… -
Immutep
@Immutep
@Immutep is pleased to share positive initial clinical data reported from our efti combined with radiotherapy and checkpoint inhibitor, from our phase II trial in soft tissue sarcoma.
Read the full announcement here: app.sharelinktechnologies.com/announcement/asx/24f49f8204…
#clinicaltrials #lag3 $IMM $IMMP -
Immutep reposted
CancerNetwork®
@CancerNetwrk
Eftilagimod alpha plus pembrolizumab as frontline therapy demonstrated preliminary responses and disease control in a small cohort of patients with recurrent or metastatic PD-L1–negative head and neck squamous cell carcinoma. #hncsm
www.cancernetwork.com/view/eftilagimod-alpha-pembrolizuma… -
Immutep
@Immutep
Immutep shares its Quarterly Report for Q3 FY24, highlights:
· First clinical data from AIPAC-003 in breast cancer
· Positive preliminary response rate in head & neck cancer
· IMP761 entering clinical trials mid-CY2024
#lag3 $IMM $IMMP
app.sharelinktechnologies.com/announcement/asx/35d064011d… -
Immutep reposted
OncLive.com
@OncLive
Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC #hncsm #oncology www.onclive.com/view/eftilagimod-alpha-plus-pembrolizumab…
-
Immutep
@Immutep
@Immutep announces positive preliminary topline results from our TACTI-003 Phase IIb trial evaluating efti in combination with MSD's KEYTRUDA® in first line metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression.
app.sharelinktechnologies.com/announcement/asx/b2451fe398… -
Immutep
@Immutep
@Immutep has appointed leading research institute, the @CHDR_NL, to perform its first-in-human clinical study of its autoimmune candidate, IMP761.
The trial is expected to begin mid-CY2024.
#lag3 #autoimmunedisease $IMM $IMMP
ASX announcement: app.sharelinktechnologies.com/announcement/asx/a98578c19e… -
Immutep
@Immutep
@Immutep is pleased to announce it has received positive feedback from the Spanish Agency for Medicines and Health Products (AEMPS) Competent Authority on our upcoming TACTI-004 Phase III trial.
app.sharelinktechnologies.com/announcement/asx/d43894001d…
#clinicaltrials #lag3 #biotechnology $IMM $IMMP -
Immutep
@Immutep
On his recent visit to Sydney, @Immutep CEO Marc Voigt caught up with the @Finnewsnetwork to talk about the Company's recent updates and clinical news. Watch the video here.
#lag3 #immunotherapy $IMM $IMMP
youtu.be/gsmtHuSGTyQ via @YouTube -
Immutep
@Immutep
You can read a great summary of our recent breast cancer results from @OncLive in their article below.
#lag3 #immunotherapy
www.onclive.com/view/eftilagimod-alpha-plus-chemotherapy-… -
Immutep
@Immutep
@Immutep is delighted to announce the first clinical data from the higher 90mg dose of efti. The data is from the safety lead-in part of the Phase II/III AIPAC-003 trial.
#lag3 #immunotherapy $IMM $IMMP
Announcement: www.immutep.com/detail/immutep-announces-first-clinical-d… -
Immutep
@Immutep
@Immutep is pleased to share its 2024 Half Year Report with shareholders including an update on its products, trials and partners.
#biotechnology #lag3 #clinicaltrials $IMM $IMMP
Read the full report here: app.sharelinktechnologies.com/announcement/asx/923355c17b… -
Immutep
@Immutep
An exciting year lies ahead for @Immutep's 2 first-in-class agonists to fight cancer and autoimmune disease: Efti (upcoming pivotal Ph3 trial) & IMP761 (launching a first-in-human clinical trial by mid-2024).
Read our Investor Update: www.immutep.com/files/content/investor/investor-update/20…
#lag3 $IMM $IMMP -
Immutep
@Immutep
@Immutep is pleased to announce the appointment of Anne Anderson as independent non-executive director (NED) of Immutep Limited.
#biotechnology #lag3 #clinicaltrials $IMM $IMMP
app.sharelinktechnologies.com/announcement/asx/c5bf709600… -
Immutep
@Immutep
Thanks to Andy Gracey from @austethical for highlighting @Immutep in his latest chat with @themotleyfool.
#lag3 $IMM $IMMP
www.fool.com.au/2024/01/27/3-ethical-asx-shares-poised-to… -
Immutep
@Immutep
@Immutep shares its Quarterly Report for Q2 FY24, including clinical data from TACTI-002 PhII trial, efficacy & tolerability data from INSIGHT-003 PhI trial & progress on its late stage & registrational trials.
#lag3 #immunotherapy $IMM $IMMP
ASX: app.sharelinktechnologies.com/announcement/asx/f974b1158e… -
Immutep
@Immutep
@Immutep has received constructive regulatory feedback from the Paul-Ehrlich Institut on its planned TACTI-004 registrational trial in metastatic non-small cell lung cancer.
#lag3 #immunotherapy
Read more: www.immutep.com/detail/immutep-receives-constructive-regu… -
Immutep
@Immutep
@Immutep is delighted to be selected as a top Healthcare pick by Thomas Wakim at @Bell_Potter Securities in their end of year note.
#lag3 #immunotherapy $IMM $IMMP
Bell Potter's top stock picks for 2024 www.livewiremarkets.com/wires/bell-potter-s-top-stock-pic… -
Immutep
@Immutep
@Immutep has received a €1,595,475 (~ A$2,628,354 ) research and development tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme.
app.sharelinktechnologies.com/announcement/asx/758d74b129…
#immunotherapy #lag3 #biotechnology $IMM $IMMP -
Immutep
@Immutep
@Immutep announces the INSIGHT-003 trial has been expanded to four sites across Germany supporting faster enrolment of the study evaluating treatment of non-squamous non-small cell lung cancer.
app.sharelinktechnologies.com/announcement/asx/5443b598e7…
#immunotherapy #lag3 #biotechnology $IMM $IMMP -
Immutep
@Immutep
How does our lead product candidate, efti, work?
Our 2-minute animation shows how efti unlocks a broad immune response to fight cancer.
#lag3 #clinicaltrials $IMM $IMMP
youtu.be/OQbuGZEBm8E -
Immutep
@Immutep
For our US friends, don’t forget to register for Baird's Video Webcast with @Immutep on Thursday 9 November at 10:30AM EST via the link below.
goto.webcasts.com/starthere.jsp?ei=1641571&tp_key=fc00458840
#immunotherapy #lag3 #biotechnology $IMM $IMMP -
Immutep
@Immutep
@Immutep announces enrolment in the TACTI-003 Phase IIb trial evaluating efti in combination with KEYTRUDA® as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.
app.sharelinktechnologies.com/announcement/asx/576b1c53d5…
#immunotherapy #lag3 #biotechnology $IMM $IMMP -
Immutep
@Immutep
The @Immutep team was excited to present our recent biomarker data which substantiates efti’s unique immune system stimulation at #sitc23 over the weekend.
Pictured: UCL's Dr Martin Forster & Dr Florian Vogl, Immutep's CMO
#lag3 $IMM $IMMP
www.immutep.com/files/content/investor/presentation/2023/… -
Immutep
@Immutep
Immutep announces the open-label safety lead-in of its integrated AIPAC-003 Phase II/III trial evaluating efti in combination with paclitaxel has been completed with no safety or tolerability issues.
app.sharelinktechnologies.com/announcement/asx/4098989f68…
#immunotherapy #lag3 #biotechnology $IMM $IMMP -
Immutep
@Immutep
@Immutep reports new biomarker data from our TACTI-002 phII trial:
Statistically significant increases of biomarkers, circulating immune cells & RNA levels of immune activating genes - linked to improved clinical outcomes
More: app.sharelinktechnologies.com/announcement/asx/f907c96ffd…
#lag3 $IMM $IMMP -
Immutep
@Immutep
@Immutep CEO Marc Voigt talks about the exciting new lung cancer results we just announced at #esmo23!
Thanks to the @Finnewsnetwork
#lag3 #biotech
youtu.be/cwXJFmLEOb4 -
Immutep
@Immutep
@Immutep is pleased to today provide its Quarterly Report to shareholders along with an update on the ongoing development of its product candidates, efti and IMP761.
Read more here: app.sharelinktechnologies.com/announcement/asx/cd609b7441…
#immunotherapy #clinicaltrials #biotechnology #lag3 -
Immutep
@Immutep
Many thanks to @StockheadAU's Nadine McGrath for delving into our recent exciting clinical results in lung cancer!
#lag3 #biotech $IMM $IMMP
Stockhead
@StockheadAU
Immutep (#asx:$IMM) is working hard to come up with more effective #cancer treatments, with #immunotherapy one of the promising approaches for personalised treatment. | #investing #stocks #shares stockhead.com.au/health/qa-immuteps-ceo-on-improving-lung…
-
Immutep reposted
Stockhead
@StockheadAU
Immutep (#asx:$IMM) is working hard to come up with more effective #cancer treatments, with #immunotherapy one of the promising approaches for personalised treatment. | #investing #stocks #shares stockhead.com.au/health/qa-immuteps-ceo-on-improving-lung…
-
Immutep
@Immutep
October is Breast Cancer Awareness Month, an opportunity to support for those affected by this widespread disease. At @Immutep, we stand alongside the fighters and survivors of breast cancer to help make a difference.
#breastcancerawareness #cancerresearch #lag3 -
Immutep reposted
-
Immutep
@Immutep
Thank you to all our shareholders who joined us today for our AGM.
We are pleased to share Chairman, Dr Russell J. Howard's Address and CEO, Marc Voigt's presentation.
Address: app.sharelinktechnologies.com/announcement/asx/f5bdb9365b…
CEO Presentation: app.sharelinktechnologies.com/announcement/asx/d94b7af4d9…
#lag3 $IMM $IMMP -
Immutep reposted
Pawel Sobczuk
@pawel_sobczuk
With @katarzynakozak9 we are presenting our baby - EFTISARC-NEO trial!
Don’t miss our poster no 1987TiP! Happy to discuss the rationale for LAG-3 protein, anti-PD-1 and radiotherapy as neoadjuvant in #sarcoma
Study supported by @Immutep @AgencjaBadanMed
@myESMO #esmo23 -
Immutep
@Immutep
@Immutep just announced excellent new Overall Survival data in lung cancer at #esmo23.
“We believe these [results] are among the strongest ever delivered in a sizable Phase II clinical trial.....," said Marc Voigt, Immutep CEO.
ASX: www.immutep.com/detail/immutep-s-efti-in-combination-with…
#lag3 #imm #immp -
Immutep
@Immutep
@Immutep announces excellent Overall Survival of 35.5 months in patients with met non-small cell lung cancer (TPS >1%) from TACTI-002 / KEYNOTE-798 Ph II trial.
Webcast today:
23 Oct, 8am AEDT
(Sun, 22 Oct, 5pm ET)
Register: us02web.zoom.us/webinar/register/WN_Mg9dmP-FRXGzpaV7ZQpK6Q
#lag3 #esmo23 $IMM $IMMP -
Immutep
@Immutep
@Immutep will share new updated data from efti, including mature Overall Survival results from the TACTI-002 Phase II trial at #esmo2023.
Join us for a webcast to discuss the data on Mon 23 Oct @ 8am AEDT/Sun 22 Oct 5pm ET.
Register: us02web.zoom.us/webinar/register/WN_Mg9dmP-FRXGzpaV7ZQpK6Q
$IMM $IMMP -
Immutep
@Immutep
Great to be picked as the most promising small-cap healthcare stock by Perennial Better Future's fund manager, Damian Cottier in The Australian Financial Review. #biotech #lag3
Perennial fundie’s top small-cap healthcare picks www.afr.com/markets/equity-markets/perennial-fundie-s-top… -
Immutep
@Immutep
@Immutep announces the publication of abstracts with data from the TACTI-002 and INSIGHT-003 trials in 1st line non-small cell lung cancer at the @myESMO Congress.
Register for our webcast here: us02web.zoom.us/webinar/register/WN_Mg9dmP-FRXGzpaV7ZQpK6Q
Read more here: app.sharelinktechnologies.com/announcement/asx/3396c0530e…
#esmo2023 #lag3 -
Immutep
@Immutep
Immutep announces an abstract has been accepted for poster presentation at the hybrid Society
for Immunotherapy of Cancer (SITC) Annual Meeting 2023 in San Diego from 1 to 5 November 2023.
#biotechnology #lag3 #clinicaltrials #sitc23 #sitc2023 $IMM $IMMP
app.sharelinktechnologies.com/announcement/asx/d3f2a52daf… -
Immutep
@Immutep
For those of you unable to join @Immutep at the @cantorfitzgerld Global Healthcare Conference earlier this week, you can watch the replay of CEO Marc Voigt's presentation via the link below.
#lag3 #biotechnology #immunotherapy #cantor
wsw.com/webcast/cantor19/register.aspx?conf=cantor19&page… -
Immutep
@Immutep
New scientific paper on 1st study of efti in combination with avelumab, authored by Salah-Eddin Al-Batran, MD in @ESMO_Open
Concludes IO-IO combination has promising activity which warrants further investigation.
#lag3 #immunooncology $IMM $IMMP
www.sciencedirect.com/science/article/pii/S205970292300858X -
Immutep
@Immutep
@Immutep is pleased to share its 2023 Annual Report, read the full report here: app.sharelinktechnologies.com/announcement/asx/73fada4edf…
#biotechnology #lag3 #clinicaltrials $IMM $IMMP -
Immutep
@Immutep
@Immutep has received regulatory authorisation of commercial scale manufacturing of efti (2,000L) for use in clinical trials across multiple European countries.
#clinicaltrials #lag3 $IMM $IMMP
ASX: app.sharelinktechnologies.com/announcement/asx/57982d4fdc… -
Immutep
@Immutep
@Immutep is pleased to share its Investor Update today, which covers our late-stage trials and catalysts ahead.
Read more here: app.sharelinktechnologies.com/announcement/asx/45f3698fcf…
#lag3 #clinicaltrials $IMM $IMMP -
Immutep
@Immutep
Dr Nuhad Ibrahim of MD Anderson Cancer Center, talks about @Immutep's AIPAC-003 trial investigating efti in breast cancer.
@MDAndersonNews
#lag3 #immunotherapy $IMM $IMMP
www.onclive.com/view/dr-ibrahim-on-the-study-of-eftilagim… -
Immutep
@Immutep
Marc Voigt, CEO of @Immutep is looking forward to providing an corporate overview at @ThisIsBTIG’s Virtual Biotechnology Conference 2023, at 9.30am (US EDT) on Tuesday, August 8, 2023.
To join the conference, email info@btig.com
#btig #immunotherapy #lag3 $IMM $IMMP -
Immutep
@Immutep
@Immutep received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for the continued development of efti.
app.sharelinktechnologies.com/announcement/asx/c42914b55a…
#immunotherapy #lag3 #biotechnology $IMM $IMMP -
Immutep
@Immutep
@Immutep will present overall survival data in 1st line non-small cell lung cancer in an Oral Presentation at #esmo2023 in October.
The new data is from TACTI-002 Ph II trial of the chemo-free combination of efti and @Merck’s KEYTRUDA.
#lag3 $IMM $IMMP
www.immutep.com/detail/immutep-to-present-overall-surviva… -
Immutep
@Immutep
During #sarcomaawarenessmonth, the team at @Immutep have been reflecting on the importance of finding new ways to stimulate the immune system to fight cancers such as #softtissuesarcoma, an orphan disease with high unmet medical need.
#innovation #lag3 #sarcoma $IMM $IMMP -
Immutep
@Immutep
@Immutep provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for its fiscal fourth quarter ended 30 June 2023 (Q4 FY23).
Read announcement here: app.sharelinktechnologies.com/announcement/asx/c09b4d888a…
#lag3 $IMM $IMMP -
Immutep
@Immutep
@Immutep is pleased to announce the first patient has been dosed in its chemotherapy-free triple combination phase II trial targeting soft tissue sarcoma.
Read more here: app.sharelinktechnologies.com/announcement/asx/90d484c14a…
#clinicaltrials #biotechnology #lag3 -
Immutep
@Immutep
Drug Discovery World's Megan Thomas spoke with @Immutep CSO, Frédéric Triebel, about his 1990 discovery of the LAG-3 immune control mechanism.
Triebel shares insights from his career and the future of immuno-oncology.
#lag3 $IMM $IMMP
www.ddw-online.com/immunotherapy-is-here-to-stay-24873-20… -
Immutep
@Immutep
A replay of @Immutep CEO, Marc Voigt's presentation to @MaximGrp's Healthcare Virtual Conference 2023 is now available.
You can watch by signing up for free through MVest via: m-vest.com/insights/marketpulse/healthcare-virtual-confer…
#immunotherapy #lag3 #biotechnology $IMM $IMMP -
Immutep
@Immutep
Fidelity International portfolio manager Zara Lyons talks through her top stock tips, including @Immutep , with Joanne Tran from @FinancialReview.
#immunotherapy #biotechnology #lag3 $IMM $IMMP
www.afr.com/markets/equity-markets/ramsay-boasts-m-and-a-… -
Immutep
@Immutep
@Immutep has been granted its third United States Patent for Eftilagimod Alpha in combination with a PD-1 pathway inhibitor.
#immunotherapy #lag3 #biotechnology
$IMM $IMMP
Read more: www.immutep.com/detail/immutep-secures-third-united-state… -
Immutep reposted
Sharecafe
@sharecafetweets
Immutep (ASX:IMM) - Webinar Presentation youtu.be/H5kCbSGonao
@Immutep $IMM -
Immutep
@Immutep
For our US friends & Australian night owls, join @Immutep's presentation at the Maxim Group Healthcare Conference, providing an overview of recent clinical results
4pm US ET, Tues 20 June
Register: m-vest.com/events/healthcare-06202023
#lag3 #immunotherapy $IMM $IMMP
Replay to be available -
Immutep
@Immutep
Last week, @Immutep presented at the @Jefferies Healthcare Conference in New York, giving a great update of the strong progress and results the team has delivered recently.
#biotechnology #lag3 #immunotherapy
Watch the replay: wsw.com/webcast/jeff281/register.aspx?conf=jeff281&page=i… -
Immutep
@Immutep
@Immutep is pleased to provide an overview of the positive final data from Part C of the TACTI-002 Phase II trial to be presented in a poster presentation at the @ASCO 2023 Annual Meeting taking place in Chicago, US.
Read more here: app.sharelinktechnologies.com/announcement/asx/39832be51c…
#asco2023 $IMM $IMMP -
Immutep
@Immutep
@Immutep is pleased to announce it has entered into an agreement with Charles River under which Charles River will conduct a GLP toxicology study for IMP761, Immutep's proprietary preclinical candidate for autoimmune diseases.
#immutep $IMM $IMMP
app.sharelinktechnologies.com/announcement/asx/7f1929f37e… -
Immutep
@Immutep
@Immutep is pleased to announce data from Part C of its TACTI-002 Phase II trial and a Trial in Progress abstract for our Phase II/III AIPAC-003 trial are available on the 2023 ASCO Annual Meeting’s official website.
app.sharelinktechnologies.com/announcement/asx/f0d78fd5e8…
#asco23 $IMM $IMMP #lag3 -
Immutep
@Immutep
Thanks to Eddy Sunarto at the @australian for picking up our recent news regarding the promising new clinical data from the triple combination therapy INSIGHT-003 trial.
#lag3 #immunotherapy #clinicaltrials $IMM $IMMP
www.theaustralian.com.au/business/stockhead/asx-health-st… -
Immutep
@Immutep
@Immutep today announces the first patient has been enrolled and safely dosed at a European clinical site for its integrated Phase II/III AIPAC-003 trial in metastatic breast cancer.
app.sharelinktechnologies.com/announcement/asx/e33ba23f3e…
#lag3 #oncology $IMM $IMMP -
Immutep
@Immutep
@Immutep is pleased to share promising new clinical data from our triple combination therapy in our INSIGHT-003 trial.
Read more here: app.sharelinktechnologies.com/announcement/asx/14e57c817b…
#lag3 #clinicaltrials #immunotherapy $IMM $IMMP -
Immutep
@Immutep
We are delighted to see @Nasdaq celebrating our recently announced positive initial Overall Survival benefit from efti in 1st line non-small cell lung cancer.
ASX data announcement: app.sharelinktechnologies.com/announcement/asx/05407d5ff0…
#lag3 #immunotherapy #clinicaltrials $IMM $IMMP -
Immutep
@Immutep
CEO Marc Voigt discusses the significance of @immutep's recent announcements with Paul Sanger from @Finnewsnetwork.
#lag3 #clinicaltrials #biotech $IMM $IMMP
youtu.be/u-yd_UR1qkY -
Immutep reposted
Targeted Onc
@TargetedOnc
The #fda is supporting a registrational trial to evaluate eftilagimod alpha for the treatment of first-line #nsclc. @VUMC_Cancer
Read more: www.targetedonc.com/view/fda-supports-further-evaluation-… -
Immutep reposted
AusBiotech
@AusBiotech
Positive results for @Immutep's cancer candidate in combination with MSD's #keytruda biotechdispatch.com.au/news/positive-results-for-immuteps…
-
Immutep reposted
OncLive.com
@OncLive
First-line Eftilagimod Alpha Plus Pembrolizumab Generates OS Benefit in PD-L1+ NSCLC
@uclcancer @uclh #lcsm
www.onclive.com/view/first-line-eftilagimod-alpha-plus-pe… -
Immutep
@Immutep
@immutep today announced that efti in combination with @Merck's anti-PD-1 therapy KEYTRUDA® achieved robust initial Overall Survival in 1st line non-small cell lung cancer patients in the Phase II TACTI-002 trial.
app.sharelinktechnologies.com/announcement/asx/05407d5ff0…
#lag3 #oncology $IMM $IMMP #immutep -
Immutep
@Immutep
@Immutep has received positive feedback from the US FDA regarding our late-stage clinical development plans for our first-in-class soluble LAG-3 protein, eftilagimod alpha, for the treatment of 1st line non-small cell lung cancer.
app.sharelinktechnologies.com/announcement/asx/2a7448991a…
#lungcancer #fda -
Immutep
@Immutep
If you missed our Key Opinion Leader event earlier this month, “Deep Dive into Efti Development in NSCLC and HNSCC Landscapes," you can catch the replay via the link: us06web.zoom.us/rec/play/H4LLDlL7f_zA4ES9Oqoesq_nd16yAkkU…
Thanks to our host Ladenburg Thalmann
#clinicaltrials #oncology #biotech #kol -
Immutep reposted
Genetic Engineering & Biotechnology News
@GENbio
#immunotherapy for #cancer A Look Back and A Look Ahead
@Immutep describes how #lag3 immunotherapies can safely tap into the immune system’s inherent power to fight cancer. Learn more: www.genengnews.com/topics/cancer/immunotherapy-for-cancer… -
Immutep
@Immutep
Join us for a @DDWJournal webinar panel discussion with @Immutep's Dr Frederic Triebel on:
'Cancer Immunotherapy - where will the future opportunities be?'
Free to attend on 10 May 8am PDT, 11am EDT, 4pm BST , 5pm CEST.
#lag3 $IMM $IMMP
Register: register.gotowebinar.com/register/446848552259361632?sour… -
Immutep
@Immutep
We're very pleased to share a new article penned by @Immutep CEO Marc Voigt in @GENbio.
It covers the #immunoncology space & Immutep's leading role in #lag3.
$IMM $IMMP
www.genengnews.com/topics/cancer/immunotherapy-for-cancer… -
Immutep
@Immutep
Join us for a #kol event: “Deep Dive into Efti Development in NSCLC and HNSCC Landscapes.”
Featuring: Martin Forster MD, PhD, of @UCL
and Wade Iams MD, MSCI of @VanderbiltU
Hosted by @LadenburgLTS
Tues May 9, 11:30am–1PM US ET
us06web.zoom.us/webinar/register/WN_KW-VeKY5T_mmuamDqGoKj… -
Immutep
@Immutep
@Immutep is pleased to announce it has received regulatory approval to initiate INSIGHT-005 Phase I trial evaluating the safety and efficacy of efti in combination with BAVENCIO in 30 patients with metastatic urothelial carcinoma.
app.sharelinktechnologies.com/announcement/asx/aeed2dc1f9…
#clinicaltrials #imm -
Immutep
@Immutep
@Immutep is pleased to announce two abstracts have been selected for poster presentation at the upcoming 2023 ASCO Annual Meeting, taking place in-person and online from 2-6 June 2023 in Chicago, Illinois.
See the presentation details here: app.sharelinktechnologies.com/announcement/asx/5db2283bd9… -
Immutep
@Immutep
@Immutep is pleased to provide an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for the quarter ended 31 March 2023.
app.sharelinktechnologies.com/announcement/asx/48a3189ce9… -
Immutep
@Immutep
@Immutep is pleased to announce that Florian D. Vogl, M.D., Ph.D., MSc, has been appointed as Chief Medical Officer (CMO) with effect from 1 May 2023.
app.sharelinktechnologies.com/announcement/asx/09b704e9bd… -
Immutep reposted
Cancer Discovery
@CD_AACR
If you enjoyed the talk by Dario Vignali on #lag3 and its inhibition during the #aacr23 session Embracing Immune Ecosystems, check out this Cancer Discovery News in Brief article on the benefit of the LAG3 targeting drug eftilagimod alpha in #nsclc—
aacrjournals.org/cancerdiscovery/article/13/1/7/712682/So… -
Immutep
@Immutep
@Immutep announces the initiation of an open-label Phase II trial evaluating eftilagimod alpha (efti), in combination with pembrolizumab and radiotherapy in up to 40 soft tissue sarcoma (STS) patients in the neoadjuvant (prior to surgery) setting.
www.immutep.com/detail/immutep-announces-initiation-of-in… -
Immutep
@Immutep
Our CSO Dr Triebel discusses history & future of #immunooncology and synergistic combination of efti (soluble #lag3) with checkpoint inhibitors given "markedly different mechanism of action" in latest @DDWJournal guide re #cancerresearch.
Learn more here: www.ddw-online.com/latest-ddw-guide-exclusive-insight-int… -
Immutep
@Immutep
The @Immutep team had a very productive meeting at the Maria Skłodowska-Curie National Research Institute of Oncology discussing the upcoming #softtissuesarcoma study.
Stay tuned for further developments. -
Immutep
@Immutep
@Immutep is pleased to announce positive final data from Part B of the TACTI-002 Phase II trial in 2nd line metastatic non-small cell lung cancer (NSCLC) patients refractory to anti-PD-(L)1 therapy.
$IMM $IMMP
app.sharelinktechnologies.com/announcement/asx/f988c1e156… -
Immutep
@Immutep
@Immutep has signed an agreement to expand the INSIGHT-003 trial evaluating the combination of eftilagimod alpha, in conjunction with standard-of-care combination of anti-PD-1 therapy and chemotherapy in 1st line non-small cell lung cancer.
$IMM $IMMP
www.immutep.com/detail/immutep-announces-expansion-of-tri… -
Immutep
@Immutep
@Immutep will announce new data evaluating efti in combination with pembrolizumab from TACTI-002 Phase II trial in non-small cell #lungcancer patients at @myESMO ELCC 2023 (29 March - 1 April 2023) in a Mini Oral presentation.
#lag3 $IMM $IMMP
www.immutep.com/detail/immutep-announces-abstract-accepte… -
Immutep
@Immutep
@Immutep has initiated its AIPAC-003 trial in #breastcancer. It is an integrated Phase II/III trial to evaluate efti in combination with paclitaxel.
The first patient is expected to be enrolled in early Q2 CY2023.
#immunotherapy $IMM $IMMP
ASX: www.immutep.com/detail/immutep-announces-initiation-of-ph… -
Immutep
@Immutep
Many thanks to Eddy Sunarto at @StockheadAU for taking the time to chat to @Immutep CEO Marc Voigt about how immuno-oncology is playing a leading role in shifting the cancer treatment paradigm.
#lag3
#immunotherapy
#chemotherapy
stockhead.com.au/health/could-immunotherapy-replace-chemo… -
Immutep
@Immutep
Marc Voigt, CEO of @Immutep, sat down with @Finnewsnetwork to talk about its consistently compelling data from efti across three key cancer indications, its ongoing clinical trials and the Company's exciting outlook ahead.
#lag3 $IMM $IMMP
youtu.be/ne6joOZwcUc -
Immutep
@Immutep
If you missed our @sharecafetweets webinar last week, you can catch the replay here. CEO Marc Voigt gives a short overview of @Immutep and its exciting late-stage clinical development plans for efti. #lag3 #clinicaltrials $IMM $IMMP
www.finnewsnetwork.com.au/archives/finance_news_network39… -
Immutep
@Immutep
Join us for an investor webinar on Friday 17 February at 12.30pm (AEDT) as part of ShareCafe's Hidden Gems series.
CEO Marc Voigt will give a quick introduction to Immutep & the development plan for our lead product, efti.
Register: us02web.zoom.us/webinar/register/WN_Hk61m9MkRnKNrHG85e1Qvg
#lag3 $IMM $IMMP -
Immutep reposted
Sharecafe
@sharecafetweets
Friday's webinar will discuss diagnostic products, water quality, mining tech & immunotherapy treatments. Register now us02web.zoom.us/webinar/register/WN_Hk61m9MkRnKNrHG85e1Qvg to hear from @shawpartners @phoslockglobal $PET @ImdexLimited $IMD @TeamRadioPharm $RAD @Immutep $IMM
-
Immutep reposted
OncLive.com
@OncLive
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC @marinagarassino @UChicagoMed @gotoPER #gotoper #wlc2023 #lcsm www.onclive.com/view/pd-1-inhibitor-combinations-alternat…
-
Immutep reposted
AusBiotech
@AusBiotech
Australian clinical-stage biotechnology company @Immutep (ASX:IMM) has announced that the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with first-line Non-small cell lung cancer. biotechdispatch.com.au/news/immutep-reaches-enrolment-tar…
-
Immutep
@Immutep
Following on from the #sitc22 meeting, it's nice to see continuing interest in the results from our TACTI-002 trial of pembrolizumab and efti in non–small cell lung cancer.
#immunotherapy #lag3 $IMM $IMMP
Targeted Onc
@TargetedOnc
Deep and durable responses were seen with #pembrolizumab in combination with #eftilagimod alpha in patients with advanced non–small cell lung cancer, according to the phase 2 TACTI-002 trial findings. #nsclc #lcsm #sitc22 | @VUMC_Cancer @VUMChealth
www.targetedonc.com/view/eftilagimod-alpha-combination-de… -
Immutep
@Immutep
@Immutep CEO Marc Voigt & CMO/CSO Frederic Triebel were delighted to speak with leading pharma publication @INVIVOnow late last year about the path ahead for #lag3 Therapeutics.
#immunotherapy $IMM $IMMP
ASX: insights.citeline.com/IV146742/The-Journey-Has-Just-Begun…
NB: free trial subscription is available -
Immutep
@Immutep
@Immutep has passed the 50% enrollment milestone for the Phase IIb TACTI-003 clinical trial for head & neck cancer patients.
Thank you to our investigators, clinical team, partners and most importantly, the patients.
#immunotherapy #lag3 $IMM $IMMP
ASX: app.sharelinktechnologies.com/announcement/asx/668470b9f1… -
Immutep
@Immutep
Many thanks Daniel Levine for taking the time to chat with us about the potential for efti and our big pharma partnerships!
#lag3 #immunotherapy $IMM $IMMP @dslevine
Daniel S. Levine
@dslevine
Marc Voigt, CEO of @Immutep, discuss the LAG-3 checkpoint, the company’s lead experimental candidate, and its partnerships with GSK and Novartis to develop therapies for cancer and autoimmune diseases.
soundcloud.com/levine-media-group/targeting-a-novel-check… -
Immutep
@Immutep
@Immutep announces a successful meeting with the US FDA on efti plus chemo, agreeing a Phase II/III trial design to address high unmet need for metastatic breast cancer patients.
#lag3 #breastcancer $IMM $IMMP
ASX: app.sharelinktechnologies.com/announcement/asx/9db9c27a2b… -
Immutep
@Immutep
@Immutep is pleased to be selected as a 'top pick' by WILSONS' analyst Melissa Benson and Bell Potter Securities' analyst Tara Speranza in their respective 2023 outlook notes.
#lag3 #biotech #healthcare #equityresearch #asx $IMM $IMMP -
Immutep
@Immutep
@Immutep has successfully scaled up its commercial #manufacturing process for Efti in preparation for late-stage #clinicaltrials & commercial production.
The first 2,000L manufacturing run was completed by @WuXiBiologics
#lag3 $IMM $IMMP
ASX: www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
@Immutep has developed a #gmp manufacturing process for IMP761, a First-in-Class LAG-3 agonist for #autoimmunedisease. Enables our IND-enabling studies in 1H’2023 & subsequent clinical testing of IMP761
#lag3 #immunotherapy #autoimmunedisease
Learn more: www.immutep.com/files/content/investor/press-release/2022… -
Immutep reposted
The ASCO Post
@ASCOPost
Wade T. Iams, MD, on NSCLC: Combining an Antigen-Presenting Cell Activator With Pembrolizumab ascopost.com/videos/sitc-2022/wade-iams-on-nsclc-combinin… #lcsm #nsclc #lungcancer #sitc22 @VUMC_Cancer @sitcancer
-
Immutep
@Immutep
@Immutep CEO, Marc Voigt, discusses the LAG-3 landscape, the company's portfolio of therapies, encouraging data from the #sitc22 conference and the outlook for 2023.
#lag3 #immunotherapy $IMM $IMMP
youtu.be/S5y2KkwduZs via @YouTube -
Immutep reposted
OncLive.com
@OncLive
.@WadeIams, of @VUMC_Cancer, discusses the rationale of targeting the LAG-3 pathway in patients with advanced non–small cell lung cancer. #lcsm #oncology www.onclive.com/view/dr-iams-on-the-rationale-of-targetin…
-
Immutep reposted
Labiotech.eu
@Labiotech_eu
The immuno-oncology firm Immutep explains why the immune checkpoint target LAG-3 is ripe for innovation in the space. 👇🏻
#biotech #lifesciences #news
www.labiotech.eu/interview/lag-3-immutep-checkpoint/ -
Immutep reposted
AusBiotech
@AusBiotech
@Immutep (ASX:IMM) has announced a new clinical trial collaboration under which the Australian company's investigative LAG-3 immunotherapy, efti, will be studied with Merck and Pfizer's PBS-listed BAVENCIO (avelumab). biotechdispatch.com.au/news/immutep-announces-new-collabo… #immunotherapy
-
Immutep
@Immutep
We are pleased to announce @Immutep has today signed a second collaboration agreement with @merckgroup and @pfizer for a new trial (INSIGHT-005) of our lead product candidate, efti, in urothelial cancer.
ASX: www.immutep.com/files/content/investor/press-release/2022…
#lag3 #immunotherapy $IMM $IMMP -
Immutep
@Immutep
It was great to see so many shareholders in person today at @Immutep's 2022 AGM.
We are pleased to share our Chairman's Address and CEO Presentation.
Chairman's Address: app.sharelinktechnologies.com/announcement/asx/75157dc9a0…
CEO Presentation: app.sharelinktechnologies.com/announcement/asx/75157dc9a0…
#lag3 $IMM $IMMP -
Immutep
@Immutep
Ahead of @Immutep's AGM tomorrow, CEO Marc Voigt chatted to @jaredm_lynch of @Australian about the strength of its recent efti results in non-small cell lung cancer.
#lag3 #immunotherapy $IMM $IMMP
www.theaustralian.com.au/business/companies/immutep-to-en… -
Immutep
@Immutep
#collaboration is at the heart of all Immutep’s scientific endeavours. To learn more about the value, depth and breadth of our collaborations, read our latest Investor Update: www.immutep.com/files/content/investor/investor-update/20…
#lag3 $IMM $IMMP -
Immutep
@Immutep
@Immutep CEO Marc Voigt presented today at the #jefferieshealthcare Conference in London, providing an overview of the company and continued progress in oncology & autoimmune disease with its pure-play #lag3 portfolio. The webcast replay is available here: wsw.com/webcast/jeff255/immp/1858869
-
Immutep reposted
Sharecafe
@sharecafetweets
Immutep (ASX:IMM) - Update on new TACTI-002 Phase II and initial INSIGHT-003 Phase 1 data presented at SITC 2022
youtu.be/RPJ7PTBcSDg
$IMM @Immutep -
Immutep
@Immutep
@Immutep has received a A$0.98m cash rebate from the Aust Fed Gov’s R&D tax incentive program for Australian TACTI-002 R&D activities in FY21.
Extends $IMM's expected cash reach into H1 of calendar year 2024.
#randdtaxcredits $IMMP
ASX: www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
@Immutep Thank you again for joining our webcast on TACTI-002 PII trial's compelling clinical results & initial clinical data from the triple combo INSIGHT-003 trial with a 72.7% response rate & 90.9% DCR in 1L #nsclc. ICYMI a replay is now available here: www.immutep.com/investors-media/presentations.html
-
Immutep
@Immutep
@Immutep's TACTI-002 results in 1st line NSCLC patients reported today at #sitc22 include an Overall Response Rate to increased 40.4% & interim median Duration of Response of 21.6 months, comparing favourably to historical controls.
More: www.immutep.com/files/content/investor/press-release/2022…
#lag3 $IMM $IMMP -
Immutep
@Immutep
@Immutep We are pleased to share compelling data from TACTI-002 Phase II trial in 1st line #nsclc at #sitc2022. A special thanks to Dr. Iams @VUMChealth for his oral presentation of our late-breaking abstract (#1470). Join our webcast today to learn more: www.immutep.com/files/content/investor/press-release/2022…
-
Immutep
@Immutep
We are looking forward to the @Jefferies London Healthcare Conference taking place from 15-17 November.
@Immutep CEO Marc Voigt will present an overview of our recent exciting progress and clinical data.
#jefferieshealthcare #immunotherapy #lag3 $IMM $IMMP -
Immutep
@Immutep
@Immutep's Late-Breaking Oral Abstract Presentation for TACTI-002 is one of just nine abstracts to be showcased in the press conference at #sitc22 out of a total of 1,500 abstract submissions!
Join our webinar regarding the results: us02web.zoom.us/webinar/register/WN_Ljob0v5lTH-3nCRicsGjvA
#lag3 $IMM $IMMP -
Immutep
@Immutep
@Immutep's Late-Breaking Abstract has been accepted for an Oral Presentation at #sitc22 next week to report new clinical data for efti in combination with pembrolizumab in 1st line NSCLC from TACTI-002/KEYNOTE-798 Ph II trial.
#lag3 $IMM $IMMP
ASX: www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
For a quick update on @immutep's active programs, see our recent Quarterly Report.
Covers:
•Clinical development strategy for efti
•Further encouraging interim data in 2nd line NSCLC
•3 upcoming abstracts for #sitc22
#immunotherapy #lag3
ASX: /bit.ly/3zwIta9 -
Immutep
@Immutep
@Immutep today announces the Independent Data Monitoring Committee for the randomised, controlled Phase IIb TACTI-003 trial has reviewed initial safety data and recommended continuing the trial with no modifications.
#lag3 #immunotherapy $IMM $IMMP
ASX: www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
Marc discusses @Immutep's first-in-class clinical candidate efti, its activation of the immune system and differentiation from #lag3 antagonist candidates, plus the value of Fast Track designation in first line NSCLC and IMM's preclinical candidate, IMP761.
Immutep
@Immutep
@Immutep CEO Marc Voigt caught up with James Cornwall PhD from @Labiotech_eu as part of its popular Beyond Biotech podcast.
Skip to 33:26 to hear from Marc, or enjoy the whole podcast.
#immunooncology #biotech #lag3 $IMM $IMMP www.labiotech.eu/trends-news/beyond-biotech-podcast-19/ via @Labiotech_eu -
Immutep
@Immutep
@Immutep CEO Marc Voigt caught up with James Cornwall PhD from @Labiotech_eu as part of its popular Beyond Biotech podcast.
Skip to 33:26 to hear from Marc, or enjoy the whole podcast.
#immunooncology #biotech #lag3 $IMM $IMMP www.labiotech.eu/trends-news/beyond-biotech-podcast-19/ via @Labiotech_eu -
Immutep
@Immutep
@Immutep is pleased to share its Annual Report with investors for the financial year 2022.
#lag3 #immunooncology $IMM $IMMP
Read the report: app.sharelinktechnologies.com/announcement/asx/774e126aab… -
Immutep
@Immutep
Great overview from @biospace of how anti-PD-1/PD-L1 cancer drugs might benefit from combination with new therapies, such as @Immutep's immunostimulant efti.
$IMM $IMMP #lag3
www.biospace.com/article/beyond-anti-pd-1-pd-li-3-compani… -
Immutep
@Immutep
@Immutep CEO, Marc Voigt explains the value of its recently awarded US FDA Fast Track Designation for efti as well as news flow ahead to @Finnewsnetwork's Tim McGowen.
#lag3 #immunotherapy #nsclc $IMM $IMMP
youtu.be/Y21MGpnNWrU via @YouTube -
Immutep
@Immutep
@Immutep will announce first interim data from the INSIGHT-003 clinical trial in a poster presentation at #sitc2022
A Trial in Progress poster on the phase IIb TACTI-003 trial will also be presented, along with a Late Breaking Abstract.
#lag3 #immunotherapy -
Immutep
@Immutep
@Immutep has been granted Fast Track designation by the US #fda for efti in combination with pembrolizumab for the treatment of 1st line NSCLC, based on encouraging PhII data for PD-L1 all-comers.
ASX: www.immutep.com/files/content/investor/press-release/2022…
#immunotherapy #lag3 #fda $IMM $IMMP -
Immutep
@Immutep
Mark Voigt, CEO of @Immutep presented at the Ladenburg Thalmann Healthcare Conference 2022 last week, covering the clinical development strategy for #efti.
A replay is available here: wsw.com/webcast/ladenburg8/register.aspx?conf=ladenburg8&…
#immunotherapy #lag3 $IMM $IMMP -
Immutep
@Immutep
CEO Marc Voigt was delighted to take part in a panel discussion on "Trends and Challenges in Immuno-Oncology" at the Cantor Fitzgerald's Oncology, Hematology & HemeOnc Conference on Wednesday in the US. (Marc Voigt: second from right in photo)
#immunotherapy #lag3 $IMM $IMMP -
Immutep
@Immutep
@Immutep has received a €1.8m (~A$2.7m) R&D tax incentive payment from the French Government. The funds will be used to support the global clinical development of #efti and the preclinical development of IMP761.
#lag3 #immunotherapy
//bit.ly/3UyWkpy -
Immutep
@Immutep
Thank you to BiotechDispatch for the highlighting our exciting news!
#biotech #immunotherapy #cancer
AusBiotech
biotechdispatch.com.au/news/immutep-provides-clinical-upd… -
Immutep reposted
cab971
@cab_971
$IMMP Regeneron, Immutep Talk LAG-3 as ESMO Highlights New I-O Approaches. $IMM.AU unique MOA via #lag3: “We activate APCs…which are involved in generating more CD8 & CD4 T cells and more NK cells…” so “potentially more targets for anti-PD-1 to work on.”
www.biospace.com/article/regeneron-immutep-discuss-lag-3-… -
Immutep
@Immutep
@Immutep announces its clinical development strategy for LAG-3 candidate, Efti.
Encouraging Ph II data supports broad therapeutic potential.
Planning & regulatory interactions ongoing with a focus now prioritising NSCLC.
#lag3 $IMM $IMMP
ASX: www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
@Immutep is delighted to appoint LAG-3 Pioneer, Prof Frederic Triebel to its Board as Executive Director.
“It is a privilege to welcome Frédéric to Immutep’s Board," said Chair, Russell J. Howard.
#lag3 #immunotherapy $IMM $IMMP
ASX: www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
@Immutep and the Maria Sklodowska-Curie National Research Institute of Oncology, Poland, announce a new PhII trial evaluating efti in combination with pembrolizumab & radiotherapy in up to 40 patients with select soft tissue sarcoma.
#lag3 $IMM $IMMP
www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
@Immutep has been granted a new patent for efti in combination with an anti-PD-(L)1 antibody by the Japanese Patent Office.
www.immutep.com/files/content/investor/press-release/2022…
#lag3 #immunotherapy -
Immutep reposted
OncLive.com
@OncLive
According to the phase 2 TACTI-002 trial, eftilagimod alpha + pembrolizumab demonstrated promising benefits in OS and PFS as a second-line treatment in patients with NSCLC who progressed on anti–PD-1/anti–PD-L1 therapy. #lcsm www.onclive.com/view/eftilagimod-alpha-pembrolizumab-comb…
-
Immutep reposted
AusBiotech
@AusBiotech
.@Immutep reports new data from phase 2 TACTI-002 trial biotechdispatch.com.au/news/immutep-reports-new-data-from…
-
Immutep
@Immutep
New interim data from Ph II TACTI-002 trial:
“It is encouraging to see efti in combination with pembrolizumab continues to report promising antitumour and safety results in 2nd line NSCLC." - Dr Frederic Triebel
#wclc22 #lag3 $IMM $IMMP
ASX: www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
Thank you, @OncLive for a great overview of how the LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.
#lag3 #imunotherapy $IMM $IMMP
www.onclive.com/view/lag-3-fills-a-complex-role-in-the-im… -
Immutep
@Immutep
Many thanks to The Motley Fool for including @Immutep in its sector article on the outlook for ASX biotech in FY23.
#lag3 #immunotherapy $IMM $IMMP
www.fool.com.au/2022/07/12/whats-the-outlook-for-asx-biot… -
Immutep reposted
Drug Discovery World
@DDWJournal
@Immutep granted Japanese patent for immunosuppressive antibody
www.ddw-online.com/immutep-granted-japanese-patent-for-im…
#biotechnology -
Immutep
@Immutep
@Immutep has been granted a new patent by the Japanese Patent Office, protecting its pre-clinical product candidate IMP761 in the treatment of T-cell mediated inflammatory and autoimmune diseases.
#immunotherapy #lag3 #patents
ASX: www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
June is Cancer Immunotherapy Month.
#immune2cancer #lag3 #clinicalresearch #immunotherapy -
Immutep
@Immutep
New data from second line non-small cell lung cancer patients (Part B) in @Immutep's Phase II TACTI-002 trial has been selected for a poster presentation at #wclc2022, 6-9 August 2022 in Vienna.
See wclc2022.iaslc.org to view the abstract from 8 July.
#lag3 $IMM $IMMP -
Immutep
@Immutep
Thank you to @LifeSciAdvisors for talking to @Immutep's CEO Marc Voigt about the company's exciting future!
#immunotherapy #lag3 #immune2cancer $IMM $IMMP
LifeSci Advisors
@LifeSciAdvisors
Episode 43 of the Benchtop Bios Podcast featuring Marc Voigt, CEO of @Immutep who discusses how the first LAG-3-targeting drug's approval, and as of ASCO 2022, Immutep’s LAG-3 asset is poised to replace IO/chemo in the front-line setting for NSCLC. Listen: lifesci.events/IMMP2
-
Immutep
@Immutep
This special edition of @Immutep's newsletter provides a detailed outline of the key results from Part A of our Phase II TACTI-002 trial presented at the world’s biggest clinical cancer research conference, #asco22, and what comes next.
#lag3 $IMM $IMMP
www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
Watch the replay of @Immutep's global #asco22 webcast of its positive TACTI-002 results in lung cancer here.
ORR of 38.6% compares favourably to historical results from anti-PD-1 monotherapies (typically around 20%)
#lag3 #immune2cancer $IMM $IMMP
www.finnewsnetwork.com.au/MediaCenter/MediaCenterMobile.a… -
Immutep reposted
Siteman Cancer Center
@SitemanCenter
Yesterday, Dr. Adkins presented the phase IIb study of eftilagimod alpha & pembrolizumab as first-line treatment of patients w/ recurrent or metastatic head&neck squamous cell carcinoma poster at @ASCO. meetings.asco.org/2022-asco-annual-meeting/14376?presenta…
Congrats to all #asco22 poster presenters! @WUSTLmed -
Immutep
@Immutep
Immutep reports positive overall response rate in lung cancer trial
#lag3 #immune2cancer #asco22 #lcsm
biotechdispatch.com.au/news/immutep-reports-positive-over… -
Immutep reposted
Siteman Cancer Center
@SitemanCenter
Douglas Adkins, MD, presents a randomized phase IIb study of eftilagimod alpha & pembrolizumab as first-line treatment of patients w/ recurrent or metastatic head and neck squamous cell carcinoma poster (#78) at 1:15pm at McCormick Place in Hall A. #asco22 meetings.asco.org/2022-asco-annual-meeting/14376?presenta…
-
Immutep
@Immutep
@Immutep's TACTI-002 met its primary objective for 1st NSCLC patients in a PD-L1 all-comer trial. Data presented at #asco22 by Dr @EnriquetaFelip
Efti + pembro - ORR of 38.6%
Encouraging responses in all PD-L1 status groups
#lcsm #immune2cancer
www.immutep.com/files/content/investor/press-release/2022… -
Immutep reposted
Stephen V Liu, MD
@StephenVLiu
#asco22 mPFS 6.9m with 11.8m in PDL1 high and 4.2m in PDL1 negative. Interesting data, looking forward to larger and comparative studies.
-
Immutep reposted
Stephen V Liu, MD
@StephenVLiu
#asco22 RR ~ 40% here but need to look at PDL1 strata. In PDL1 high, RR 53% and in PDL1 negative, impressive RR 28%.
-
Immutep reposted
Stephen V Liu, MD
@StephenVLiu
#asco22 Included 114 pts with median f/u 11.2m, 70% PDL1 < 50%. About 10% stop due to TRAEs.
-
Immutep reposted
Stephen V Liu, MD
@StephenVLiu
#asco22 TACTI-002 is a multinational open label trial with 3 different potential indications. Here, Part A (n=114) which looks at efti + pembro as 1L therapy in NSCLC, no PDL1 selection. Primary endpoint RR by iRECIST (right endpoint / assumptions here?)
-
Immutep reposted
Stephen V Liu, MD
@StephenVLiu
Congratulations to Dr. @EnriquetaFelip! #asco22
-
Immutep reposted
James Flinn
@FlinnJP
The favourable activity was also coupled with a low patient discontinuation rate (< 10%).
$IMMP
James Flinn
@FlinnJP
The all-comer result is strong, although the TPS <1% and TPS 1-49% groups are where things are especially interesting - e.g for the TPS 1-49% group, the ORR reported today was 41.7% compared to ~17% for PD-1 monotherapy in historical studies.
Thus, ~2.5 fold better.
$IMMP
Sébastien Couraud 🫁🚭🌍
@s_couraud
Adding a LAG-3 protein in combination to Pembrolizumab in front-line of NSCLC (all PDL1): the TACTI-002 trial.
Safety profile concerning. Efficacy outcomes not exciting. In french we say: "bof".
#asco22 @OncoAlert -
Immutep reposted
Aakash Desai
@ADesaiMD
#asco22 @EnriquetaFelip presents Abs#9003 (TACTI-002) investigating eftilagimod alpha (soluble LAG-3 protein) and #pembrolizumab: Updated results from a PD-L1 unselected population in 1st Line #lcsm, encouraging results:
➡️ORR 37%, DCR: 73% 🚨
meetings.asco.org/abstracts-presentations/209503 @OncoAlert -
Immutep reposted
Laia Vilà
@_Vila_L
TACTI-002: a phase-2 study of Pembro+ Eftilagimod (LAG-3 inhib) for mNSCLC unselected PD-L1 (n=114) --> ORR 36.8% iRECIST ORR 42.7% DCR 73.7% mDOR NR ; mPFS 6.9 mo. 28.1% ORR in PD-L1 neg tumor #asco22 #lcsm
🧐We're proud to be part of that in @parctauli @JuliaGinerJ @I3ptT -
Immutep reposted
MEDSIR
@wearemedsir
Dr. Enriqueta Felip from @VHIO shares data showing efficacy in terms of ORR by irRECIST (38.6%)/RECIST (37.7%) and mPFS (6.9 months) along with a safe/tolerable profile of eftilagimod alpha as 1L regimen of mNSCLC irrespective of PD-L1
#asco22 -
Immutep reposted
Stephen V Liu, MD
@StephenVLiu
#asco22 Dr. @EnriquetaFelip presents phase II study of 1L eftilagimod alpha (soluble LAG-3 protein) + pembro in PDL1 unselected population. Efti (subcutaneous) activates APCs and leads to more activated T cells with synergy with PD-1 inhibition.
-
Immutep reposted
James Flinn
@FlinnJP
The all-comer result is strong, although the TPS <1% and TPS 1-49% groups are where things are especially interesting - e.g for the TPS 1-49% group, the ORR reported today was 41.7% compared to ~17% for PD-1 monotherapy in historical studies.
Thus, ~2.5 fold better.
$IMMP
Sébastien Couraud 🫁🚭🌍
@s_couraud
Adding a LAG-3 protein in combination to Pembrolizumab in front-line of NSCLC (all PDL1): the TACTI-002 trial.
Safety profile concerning. Efficacy outcomes not exciting. In french we say: "bof".
#asco22 @OncoAlert -
Immutep
@Immutep
Join us for a global webcast to discuss @Immutep's new data from 1st line NSCLC patients in the PhII TACTI-002 trial.
5pm CDT Mon 6 Jun/8am AEST Tues 7 Jun, after #asco22.
#lag3 #immune2cancer $IMM $IMMP
Register:us02web.zoom.us/webinar/register/3616539572927/WN_fAVtcc3… -
Immutep
@Immutep
Data from NSCLC patients in our TACTI-002 trial will be presented by @EnriquetaFelip in an Oral Presentation at #asco22.
Importantly, it will present data from all 114 patients with a more recent data cut off (than the abstract).
#lag3 #immunotherapy $IMM $IMMP
Aakash Desai
@ADesaiMD
@EnriquetaFelip will present at #asco22 Abs#9003 (TACTI-002) investigating eftilagimod alpha (soluble LAG-3 protein) and #pembrolizumab: Updated results from a PD-L1 unselected population in 1st Line #lcsm, encouraging results:
➡️ORR 37%, DCR: 73.3%
meetings.asco.org/abstracts-presentations/209503 -
Immutep reposted
Stephen V Liu, MD
@StephenVLiu
#asco22 Abstract #9003 looks intriguing. Eftilagimod alpha (soluble LAG-3 protein, subQ) plus pembro for 1L NSCLC showed RR 37% including 55% in PDL1 high and 27% in PDL1 negative NSCLC. Hope to see data on durability in oral presentation to be given by Dr. @EnriquetaFelip. #lcsm
-
Immutep reposted
Finance News Network
@Finnewsnetwork
Immutep (ASX:IMM) Presentation, FNN Investor Event, May 2022
www.finnewsnetwork.com.au/archives/finance_news_network38… -
Immutep
@Immutep
@Immutep announced new interim data from Part A of PhII TACTI-002 trial in 1st line NSCLC in an abstract at #asco22.
More recent data from all 114 patients will be announced in its Oral Presentation on 3 June.
#lungcancer #immunology #lag3
ASX: app.sharelinktechnologies.com/announcement/asx/815497295c… -
Immutep
@Immutep
Welcome to our new Clinical Advisory Board Members!
Scott Antonia, MD, PhD @DukeCancer Center for Cancer Immunotherapy
Leisha A Emens, MD, PhD @UPMC Hillman Cancer Center
Martin Forster, MD, PhD @ucl
Hans Wildiers, MD, PhD University Hospital Leuven, Belgium
$IMM $IMMP -
Immutep
@Immutep
@Immutep welcomes 4 leading oncologists to its Clinical Advisory Board
“The CAB’s experience in the development of ground-breaking new cancer therapies will be invaluable...” said CSO & CMO, Frederic Triebel
#lag3 $IMM $IMMP
ASX: app.sharelinktechnologies.com/announcement/asx/70b6097d27… -
Immutep reposted
James Flinn
@FlinnJP
The chemo-free combination therapy of efti and pembro produced an interim disease control rate of 36.1% in 2nd line NSCLC.
These are pts that had confirmed progressive disease (i.e. in effect, no disease control) after 1st line therapy with standard of care anti-PD-(L)1.
$IMMP
OncLive.com
@OncLive
According to the phase 2 TACTI-002 trial, eftilagimod alpha & pembro produced an encouraging early OS rate of 73% at the 6-month landmark when used as second-line treatment in pts w/ PD-1/PD-L1–refractory, metastatic NSCLC. @TheChristieNHS #lcsm #oncology www.onclive.com/view/second-line-eftilagimod-alpha-plus-p…
-
Immutep reposted
The Market Online AU
@marketonlineau
Immutep (ASX:IMM) has reported new biomarker and exploratory analysis data from its phase IIb AIPAC trial.
#themarketherald #news #asx
themarketherald.com.au/immutep-asximm-shares-positive-dat… -
Immutep
@Immutep
Today, @Immutep presented new and significant biomarker and exploratory analysis data from its Phase IIb AIPAC study in breast cancer at #esmobreast22.
Announcement: www.immutep.com/files/content/investor/press-release/2022…
Poster: www.immutep.com/files/content/investor/presentation/2022/…
#lag3 #immunotherapy #efti $IMM $IMMP -
Immutep
@Immutep
@Immutep's update on the ongoing development of efti and IMP761 for Q3 FY22 includes:
•New interim TACTI-002 data
•Constructive feedback from US FDA
•Distinguished Australian businesswoman, Lucy Turnbull AO, re-joins Board
ASX: app.sharelinktechnologies.com/announcement/asx/60bfd95c55…
#lag3 $IMM $IMMP -
Immutep
@Immutep
New interim data from 1st line NSCLC patients in @Immutep's PhII TACTI-002 trial has been selected for a prestigious Oral Presentation at #asco22 taking place in the US from 3-7 June.
#cancerresearch #immunotherapy #lag3
Read the full ASX announcement: www.immutep.com/files/content/investor/press-release/2022… -
Immutep reposted
James Flinn
@FlinnJP
@Immutep CEO Marc Voigt explains how the #biotech company is advancing eftilagimod alpha ("efti") as a promising new treatment option for patients with head & neck cancer - with Fast Track designation by the #fda.
#lag3 #cancers #cancerresearch
#asx #nasdaq $IMM $IMMP
Newswires
@newswiresau
$IMM How Immutep Treats Head & Neck Cancer (via ShareCafe) newswires.com.au/s/HTR #imm #immutep #asx #ausbiz #smallcaps #microcaps #ausstocks
-
Immutep reposted
Bell Potter
@Bell_Potter
Market Analyst Sophia Mavridis speaks with global biotechnology company @Immutep's (ASX:IMM) Executive Director and CEO Marc Voigt.
#investing #asx #ausbiz
www.youtube.com/watch?v=s-vaNPnNOuA -
Immutep
@Immutep
@Immutep CEO, Marc Voigt recently chatted with Naureen Quibria, PhD at the Maxim Group 2022 Growth Conference about LAG-3, giving an overview of the Company and its future plans.
#biotechnology #lag3 #growthstocks $IMM $IMMP
youtu.be/jYKMmtEBK2w via @YouTube -
Immutep reposted
Bell Direct
@belldirect
In our latest 'From the helm', Sophia Mavridis chats with @Immutep's Executive Director & CEO, Marc Voigt. Marc covers the impact of the FDA's recent feedback on its lead product, $IMM's collaborations, plus what's coming up for $IMM. #ausbiz #belldirect youtu.be/3ocb9Kb-7bI
-
Immutep reposted
Jean-Pierre Armand
@jpaArmand
LAG3 was discovered in 1990 by Frédéric Triebel (currently Chief Scientific Officer at Immutep) when he headed the cellular immunology group in the Department of Clinical Biology at the Institut Gustave Roussy. www.cancerresearch.org/en-us/blog/march-2022/fda-approves…
-
Immutep
@Immutep
In this 2nd video interview with @Finnewsnetwork, CEO Marc Voigt talks about @Immutep's recent encouraging interim results from TACTI-002 in second-line non-small cell #lungcancer patients.
#lag3 #immunotherapy $IMM $IMMP
youtu.be/ON0kISvnhuo via @YouTube -
Immutep reposted
OncLive.com
@OncLive
Second-Line Eftilagimod Alpha Plus Pembrolizumab Shows Promising Activity in Metastatic Lung Cancer @TheChristieNHS #lcsm #oncology www.onclive.com/view/second-line-eftilagimod-alpha-plus-p…
-
Immutep
@Immutep
@Immutep CEO Marc Voigt recently spoke with @Finnewsnetwork about its LAG-3-related therapies, outlining future plans and expected data readouts for our lead drug, efti. Enjoy the video.
#lag3 #immunotherapy #biotechnology
$IMM $IMMP
youtu.be/CWkRACOwBIY via @YouTube -
Immutep reposted
Finance News Network
@Finnewsnetwork
Immutep (ASX:IMM) announces encouraging trial data for lung cancer therapy
www.finnewsnetwork.com.au/archives/finance_news_network37… -
Immutep
@Immutep
@Immutep's efti in combination with MSD’s pembrolizumab is showing encouraging antitumor activity in difficult to treat 2nd line NSCLC patients in phII TACTI-002 trial interim data.
ESMO's ELCC 2022 Conference poster ASX: www.immutep.com/files/content/investor/press-release/2022…
#lag3 #lungcancer #biotechnology -
Immutep
@Immutep
@Immutep Prof Frederic Triebel talks to @DDWJournal about how the immunotherapy landscape has changed for the better since the importance of the LAG-3/MHC class II interaction was validated with the FDA's approval of the first LAG-3 drug.
#immunotherapy #fda #biotechnology #lag3
Drug Discovery World
@DDWJournal
DDW Deputy Editor Reece Armstrong speaks to Professor Frederic Triebel, CSO of Immutep about the approval of Bristol Myers Squibb’s LAG-3 antibody and why it’s causing so much excitement in the sector.
www.ddw-online.com/interview-what-an-fda-approval-means-f…
#immunotherapy -
Immutep
@Immutep
@Immutep has published new interim data from 2nd line NSCLC patients (Part B) of its phase II TACTI-002 trial in an abstract in advance of @myESMO ELCC 2022
#clinicaltrials #lag3
ASX: www.immutep.com/files/content/investor/press-release/2022… -
Immutep reposted
Nature Reviews Drug Discovery
@NatRevDrugDisc
FDA approves first-in-class immune checkpoint inhibitor targeting LAG3, for melanoma, in combination with PD1 inhibitor nivolumab bwnews.pr/3ueh9tM
For more on the history of targeting LAG3 and the future of the pipeline, here's a news article go.nature.com/3wkFUaE ICYMI -
Immutep
@Immutep
@Immutep will present biomarker and multivariate analysis data from its PhIIb AIPAC trial at @myESMO Breast Cancer Congress 2022 - onsite & virtual in Berlin, Germany on 3-5 May 2022
#breastcancer #clinicaltrials #lag3 $IMM $IMMP
www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
@Immutep has received constructive feedback from the US FDA regarding its clinical development program for efti in metastatic breast cancer.
Read the full ASX: www.immutep.com/files/content/investor/press-release/2022…
#lag3 #biotechnology $IMM $IMMP -
Immutep
@Immutep
Join CEO Marc Voigt for a fireside chat at the @MaximGrp 2022 Virtual Growth Conference on Monday 28 March 2022.
@Immutep will also deliver a corporate presentation at the conference.
#biotech $IMM $IMMP
Maxim Group LLC
@MaximGrp
RSVP now for our upcoming #2022virtualgrowthconference on March 28, 29, and 30
m-vest.com/events/2022-virtual-growth-conference
We will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.
#maximgroup -
Immutep
@Immutep
Speaking to @YolandaRedrup of @FinancialReview about rejoining the Board, @LucyTurnbull_AO talks about the exciting path ahead for @Immutep and what's needed to keep improving the diversity of corporate boards.
#biotechnology #boarddiversity
www.afr.com/companies/healthcare-and-fitness/why-immutep-… -
Immutep
@Immutep
@Immutep is pleased to welcome @LucyTurnbull_AO back to its Board as Non-executive Director.
Ms Turnbull is a distinguished Australian businesswoman, philanthropist and former local government politician.
ASX: www.immutep.com/files/content/investor/press-release/2022…
#biotechnology -
Immutep
@Immutep
We are pleased to share @Immutep's Half Year Report for FY22.
#immunotherapy #lag3 #biotechnology
Read the Report: www.immutep.com/files/content/investor/financial/Half-Yea… -
Immutep
@Immutep
@Immutep is pleased to share its latest Investor Update, including a Message from the CEO outlining the recent transformational period as Immutep moves ahead with late-stage trials and upcoming news flow.
#lag3 #immunotherapy #efti
Investor Update: www.immutep.com/files/content/investor/investor-update/20… -
Immutep
@Immutep
This review article in @NatRevDrugDisc highlights LAG-3's widespread recognition as the next promising immune checkpoint. LAG-3 was discovered back in the 1980s by @Immutep's CMO and CSO, Frédéric Triebel.
#lag3 #immunotherapy #cancer #drugdiscovery
www.nature.com/articles/d41573-022-00036-y -
Immutep reposted
Nature Reviews Drug Discovery
@NatRevDrugDisc
LAG3 pushes immuno-oncology’s leading edge go.nature.com/3GYk4vl BMS’s LAG3-targeted antibody relatlimab is poised to expand the checkpoint inhibitor class beyond PD1 and CTLA4. Find out about key issues for the pipeline of LAG3-based agents in this new article by @AsherMullard
-
Immutep
@Immutep
@Immutep will present new data from Part B of its PhII TACTI-002 trial of efti in combination with @Merck's Keytruda in 2nd line NSCLC at @myESMO's #elcc22.
Prague, Czech Republic 30 Mar - 2 Apr 2022 CEST
#immunotherapy #lag3
ASX: www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
@Immutep has been granted a new patent by the Australian Patent Office protecting #efti in combination with a PD-1 pathway inhibitor.
#intellectualproperty #lag3 #immunotherapy
ASX: www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
@Immutep is participating in the virtual 11th Annual SVB Leerink Global Healthcare Conference - 14-18 Feb
CEO Marc Voigt will hold 1-to-1 investor meetings & present at 3.40pm US ET on Fri, 18 Feb
Join the webcast: wsw.com/webcast/svbleerink67/register.aspx?conf=svbleerin…
$IMM $IMMP #biotech -
Immutep
@Immutep
Immutep is pleased to provide an update on the ongoing development of its product candidates, eftilagimod alpha (“efti”) and IMP761 for the second quarter of FY22 ended 31 December 2021.
See the full announcement for further information. www.immutep.com/files/content/investor/press-release/2022… -
Immutep
@Immutep
Last video from #sitc21, AIPAC PI, Dr Hans Wildiers of University Hospitals Leuven discusses the limited options for endocrine-refractory luminal metastatic #breastcancer patients & how efti may be a new effective strategy.
#lag3 #immunotherapy
www.youtube.com/watch?v=fzd4Fb8PflM -
Immutep
@Immutep
@Immutep is proud to be taking a leading role in the first ever LAG-3 Targeted Drug Development Summit next week.
Marc Voigt, CEO - Opening Remarks
Dr Frederic Triebel, CMO/CSO - My Journey Through the LAG-3/MHC Class II Landscape
#immunotherapy
lag3-drugdevelopment.com -
Immutep
@Immutep
In this next series of #sitc21 videos, AIPAC Principal Investigator, Dr Hans Wildiers MD PhD of Uni Hospitals Leuven explains the MoA of efti when used with chemotherapy in HR+ / HER2- metastatic breast cancer patients.
#lag3 #immunotherapy #oncology
www.youtube.com/watch?v=4fNSLXpchp4 -
Immutep
@Immutep
In video 2 of 2 from #sitc21, Dr Triebel discusses the recent clinical results from efti from our TACTI-002 PhII trial: a doubling of overall response rate in patients with 2nd line HNSCC, plus the trial design for TACTI-003.
#lag3 #efti $IMM $IMMP
www.youtube.com/watch?v=h2nD9lg7Fsw -
Immutep
@Immutep
Great to see newly validated immunotherapy target LAG-3 attracting increased interest from the medical and investment communities in recent days!
#lag3 #immunotherapy $IMM $IMMP
www.fool.com/investing/2022/01/09/3-big-fda-approvals-to-… -
Immutep
@Immutep
@Immutep's CSO & CMO, Dr Frederic Triebel was interviewed by @VJOncology following #sitc21
In this first video (1 of 2), Dr.Triebel discusses the final results from the Phase IIb AIPAC trial
#lag3 #efti $IMM $IMMP
youtu.be/V2xMet4QWpM
youtu.be/V2xMet4QWpM via @YouTube -
Immutep
@Immutep
Congratulations to Dr Hussein Tawbi & the #relativity047 team on their paper in #nejm!
LAG-3, discovered by @Immutep's Dr Frederic Triebel, promises to become the third pillar of immune checkpoint therapy & meaningfully improve patient outcomes.
www.nejm.org/doi/full/10.1056/NEJMoa2109970 -
Immutep
@Immutep
As we kick off 2022, CEO Marc Voigt talks to @sharecafetweets about the clinical momentum built in 2021 and how the company is moving into the new year.
#biotech #immunotherapy #lag3
www.sharecafe.com.au/2021/12/15/latest-from-immutep-asx-i… -
Immutep
@Immutep
@Immutep has appointed @NorthwayBiotech, an end-to-end biopharmaceutical contract development and manufacturing organisation, to manufacture IMP761 ahead of clinical testing.
#biotechnology #autoimmunedisease #lag3
ASX: www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
@Immutep's CSO & CMO and LAG-3 pioneer, Frederic Triebel discusses its potential in #immunotherapy.
$IMM #immp
BioSpace
@biospace
LAG-3 pioneer Frédéric Triebel discusses its potential in immunotherapy
#medicalpioneer #medicalnews
www.biospace.com/lag-3-pioneer-triebel-discusses-its-pote… -
Immutep reposted
James Flinn
@FlinnJP
A research report of interest entitled "Healthcare in 2022: The Top Six" by Shane Storey and Melissa Benson of WILSONS equities research!
Great to see Immutep Limited included in the list!
#biotech #healthcare #equityresearch #asx
$IMM $IMMP login.wilsonsadvisory.com.au/rsearch/Healthcare - 7 Decem… -
Immutep reposted
Christoph Zielinski
@cczielinski
The next development of immunotherapy of cancer beyond PD-(L)1 and CTLA-4 targeting?: Eftilagimod Alpha Plus Paclitaxel May Improve Survival in HR-Positive, HER2-Negative Metastatic Breast Cancer ascopost.com/news/december-2021/eftilagimod-alpha-plus-pa…
-
Immutep
@Immutep
@Immutep is pleased to see @Jefferies healthcare analyst Dr Dave Stanton MD, initiating research coverage of Immutep this week.
#healthcare #immunotherapy #lag3 -
Immutep reposted
OncLive.com
@OncLive
Patients with low monocytes who received eftilagimod alpha/paclitaxel had a median OS of 32.5 months vs 12.9 months for patients with low monocytes in the placebo group @HansWildiers @sitcancer #sitc21 #oncology #bcsm www.onclive.com/view/eftilagimod-alpha-paclitaxel-combo-s…
-
Immutep
@Immutep
@Immutep announces the first 5 patients have been treated in the INSIGHT-003 study.
The INSIGHT-003 study has commenced well. We are very pleased with the safety of the triple combination so far and all patients are still participating.
#lag3
ASX: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Immutep
@Immutep
For those following IMM's study in NSCLC, Cancer Network has published a good update article, including the completion of enrolment into our TACTI-002 trial.
#lag3 #clinicaltrials #lungcancer #oncology
www.cancernetwork.com/view/2021-pipeline-updates-upcoming… via @CancerNetwrk -
Immutep
@Immutep
@Immutep has enrolled the last patient in the expansion stage of Part A of its Phase II TACTI-002 study, completing recruitment into the entire trial.
#immunotherapy #lag3 #clinicaltrials
www.immutep.com/files/content/investor/press-release/2021… -
Immutep reposted
James Flinn
@FlinnJP
A very nice summary by Ariana Pelosci for those that follow Immutep Limited and developments in breast cancer clinical research.
#lag3 #immunotherapy #breastcancer $IMM $IMMP www.cancernetwork.com/view/eftilagimod-alpha-plus-paclita… -
Immutep reposted
LifeSci Advisors
@LifeSciAdvisors
Please join us for the @Immutep Webinar to Discuss Final Overall Survival Data Presentation from the AIPAC Study of Eftilagimod in Metastatic Breast Cancer at SITC 2021. A live Q&A session will follow. Register here: lifesci.events/IMMP
-
Immutep
@Immutep
@Immutep invites you to join a global webcast for investors to discuss the AIPAC final overall survival results and TACTI-002 Part C interim results.
You can join us at 8.00 am AEDT on Wednesday 17.11.2021 / 4.00 pm EST on Tuesday 16.11.2021.
fnn.webex.com/fnn/onstage/g.php?MTID=ef12af93633b5d17a2e4…
#lag3 -
Immutep
@Immutep
@Immutep’s is pleased to share new interim data from its ongoing Phase II TACTI-002 trial study. The data shows an encouraging Objective Response Rate of 29.7% for patients with 2nd line head and neck squamous cell carcinoma.
#immunotherapy #lag3
www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
@Immutep is excited to report an improved and statistically significant survival benefit from efti for three key metastatic breast cancer patient groups, in the final Phase IIb AIPAC study results released today at #sitc21.
#breastcancer #lag3
www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
Our CEO Marc Voigt had the pleasure of talking with Nadine Blayney about @Immutep as part of the @ASX and @ausbiztv's 'Biotech Unlocked' webinar for investors.
You can catch Marc's interview from 34 mins.
#lag3 #clinicalresearch #immunotherapy
www.bigmarker.com/ausbiz/Investor-Masterclass-Showcasing-… -
Immutep
@Immutep
@Immutep has been granted a new patent by the Chinese Patent Office. The #patent forms part of a broad and growing portfolio of patent families for the Company’s lead product candidiate efti in key global markets including China.
ASX: www.immutep.com/files/content/investor/press-release/2021…
#lag3 #immunotherapy -
Immutep
@Immutep
A productive week for the @Immutep team with a Regulatory Update just announced today (www.immutep.com/files/content/investor/press-release/2021…), the release of ASX and NASDAQ Annual Reports, AGM Notice & Q1FY22 Quarterly!
Also, CEO Marc Voigt presented at @AusBiotech’s #ausbioinv and attended #bioeurope21. -
Immutep
@Immutep
@Immutep provides an update on the ongoing development of its product candidates, #efti and IMP761, for Q1 FY22: www.immutep.com/files/content/investor/press-release/2021…
#biotechnology #lag3 #oncologyclinicalresearch -
Immutep
@Immutep
@Immutep invites shareholders to its AGM 2021 which will be held virtually at 10.00 am (AEDT) on Friday, 26 November 2021.
See our Notice of Meeting for further details: www.immutep.com/files/content/investor/investor-update/20…
#biotechnology #immunotherapy #lag3 -
Immutep
@Immutep
@Immutep is pleased to share its Annual Report for the 2021 financial year with shareholders. www.immutep.com/files/content/investor/financial/2021/Ann…
#lag3 #biotechnology #immunotherapy -
Immutep reposted
Newswires
@newswiresau
$IMM $TLX $IMU MoneyTalks: Here’s why this fund backs these 2 big ASX biotechs alongside Merck and Novavax (via Stockhead) newswires.com.au/s/E4C #imm #immutep #tlx #telixpharmaceuticals #imu #imugene #asx #ausbiz #smallcaps #microcaps #ausstocks
-
Immutep
@Immutep
Join us on Thursday, 4 November as @Immutep's Marc Voigt presents at 9.35am as part of the @ASX and @ausbiztv's 'Biotech Unlocked: Showcasing Australia's Next Investment Horizon' investor event.
#biotechnology #lag3 #immunotherapy $IMM $IMMP
ausbiz.com.au/events/2021-11-04-In+partnership+with+the+A… -
Immutep
@Immutep
Two analysts have newly initiated coverage of @Immutep:
CLSA has initiated with a BUY recommendation and A$1.19 target price @CLSAInsights
@CorporateConne3 initiated coverage with a A$2.20 target price
#healthcare #immunotherapy #lag3 -
Immutep
@Immutep
@Immutep CEO Marc Voigt will present at @AusBiotech's #ausbioinv on 26 October. We look forward to seeing you there, virtually!
#ausbio21 #lag3 #immunotherapy
www.ausbiotechinvestment.com.au/programme -
Immutep reposted
Newswires
@newswiresau
$IMM Immutep Taking the Fight to Cancer (via ShareCafe) newswires.com.au/s/DuY #imm #immutep #asx #ausbiz #smallcaps #microcaps #ausstocks
-
Immutep reposted
Corporate Connect Research
@CorporateConne3
Following on from his previous report on the company, Corporate Connect analyst Marc Sinatra has today published an updated analysis of ASX-listed biotech Immutep Ltd, valuing the company at $A2.20 per share. @Immutep www.corporateconnect.com.au/wp-content/uploads/2021/10/Im…
-
Immutep
@Immutep
@Immutep is pleased to announce data from Part C of PhII TACTI-002 & study design for PhIIb TACTI-003 will be presented at #sitc21.
ASX: www.immutep.com/files/content/investor/press-release/2021…
As previously announced, final OS data from PhIIb AIPAC trial will also be presented.
#immunotherapy #lag3 -
Immutep
@Immutep
We are delighted Frederic Triebel, @Immutep's CSO & CMO will present "My Journey Through the LAG-3/MHC Class II Landscape: 1988-2021" at the first ever LAG-3 Targeted Drug Development Summit in January 2022.
#immunotherapy #lag3
lag3-drugdevelopment.com -
Immutep
@Immutep
@Immutep has received a €2,126,617 (~ A$3,430,952) R&D tax incentive payment in cash from the French Government.
The funds will be used to support the global clinical development of efti and the preclinical development of IMP761.
#biotech #lag3
www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
@Immutep is delighted to kick off the week attending the 2021 Cantor Fitzgerald Global Healthcare Conference which is taking place virtually from 27-30 September 2021.
#cantorhealthcare2021 #biotechnology
www.cantor.com/global-healthcare-2021/ -
Immutep
@Immutep
Dr Irene Brana of Vall d’Hebron University Hospital, Spain discusses @Immutep's updated TACTI-002 efficacy results from efti & pembrolizumab in patients 2nd line head and neck carcinoma.
The interview was published by @VJOncology as part of #asco21.
www.vjoncology.com/video/_2j1ylz25dw-eftilagimod-alpha-an… -
Immutep reposted
Kalkine Media Australia
@kalkineau
Top 5 #asx-listed #cancerstocks
#healthcare #stockmarket $IMU $PTX $IMM $PXS $KZA
kalkinemedia.com/au/stocks/healthcare/five-asx-listed-can… -
Immutep
@Immutep
@Immutep will report final Overall Survival data from its Phase IIb AIPAC trial of efti in breast cancer at #sitc21 10-14 November 2021 and will host a global webinar for investors after the conference.
#immunotherapy #breastcancer #lag3
www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
If you missed Marc Voigt at the @ASX Conference last week, you can watch his presentation here.
#immunotherapy #lag3
youtu.be/HYnNTqRDFYQ?list=PLUm38kI3ZeYtXzRNVAWBBwI16GI_JdKaQ -
Immutep
@Immutep
@Immutep is participating in the virtual #esmo21 Congress which kicks off today with a line-up of posters and presentations from our partners, Novartis and IKF, and other key players in the LAG-3 space, including @bmsnews.
#lag3 #immunotherapy
oncologypro.esmo.org/meeting-resources/esmo-congress-2021… -
Immutep
@Immutep
CEO Marc Voigt participated in the @ASX Small and Mid-Cap conference this week, providing an overview of the Company's product portfolio and recent progress.
Watch the video below for a quick snapshot.
#biotech #immunotherapy #lag3
youtu.be/iuHdGGwqedc?t=15 -
Immutep
@Immutep
Join us today at 3pm (AEST) to hear @Immutep CEO Marc Voigt present at the @ASX Small and Mid-Cap Conference. You can register via the link below.
www2.asx.com.au/investors/investment-tools-and-resources/… -
Immutep
@Immutep
Fund manager James McDonald talks about the Pengana High Conviction Equities Fund and its investment in @Immutep
#biotech $IMM $IMMP
youtu.be/zpXrRq0Amok -
Immutep
@Immutep
@Immutep reports the last NSCLC patient has been enrolled in Part B of its Phase II TACTI-002 study (also designated KEYNOTE-798).
ASX: www.immutep.com/files/content/investor/press-release/2021…
Further data from TACTI-002 expected in calendar year 2021 or early calendar year 2022.
#immunotherapy #efti #lag3 -
Immutep
@Immutep
@Immutep 2021 Full Year Accounts provides a summary of activities and an update: announcements.asx.com.au/asxpdf/20210830/pdf/44zy9kjl9f3c…
Chairman Dr. Russell Howard said: "Immutep is transforming into a late-stage biotech as it continues to progress efti towards the path to registration... -
Immutep
@Immutep
Dr Frederic Triebel shares his story of discovering LAG-3 in @LifeSciAdvisors latest Benchtop Bios podcast by Neil Canavan
#lag3 #podcast #immunotherapy $IMM
LifeSci Advisors
@LifeSciAdvisors
Tune in to Ep. #12 of the LifeSci Partners Benchtop Bios Podcast, featuring Dr. Frederic Triebel, Founder and CSO/CMO of Immutep, who explains how his discovery – the checkpoint molecule called LAG-3 – is finally ready to reach for the stars. Listen here: lifesci.events/BBli
-
Immutep reposted
LifeSci Advisors
@LifeSciAdvisors
Tune in to Ep. #12 of the LifeSci Partners Benchtop Bios Podcast, featuring Dr. Frederic Triebel, Founder and CSO/CMO of Immutep, who explains how his discovery – the checkpoint molecule called LAG-3 – is finally ready to reach for the stars. Listen here: lifesci.events/BBli
-
Immutep
@Immutep
@Immutep congratulates its Chinese partner for efti, EOC Pharma, which has announced plans to advance efti's development (EOC202 in China) with world-class contract development and manufacturing organisation, Chime Biologics
www.contractpharma.com/contents/view_breaking-news/2021-0…
#lag3 #immunotherapy -
Immutep
@Immutep
@Immutep announces the grant of a new patent for LAG525 (out-licensed to @Novartis) by the Chinese Patent Office.
ASX: www.immutep.com/files/content/investor/press-release/2021…
#intellectualproperty #lag3 #patents -
Immutep reposted
Bell Direct
@belldirect
In our latest 'From the helm', @JessicaDAmir chats with
@Immutep's Marc Voigt. He discusses promising results from an $IMM study in collaboration with @Pfizer and @Merck; its unique discovery in immunotherapy; as well as key catalysts that could drive share price growth. #ausbiz -
Immutep
@Immutep
@Immutep reports the first patient in the new INSIGHT-003 study evaluating efti as part of a triple combination therapy has been safely dosed.
First results are expected in calendar year 2022.
#clinicaltrials #efti #biotech #immunotherapy
ASX: www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
Marc Voigt presented an overview of @Immutep's recent progress at the @LadenburgLTS Healthcare Conference 2021 last week, as it continues to evolve into a late-stage #biotech at the forefront of the LAG-3 #immunotherapy space.
Webinar: wsw.com/webcast/ladenburg7/register.aspx?conf=ladenburg7&…
#lag3 -
Immutep
@Immutep
@Immutep has completed all the necessary steps with the US FDA to commence its phase IIb TACTI-003 trial in the United States.
Patient recruitment for the TACTI-003 trial is expected to begin within this quarter.
ASX: www.immutep.com/files/content/investor/press-release/2021…
#clinicaltrials #immunotherapy -
Immutep
@Immutep
Following a busy week with the announcement of @Immutep's $60m placement, CEO Marc Voigt spoke with @themarketherald about the opportunity the new funding opens up to initiate late-stage clinical trials for #efti.
#biotechnology #immunotherapy
themarketherald.com.au/immutep-asximm-to-begin-efti-trial… -
Immutep
@Immutep
@Immutep is featured as one of 'Three stock picks with an ethical twist' by @austethical's Andy Gracey, following our recently announced $60m capital raise and plans to expand our trial pipeline with new late-stage trials
#immunotherapy
www.ausbiz.com.au/media/three-stock-picks-with-an-ethical… -
Immutep
@Immutep
@Immutep's Marc Voigt caught up with @AlanKohler of @eurekareport to talk about $IMM's plans & recent encouraging clinical results from efti.
$IMMP #immunotherapy #efti #lag3
omny.fm/shows/ceo-interviews/marc-voigt-immutep -
Immutep
@Immutep
Today, and everyday, the team at @Immutep supports #immune2cancer!
#immunotherapy #cancerresearch -
Immutep
@Immutep
@Immutep has revealed a new anti-LAG-3 research program in collaboration with @cardiffuni to advance a new generation of small molecule anti-LAG-3 therapies as oral treatments for cancer patients at a lower cost.
ASX announcement: www.immutep.com/files/content/investor/press-release/2021…
#lag3 #immunotherapy -
Immutep
@Immutep
@Immutep CEO Marc Voigt caught up with @YolandaRedrup at the @FinancialReview to talk about the Company's very encouraging clinical results from its trials of lead product candidate, efti.
#lag3 #efti #immunotherapy @austethical Firetrail Investments
www.afr.com/technology/investors-buoyed-by-positive-data-… -
Immutep
@Immutep
@Immutep invites investors to a global webcast to discuss the new data from its TACTI-002 Phase II and INSIGHT Phase I clinical trials, as reported at #asco21.
Thurs 10 June 21 @ 7am AEDT / Wed 9 June 21 @ 5pm US ET
Register here: fnn.webex.com/fnn/onstage/g.php?MTID=ebcdb72840d84111e577…
#lag3 #immunotherapy -
Immutep
@Immutep
@Immutep's INSIGHT-004 Phase I Final Results reported at #asco21: Encouraging activity signals from the combination of efti & avelumab with a response rate of 41.7% in different solid tumours.
ASX: www.immutep.com/files/content/investor/press-release/2021…
#lag3 #biotech #immunotherapy $IMM $IMMP #oncology -
Immutep
@Immutep
@immutep's TACTI-002 Phase II Interim Results reported at #asco21: Combination therapy of efti & pembrolizumab demonstrates v favourable overall response rate & favourable duration & depth of responses in 1st line NSCLC patients and 2nd line HNSCC.
ASX:www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
@Immutep has been granted a new patent by the European Patent Office protecting its intellectual property relating to combined therapeutic preparations comprising efti and a PD-1 or PD-L1 inhibitor.
#patents #efti #lag3
ASX: www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
@Immutep enters a new #collaboration with @merckgroup for a PhI/IIa trial in 12 patients with solid tumours, called INSIGHT-005.
Evaluates #efti with bintrafusp alfa.
First patient to be enrolled & dosed in H2 CY 2021
ASX: www.immutep.com/files/content/investor/press-release/2021…
#immunooncology #lag3 -
Immutep
@Immutep
@Immutep has been granted a new patent by the Chinese Patent Office protecting its intellectual property relating to combination therapy comprising efti and a chemotherapy agent.
#patents #biotech #immunotherapy #lag3 #efti
www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
@Immutep CEO Marc Voigt will present at the Jefferies Virtual Healthcare Conference at 12:30 pm US ET on June 4th.
Join the live webcast of this event: wsw.com/webcast/jeff174/register.aspx?conf=jeff174&page=i…
#biotech #lag3 #immunotherapy -
Immutep
@Immutep
@Immutep is presenting new data in 3 posters at this year's ASCO. #checkpoint
LAG3 to steal the spotlight from TIGIT at ASCO21 www.biocentury.com/article/636492/lag3-to-steal-the-spotl… -
Immutep
@Immutep
Highly anticipated ph3 data from @bmsnews showing relatlimab (anti-LAG-3 antibody) with Opdivo is safely helping melanoma patients live significantly longer without disease progression.
#lag3 now represents an important new immunotherapy target.
#asco21
Bristol Myers Squibb
@bmsnews
#media: Announcing new data for a BMS LAG-3-blocking antibody combination for the treatment of previously untreated unresectable or metastatic #melanoma. #asco21 news.bms.com/news/corporate-financial/2021/Bristol-Myers-…
-
Immutep reposted
Seeking Alpha
@SeekingAlpha
$IMMP - Immutep - Relatively Unknown Pure Play On LAG3 Surrounded By Major Pharma; Positioned Well For Large Biobucks Deal Or Takeout. seekingalpha.com/article/4429440-immutep-relatively-unkno… #business #economy #trading
-
Immutep
@Immutep
Did you know #lag3 can be leveraged through two modes of action?
Efti sits on its own as an MHC II agonist, a molecule that binds to a receptor and activates it to produce an immune response.
See our Mode of Action video for efti youtu.be/6EISCGYAGQw via @YouTube -
Immutep
@Immutep
@Immutep today provides an update, including:
· AIPAC reaches ~72% of events
· TACTI-003 clinical trial design announced
· Robust financial position with cash runway into calendar year 2023
ASX announcement: www.immutep.com/files/content/investor/press-release/2021…
#immunotherapy -
Immutep
@Immutep
From an industry perspective, @bmsnews's validation of LAG-3 as the next emerging immunotherapy target was a very significant moment.
In a landscape where @Immutep remains the only LAG-3 pure-play - this was very exciting news.
Read more: www.immutep.com/files/content/investor/investor-update/20…
#lag3 -
Immutep
@Immutep
@Immutep's CSO & CMO and LAG-3 pioneer, Dr Frederic Triebel, recently spoke with Mark Zipkin of labiotech.eu to talk about the emerging LAG-3 immune checkpoint.
IMM and BMS are set to present at #asco21
#lag3 #immunotherapy #cancer #biotech
www.labiotech.eu/trends-news/immune-checkpoint-inhibitor-… -
Immutep
@Immutep
@Immutep will announce new data from its TACTI-002 and INSIGHT-004 studies in 3 posters at #asco21.
Immutep will also hold a webcast after ASCO to discuss the data.
Poster details: www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
@Immutep shares its Quarterly Report for Q3 FY21: www.immutep.com/files/content/investor/press-release/2021…
It has also received a A$1.15m cash rebate from the Australian Government’s R&D tax incentive program.
“We are well-positioned for long-term success," said CEO Marc Voigt
#immunotherapy #biotech -
Immutep
@Immutep
Immutep has received Fast Track designation from the US FDA for its lead product candidate efti, a soluble LAG-3 protein, in 1st line recurrent or metastatic head and neck cancer.
Full announcement - www.immutep.com/files/content/investor/press-release/2021…
$IMM -
Immutep
@Immutep
A great article on Immutep following Marc Voigt’s presentation at the Benzinga Biotech Small-Cap Conference. #immunotherapy #lag3
finance.yahoo.com/news/biotech-immunotherapy-company-immu… via @Yahoo -
Immutep
@Immutep
Marc Voigt caught up with @ausbiztv to dive deeper into @bmsnews's recent news and what it means for @Immutep's lead product candidate, efti.
#immunotherapy #lag3
Watch the interview: ausbiz.com.au/media/announcement-of-trial-drug-good-news-… -
Immutep
@Immutep
Congratulations @bmsnews! Its ph3 trial of relatlimab, an anti-LAG-3 antibody, & Opdivo in #melanoma met its primary endpoint of progression-free survival.
Brings further validation of #lag3 as the next immune checkpoint therapy. #immunotherapy
Bristol Myers Squibb
@bmsnews
#media: Announcing results from our trial evaluating new immunotherapy combination for patients with previously untreated #metastatic or #unresectable #melanoma. news.bms.com/news/corporate-financial/2021/Bristol-Myers-…
-
Immutep
@Immutep
Marc Voigt talks to @ausbiztv about its second collaboration with @Merck and new Phase IIb called TACTI-003, to evaluate efti in combination with KEYTRUDA in 1st line head and neck squamous cell carcinoma.
#immunotherapy
(A... youtu.be/yawvX3BX4S0 via @YouTube -
Immutep
@Immutep
@Immutep CEO Marc Voigt spoke with @FinancialReview's @YolandaRedrup about its second collaboration agreement with @Merck for a new Phase II clinical trial in head and neck cancer.
#biotechnology #immunotherapy #clinicaltrials
www.afr.com/companies/healthcare-and-fitness/small-cap-bi… -
Immutep
@Immutep
@Immutep enters into 2nd collaboration with @Merck to conduct a new Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line HNSCC.
#collaborations #immunotherapy
ASX: www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
@Immutep has secured a 2nd US patent for efti in combination with a PD-1 inhibitor.
“We are very pleased to add another US patent because of its direct relevance to our clinical development programs.
#immunotherapy
ASX: www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
@Immutep has expanded Part B of its TACTI-002 Phase II study following a positive efficacy and safety review.
It has commenced the recruitment of an additional 13 second line NSCLC patients, forming Stage 2 of Part B.
#oncologytrials
ASX: www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
@Immutep shares its HY Report FY21: announcements.asx.com.au/asxpdf/20210223/pdf/44sytvpn9s6r…
Following the encouraging clinical results for efti, Immutep is in a very robust financial & operational position.
•increasing confidence in efti
•scaling up efti manufacturing
•advancing business development -
Immutep
@Immutep
Marc Voigt, CEO of @Immutep speaks with @Finnewsnetwork to provide an update on recent Immutep activity.
#biotechnology #immunotherapy $IMM youtu.be/rxsm48Gq4LQ via @YouTube -
Immutep
@Immutep
@Immutep is advancing to the randomised portion of its phase II EAT COVID (investigator-initiated) trial in up to 110 COVID-19 patients in the Czech Republic, following independently reviewed safety run-in data.
#covid19 #biotechnology
ASX: www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
@Immutep has completed the recruitment of Head and Neck Cancer Patients for its Phase II TACTI-002 study
Also, the recruitment of an additional 74 patients with 1st line NSCLC has commenced with 4 patients newly recruited
#biotech #clinicaltrials
www.immutep.com/files/content/investor/press-release/2021… -
Immutep
@Immutep
@Immutep continues to strengthen its intellectual property for efti, with a new US patent protecting it for combined preparations with a PD-1 pathway inhibitor, such as pembrolizumab or nivolumab.
#patents #intellectualproperty
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
@Immutep CEO Marc Voigt recently caught up with @sharecafetweets to provide an update on its encouraging results for efti and multiple catalysts for ahead for the early part of 2021.
#biotechnology #clinicaltrials
www.sharecafe.com.au/2020/12/17/immutep-fighting-the-good… -
Immutep
@Immutep
@Immutep is scaling up the manufacturing of its lead product candidate eftilagimod alpha.
Follows very encouraging interim results from efti clinical trials.
To be funded by the recent conversion of warrants providing an additional US$7.7m.
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
@Immutep's Chinese Partner EOC Pharma will start a new Phase II clinical trial of efti in patients with metastatic #breastcancer in Q1 CY2021.
#pharma #biotechnology #oncology
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
"The [AIPAC] Overall Survival data in subgroups such as those below age 65 years are highly encouraging and may lead to more effective treatment options for metastatic breast cancer patients” - AIPAC PI, Hans Wildiers of University Hospital Leuven
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep reposted
James Flinn
@FlinnJP
Very encouraging updates from Immutep Limited's Phase IIb AIPAC trial in metastatic breast cancer and a new Phase II trial in China in conjunction with licensee, EOC Pharma.
#biotech #immunotherapy #breastcancer biotechdispatch.com.au/news/immutep-updates-on-aipac-brea… -
Immutep
@Immutep
@Immutep has reported a statistically significant survival benefit for key patient groups in the ongoing PhIIb AIPAC study in #breastcancer.
Plus., Chinese Partner, EOC Pharma, will start a PhII #clinicaltrial in breast cancer.
Read the announcements: www.immutep.com -
Immutep
@Immutep
Speaking to @Finnewsnetwork, @Immutep (ASX:IMM), CEO Marc Voigt discusses the Company's recent encouraging clinical results for efti, along with what's coming up.
#biotechnology #clinicaltrials #oncology
youtu.be/Q9EyWkFWPqo via @YouTube -
Immutep
@Immutep
@Immutep CEO Marc Voigt recently spoke with @themarketherald about the busy period ahead in December 2020 and into 2021.
$IMM #biotechnology #cancer #capitalraising
themarketherald.com.au/immutep-asximm-pockets-nearly-30m-… -
Immutep
@Immutep
The results of @Immutep's Phase I TACTI-mel trial were recently published in the Journal for ImmunoTherapy of Cancer.
Provides a good discussion on how efti differs from a classical blocking antibody.
#biotech #melanoma #immunotherapy
jitc.bmj.com/content/jitc/8/2/e001681.full.pdf -
Immutep
@Immutep
@Immutep announces a $29.6m Placement, plus expansion of ongoing TACTI-002 phII trial & new phII trial.
@austethical, Perennial, Regal, Firetrail, & US-based, Ridgeback Capital were all leading participants.
ASX: www.immutep.com/files/content/investor/press-release/2020…
#biotechnology #investment -
Immutep
@Immutep
@Immutep has reported encouraging new interim data from its ongoing Phase II TACTI-002 study evaluating the combination of efti with @Merck’s KEYTRUDA® at #sitc20.
ASX: www.immutep.com/files/content/investor/press-release/2020…
#biotechnology #immunotherapy -
Immutep
@Immutep
@Immutep & its partner, @Novartis, have been granted a new patent by the Australian Patent Office for LAG525, a humanised form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG.
ASX: www.immutep.com/files/content/investor/press-release/2020…
#intellectualproperty #patents #ip -
Immutep
@Immutep
@Immutep will report more mature interim data from its phase II TACTI-002 study of efti at #sitc20
Poster presentation available: Mon 9 Nov 2020, 8am US EST.
ASX: www.immutep.com/files/content/investor/press-release/2020…
#cancer #immunotherapy -
Immutep
@Immutep
@Immutep has entered into a Licence & Collaboration Agreement @LabCorp (NYSE: LH) for the development of immuno-oncology products or services.
Upfront fee of US$125,000 and potential further commercial milestones and service payments.
ASX: cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research… -
Immutep
@Immutep
Thank you to all our shareholders who joined our virtual AGM 2020 today.
If you missed the meeting, you can read the Chairman's Address here: www.immutep.com/files/content/investor/press-release/2020… and the CEO Presentation here: www.immutep.com/files/content/investor/press-release/2020….
#biotechnology -
Immutep
@Immutep
@Immutep CEO Marc Voigt spoke with Stockhead about the newly announced EAT COVID trial.
stockhead.com.au/health/czech-hospital-begins-covid-study… -
Immutep
@Immutep
@Immutep has signed an agreement with University Hospital Pilsen, Czech Republic to enable a PhII clinical trial of efti in up to 110 COVID-19 patients.
Initial interim results expected: early 2021.
ASX: www.immutep.com/files/content/investor/press-release/2020…
#coronavirus #covid19 #biotechnology -
Immutep
@Immutep
@Immutep provides its Quarterly Report & 4C:
* Encouraging clinical results from TACTI-002 and INSIGHT-004 trials of efti
* Completes recruitment for Stage 1 of Part B in TACTI-002
* US patent grants relating to efti & LAG525
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
Interim Overall Survival results from @Immutep's Phase IIb AIPAC study has been selected to be presented in a spotlight presentation at #sabcs20 on Fri 11 Dec 20 CST / Sat 12 Dec 20 AEDT.
#breastcancer #immunotherapy #biotechnology
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
@Immutep's partner IKF presented data from ph I, INSIGHT and INSIGHT-004 trials of efti at #dgho, the annual meeting of the German, Swiss and Austrian Societies of haematology and medical oncology.
Data is in ESMO posters: www.immutep.com/investors-media/presentations.html -
Immutep
@Immutep
@Immutep has published its Annual Report 2020: www.immutep.com/files/content/investor/financial/AnnualRe…
"Results from multiple trials of efti will be reported throughout the coming financial year, which could further expand the intrinsic value of this promising asset," said Chairman Russell Howard. -
Immutep
@Immutep
@Immutep is pleased to invite shareholders to its 2020 AGM at 10:30 am (AEDT) on Tuesday, 27th October 2020.
Due to the COVID-19 pandemic and related issues, the AGM will be held virtually this year.
Read the AGM Notice of Meeting: www.immutep.com/files/content/investor/financial/AGM_Noti…
#biotechnology -
Immutep
@Immutep
@Immutep CEO Marc Voigt spoke with @ausbiztv this week about the recent encouraging clinical trial results for efti reported at #esmo20.
Visit Ausbiz to watch the video.
#biotechnology #immunotherapy
www.ausbiz.com.au/media/immutep-surges-after-two-cancer-d… -
Immutep
@Immutep
Australian broker Bell Potter Securities has initiated research on @Immutep with a speculative BUY recommendation.
#biotechnology -
Immutep
@Immutep
@Immutep presented new & improving interim data at #esmo20.
TACTI-002 ph II: 3 complete responses (complete disappearance of lesions): www.immutep.com/files/content/investor/press-release/2020…
INSIGHT-004 ph I: encouraging early anti-tumour activity signals: www.immutep.com/files/content/investor/press-release/2020…
#immunotherapy $IMM -
Immutep
@Immutep
Presenting at the @ASX Small and Mid-Cap Virtual Conference recently, @Immutep CEO Marc Voigt talks the encouraging clinical results from efti and gives an outline of the milestones ahead.
#biotechnology #asx #immunotherapy
youtu.be/EixXahNJjwg via @YouTube -
Immutep
@Immutep
@Immutep CEO Marc Voigt recently spoke with @180Markets about our LAG-3 therapeutics and corporate strategy to develop efti for cancer patients.
#oncology #biotech #asx #equities
youtu.be/_tx2e2JuQ2U via @YouTube -
Immutep
@Immutep
@Immutep will present new efti data in 4 poster presentations at #esmo20 from 19-21 Sept 20 CEST.
Data is from Immutep’s phase II TACTI-002 & the investigator-initiated phase I clinical trial, INSIGHT & INSIGHT-004.
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
@Immutep is pleased to report it has enrolled and safely dosed the last patient for stage 1 of Part B of its TACTI-002 Phase II study, completing recruitment of stage 1 of Part B.
#immunooncology #biotechnology $IMM
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
@Immutep is pleased to provide its August 2020 Investor Update for shareholders: www.immutep.com/files/content/investor/investor-update/20…
In this issue:
•Message from the CEO
•Industry conferences & poster presentations
•Operational snapshot
•Outlook
#biotechnology #immunotherapy -
Immutep
@Immutep
@Immutep CEO Marc Voigt spoke with @sharecafetweets about the recent interest in IMM's Nasdaq stock and its encouraging results from efti in TACTI-002.
www.sharecafe.com.au/2020/08/12/investors-are-listening-a… -
Immutep
@Immutep
@Immutep granted a new patent by the US Patent Office protecting its IP for its lead candidate efti in combination with a chemotherapy agent.
ASX: www.immutep.com/files/content/investor/press-release/2020…
#biotechnology #intellectualproperty #patents #immunotherapy -
Immutep
@Immutep
@Immutep today lodged its Quarterly Report and provided an update on the ongoing development of its product candidates, efti & IMP761, its partners, and the minimal impacts to the business from the COVID-19 pandemic.
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
@Immutep announces a new patent has been granted by the United States Patent and Trade Mark Office directed to embodiments of LAG525, a humanised form of Immutep’s IMP701 antibody which is out-licensed to @Novartis AG.
ASX: www.immutep.com/files/content/investor/press-release/2020…
#immunotherapy #biotechnology -
Immutep
@Immutep
@Immutep has enrolled & safely dosed the last patient for stage 2 of Part A (1st line NSCLC) of its TACTI-002 Phase II study, completing recruitment for Part A.
Further interim data throughout CY20.
#immunotherapy #biotechnology
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
@Immutep CEO Marc Voigt spoke this week with the @Finnewsnetwork about the Company's recent clinical results and leadership in the LAG-3 immunotherapy space.
Watch the video below. #biotechnology
youtu.be/CBMu5ZpqWZA via @YouTube -
Immutep
@Immutep
@Immutep's partner, CYTLIMIC presented interim results from its Phase I YCP02 study at #aacr20
Tumor cell death & infiltration of T cells into tumor regions reported in 6/9 patients treated with CYT001, a peptide vaccine including Immutep's efti.
More: www.cytlimic.com/news/20200622_en.html -
Immutep
@Immutep
@Immutep has received a A$1.4m payment from the Australian Federal Government’s R&D tax incentive program.
Immutep will apply the funding towards its current active clinical trial programs for efti.
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
Today's Australian Financial Review:
"Mr Gracey said Australian Ethical was also invested in ..... @Immutep, .... which raised $12 million in late April and is expected to release data for phase two of its immunotherapy clinical trial this year and next."
www.afr.com/companies/healthcare-and-fitness/momentum-bui… -
Immutep
@Immutep
@Immutep announced at #asco20 the first interim data from its ongoing INSIGHT-004 Ph1 trial: Encouraging early activity signals.
Overall, 33% of patients showed a Partial Response
Collaboration with @merckgroup and @pfizer and sponsor, IKF
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
@Immutep: new interim data at #asco20 from Ph2 TACTI-002 #cancer study:
•First complete response in 2nd line HNSCC
•Improving Overall Response Rate in HNSCC: 38.9% from 33%
•Progression free survival in NSCLC patients: more than 9 months
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
@Immutep has received a €2,173,454 (~ A$3,630,000) R&D tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme.
ASX: www.immutep.com/files/content/investor/press-release/2020…
#biotechnology -
Immutep
@Immutep
Join us for a global webcast with analyst Q&A to discuss new clinical data from our ongoing Phase II TACTI-002 study and the first interim data from our ongoing INSIGHT-004 Phase I clinical trial at #asco20.
Register for the webcast: fnn.webex.com/mw3300/mywebex/default.do?nomenu=true&siteu…
#biotechnology -
Immutep
@Immutep
If you missed CEO Marc Voigt's recent corporate presentation at the NWR Virtual Small Cap Health Conference, you can watch the replay here.
Watch the Replay: us02web.zoom.us/webinar/register/rec/WN_fHBmdyNGRmi6plW2g…
#biotech #immunotherapy -
Immutep
@Immutep
@Immutep invites you to join a corporate presentation by CEO, Marc Voigt at the NWR Virtual Small Cap Health Conference on Monday 4 May 2020 at 2.50 pm AEST.
The event is free and investors can register online to attend via the link below.
Register: us02web.zoom.us/webinar/register/WN_fHBmdyNGRmi6plW2gsnDjw -
Immutep
@Immutep
@Immutep will announce first INSIGHT-004 data and new TACTI-002 data in two poster presentations during #asco20, a leading global scientific meeting for oncology professionals (29 May – 31 May)
Data to also be available at www.immutep.com
ASX: www.immutep.com/files/content/investor/press-release/2020… -
Immutep
@Immutep
@Immutep is pleased to share further positive interim data from its ongoing Phase II TACTI-002 study, showing improving efficacy results.
53% of NSCLC Lung Cancer patients are now responding and we expect PFS to be more than 9 months.
ASX: www.immutep.com/files/content/investor/press-release/2020…
#biotech -
Immutep
@Immutep
The last patient has been enrolled & safely dosed in the INSIGHT-004 PhI clinical trial, completing enrollment.
Investigator: IKF, Germany
Collaborators: @merckgroup, Germany & @pfizer
Initial results: Second quarter of 2020
ASX: www.immutep.com/files/content/investor/press-release/2020…
#biotech -
Immutep
@Immutep
@Immutep lodges its Quarterly Report Q3FY20
Highlights:
Highly encouraging data from efti in TACTI-002 study
AIPAC Phase IIb study reported first results
Limited impact from COVID-19 to date
Further significant data to be reported 2020
#biotech
ASX: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep has advanced its LAG-3 agonist for #autoimmunediseases, IMP761
Manufacturing partner, @Batavia_Bio developed a pharmaceutical-grade, cell line with significantly high product yields
Next: preparations for GMP compliance, clinical testing
ASX: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep's interim Ph II TACTI-002 data has been selected for a poster short talk presentation as part of the high-impact paper presentation program @AACR Virtual Annual Meeting, 27 and 28 April 2020.
Abstract title: www.abstractsonline.com/pp8/
#biotech #immunooncology -
Immutep
@Immutep
@Immutep's Chinese partner, EOC Pharma, has confirmed its plans to continue advancing efti in metastatic breast cancer, following its analysis of PFS data, including subgroup analysis, from Immutep's AIPAC study.
ASX: www.immutep.com/files/content/investor/press-release/2019…
#breastcancer #biotech -
Immutep
@Immutep
@Immutep's partner, CYTLIMIC announced positive results from its YNP01 ph I study, testing efti as part of a vaccine.
Approx 70% of patients showed an immune response to each protein.
Published: Cancer Immunology, Immunotherapy: idp.springer.com/transit?redirect_uri=https%3A%2F%2Flink.…
#immunotherapy -
Immutep
@Immutep
If you missed @Immutep's webcast exploring the recent AIPAC study data, you can listen to the replay by following the link: viavid.webcasts.com/starthere.jsp?ei=1293523&tp_key=935ff…
#biotech #breastcancer -
Immutep
@Immutep
@Immutep will hold a global webcast to discuss the AIPAC study results and their meaning for patients, the Company and shareholders.
Time & date: 8am AEDT, Thursday 26 March / 5pm US EDT, Wednesday 25 March
Please register via: viavid.webcasts.com/starthere.jsp?ei=1293523&tp_key=935ff…
#biotech #breastcancer -
Immutep
@Immutep
@Immutep's AIPAC trial showed 63% of patients who received paclitaxel + efti were progression-free at 6 months, comparing favourably to 54% for placebo.
Favourable results were reported in multiple predefined patient subgroups.
Full ASX: www.immutep.com/files/content/investor/press-release/2019…
#breastcancer -
Immutep
@Immutep
Speaking with Health Kick’s Tim Boreham @Immutep CEO Marc Voigt highlights its lead candidate efti and its broader potential as an immune activator to also treat various infectious diseases such as infections caused by #coronavirus.
#breastcancer
stockhead.com.au/health/health-kick-podcast-understanding… -
Immutep
@Immutep
@Immutep's Chinese partner, EOC Pharma, has completed patient recruitment for its phase I study in metastatic #breastcancer.
Data throughout 2020. Registration trial in China is planned.
AIPAC to report MBC results this month.
Full ASX: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep CEO Marc Voigt recently spoke with Tom Piotrowski of @CommSec's Executive Series, highlighting the Company's important and decisive milestone on the horizon - its Phase IIb AIPAC results, due this month.
#biotech #breastcancer
youtu.be/BRB39O-6D0Q via @YouTube -
Immutep reposted
James Flinn
@FlinnJP
A very informative presentation by Marc Voigt, Frederic Triebel and Christian Mueller from Immutep Limited on the company's lead product candidate, eftilagimod alpha ("efti" or "IMP321"). #biotech #cancer #breastcancerresearch www.linkedin.com/signup/cold-join?session_redirect=https%…
-
Immutep
@Immutep
Speaking with @belldirect, @Immutep CEO Marc Voigt talks about the impact that positive results from its AIPAC PhIIb trial, due in Mar '20, may have for patients, the immuno-oncology landscape and shareholders.
#biotechnology #breastcancer youtu.be/GfIHkdgXvn4 via @YouTube -
Immutep
@Immutep
@Immutep CEO, Marc Voigt spoke with Finance News Network recently to give an update on recent activities and the important clinical data expected from its largest and most advanced trial, AIPAC, in March 2020.
#biotechnology #breastcancer
youtu.be/EB5fBKEui4E via @YouTube -
Immutep
@Immutep
@Immutep's partner, CYTLIMIC, has commenced its CRESCENT 1 Ph1 trial in advanced hepatocellular carcinoma evaluating Immutep’s efti as part of a cancer peptide vaccine, CYT001.
Read CYTLIMIC’s ASCO GI abstract: meetinglibrary.asco.org/record/182383/abstract -
Immutep
@Immutep
@Immutep has received approval for its 2nd IND from the US FDA for efti.
•Enables Immutep to initiate its AIPAC-002 study in metastatic breast cancer
•AIPAC-002 to expedite the possible use of efti for patients in the US
ASX: www.immutep.com/files/content/investor/press-release/2019…
#biotechnology -
Immutep
@Immutep
@Immutep invites you to join its TACTI-002 Clinical Results & Update Global Webcast Presentation
Date & Time: Wed, Feb 26, 2020, 8am Australian EDT / Feb 25, 2020, 4pm US EDT
Join the webcast via fnn.webex.com/mw3300/mywebex/default.do?nomenu=true&siteu… -
Immutep
@Immutep
@Immutep is pleased to share its half year report for the period ended 31 December 2019, on Immutep Ltd and its subsidiaries.
Read the Half Year Report: www.immutep.com/investors-media/financial-information.html -
Immutep
@Immutep
Positive results from @Immutep's TACTI-002 phII trial were presented at the German Cancer Congress in Berlin by Principal Investigator, Dr. Bernhard Doger of START Madrid, Spain.
Read the results: www.immutep.com/investors-media/whats-new.html
#biotechnology -
Immutep
@Immutep
@Immutep is pleased to report more positive results from its phase II clinical trial, TACTI-002 today with encouraging Overall Response Rates from stages 1 of Parts A and C, 47% in 1st line NSCLC and 33% in 2nd line HNSCC respectively.
ASX: www.immutep.com/investors-media/whats-new.html -
Immutep reposted
James Flinn
@FlinnJP
@Immutep lead candidate, eftilagimod alpha or “efti”, is being developed for the treatment of various cancers including mBC but also has promise in the treatment of infectious diseases.
#biotech #cancer #coronavirus #breastcancer
More via LinkedIn: www.linkedin.com/signup/cold-join?session_redirect=https%… -
Immutep
@Immutep
Hear @Immutep CEO, Marc Voigt insights into the very important and decisive period ahead for the Company, especially as it prepares to report the first clinical data from its late-stage AIPAC study in metastatic breast cancer.
youtu.be/xG7APbULFww via @YouTube -
Immutep
@Immutep
@Immutep will present more mature interim clinical data from its TACTI-002 phase II study at the 34th German Cancer Congress in Berlin on 19 February at 5pm CEST.
#dkk2020 #cancer
ASX: www.immutep.com/investors-media/whats-new.html -
Immutep
@Immutep
@Immutep updates on the ongoing development of its product candidates, efti and IMP761.
•First data from late-stage Phase IIb breast cancer study, AIPAC, in March 2020
•More mature data from TACTI-002 in Feb 2020
ASX: www.immutep.com/files/content/investor/press-release/2019…
#biotechnology -
Immutep
@Immutep
@Immutep is excited its scientific paper on its preclinical product candidate IMP761 has been published in the prestigious peer-reviewed @J_Immunol
IMP761 is a promising new therapeutic approach for treating the root cause of #autoimmunediseases.
Paper: academic.oup.com/jimmunol -
Immutep
@Immutep
Another good meeting at #jpmhc20 with Shun Doi, CEO Cytlimic, our clinical partner testing our lead product candidate efti as part of a cancer vaccine and Frederic Triebel, our CSO and CMO.
Jammed packed agenda of meetings at #jpmhc20 this year!
#biotechnology #pharma -
Immutep
@Immutep
Congratulations to WuXi Biologics CEO, Chris Chen, and the team for their deal to take over a Bayer plant in Leverkusen, Germany!
It was great to catch up with him at JP Morgan #jpmhc20.
WuXi is Immutep Limited's manufacturing partner for efti.
#biotechnology #pharma -
Immutep
@Immutep
@Immutep has expanded Part C of its TACTI-002 phase II trial, following positive results, to include an additional 19 Head and Neck Squamous Cell Carcinoma patients, creating stage 2 of Part C.
#biotech
ASX announcement: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep reports recruitment has commenced for the 2nd cohort of 6 patients in its INSIGHT-004 PhI study.
No new safety signals observed in the first cohort, with 1 patient reporting a partial response.
More data expected H1 CY2020.
#biotechnology
www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
Hear @Immutep CEO Marc Voigt talk about the recently announced positive TACTI-002 data, what it means for Immutep and patients as well as what's ahead.
#biotechnology #immunooncology
youtu.be/LegPiJKuyy8 via @YouTube -
Immutep
@Immutep
The @Immutep team presented our scientific poster last week at SITC, the annual Society For Immunotherapy Of Cancer meeting.
It provides an update on TACTI-002, our ongoing Ph II clinical trial.
Poster: www.immutep.com/files/content/investor/presentation/2019/…
#lag3 #immunooncology #biotechnology -
Immutep
@Immutep
@Immutep reports positive interim data from TACTI-002 PhII clinical trial.
Preliminary Overall Response Rate = 41% from stage 1 of Part A patients, comparing favourably to standard of care treatments.
More mature data: Q1 2020
#immunotherapy
ASX: www.immutep.com/investors-media/whats-new.html -
Immutep
@Immutep
Immutep takes part every year in the annual meeting of SITC. This week the company will have a poster presentation about the latest updates one of its ongoing cancer immunotherapy.
You can check the upcoming events here:
www.immutep.com/investors-media/events.html
#immutep #lag3 #immunooncology -
Immutep
@Immutep
@Immutep's CSO/CMO, Frederic Triebel is presenting at the Drug Development & Discovery in Oncology Symposium in Melbourne.
His presentation is on IMM’s lead product candidate, efti in therapeutic combination with pembrolizumab, as per TACTI-002 Ph 2 trial.
#biotechnology -
Immutep
@Immutep
@Immutep provides an operational update, including significant efti clinical data expected:
o AIPAC PhII data - Q1 2020
o TACTI-002 PhII data - SITC Nov 2019
o TACTI-mel PhI final safety data - H1 2020
o INSIGHT-004 PhI initial safety data -Q4 2019
ASX: www.immutep.com/investors-media/whats-new.html -
Immutep
@Immutep
@Immutep was honoured to host Chinese officials yesterday, led by His Excellency Mr Zhang Hu, Vice Governor, People’s Government of Guangdong Province.
IMM has strong operational links with China through its partners WuXi Biologics and EOC Pharma.
#biotechnology -
Immutep
@Immutep
@Immutep was delighted to host a group of specialist medical investment funds from the Guangdong Medical Valley Group, China yesterday to discuss Immutep’s opportunities and recent progress.
More about the Guangdong Medical Valley Group: gdyg13726270515.tecenet.com
#biotechnology -
Immutep
@Immutep
@Immutep's Ph I trial in melanoma (TACTI-mel) has reported positive results today:
•Favourable safety profile
•Deep and durable responses - tumour shrinkage in 56% and 66% of patients in part A & B respectively
ASX: www.immutep.com/investors-media/whats-new.html
#biotechnology -
Immutep
@Immutep
@Immutep has received a €1,568,399 (~A$2,546,929) R&D tax incentive payment from the French Government under its Crédit d’Impôt Recherche scheme.
The funds will be used to support the development of efti and IMP761.
ASX: www.immutep.com/investors-media/whats-new.html
#biotechnology -
Immutep
@Immutep
Good to see the trend of ASX-listed life sciences companies maturing and enhancing perceptions of the industry with @Immutep part of the next wave of Phase II companies. #immunotherapy #biotechnology www.afr.com/companies/healthcare-and-fitness/small-cap-he…
-
Immutep
@Immutep
@Immutep has expanded Part A of its TACTI-002 Phase II trial due to positive interim data.
CSO & CMO, Dr Frederic Triebel said: “We are encouraged by the early signals of efficacy seen in the more advanced part A of the study....
ASX: www.immutep.com/investors-media/whats-new.html
#biotechnology -
Immutep
@Immutep
"We are entering a very important period with the company," said Marc Voigt of @Immutep .... in @australian talking about the $7.4 million milestone payment expected from @GSK.
#biotechnology
www.theaustralian.com.au/news/latest-news/immutep-to-rece… -
Immutep
@Immutep
@Immutep will receive a £4m (~A$7.39m/US$5.02m) milestone payment from its partner, @GSK
Eligible to receive up to £64m (~A$118m) in payments plus royalties, if GSK2831781 (from $IMM's IMP731) is commercialised.
ASX: www.immutep.com/files/content/investor/press-release/2019…
#biotechnology -
Immutep
@Immutep
Congratulations to Emeritus Prof Jacques Miller of @WEHI_research who is the joint winner of one of the world's top science prizes, the Albert Lasker Basic Medical Research Award @LaskerFDN!
This monumental discovery helps @Immutep everyday.
youtu.be/q3f1A_7s6lE via @YouTube -
Immutep reposted
Sarah-Jane Tasker
@SarahJaneTasker
After 11 fabulous years at The Aus, it's time for a new challenge. I look forward to joining @AnthDeCeglie and his team next month. thewest.com.au/business/media/sarah-jane-tasker-is-good-b…
-
Immutep
@Immutep
@Immutep has been granted a new patent by the Japanese Patent Office for the use of LAG525 (a humanised form of Immutep’s IMP701 antibody) in the treatment of #cancer and infectious disease.
The patent is co-owned by @Novartis AG and Immutep.
Full ASX: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep is delighted to be recognised in the 100 most innovative companies in the APAC region.
It was one of just 14 Australian companies to be included in the small - mid-sized category, Cortellis, ‘Pharmaceutical Innovation in the APAC Region’: clarivate.com/life-sciences-healthcare/blog/ -
Immutep
@Immutep
@Immutep granted a new patent for efti entitled “LAG-3 dosage regime for use in the treatment of cancer” by the European Patent Office.
ASX: www.immutep.com/investors-media/whats-new.html
#immunotherapy -
Immutep
@Immutep
@Immutep is pleased to share its 4E & Annual Report 2019.
"The year ahead will be very busy and exciting for Immutep," said Dr. Russell Howard in his Chairman's Letter.
Read the Report: www.immutep.com/investors-media/financial-information.html
#biotechnology #immunotherapy -
Immutep
@Immutep
Congratulations to our partner CYTLIMIC which just announced a 1.3 Billion Yen (~US$12m) financing with shareholders, incl. @NEC_corp
Plus, a collaboration with Chiba University to start a new Phase I trial of CYT001, includes @Immutep efti.
More: www.cytlimic.com/news/index_en.html -
Immutep
@Immutep
@Immutep completed its fully underwritten Entitlement Offer.
Included Immutep management team and director participation.
Total capital raised is A$10.0m, incl Entitlement Offer + Placement.
Extends cash runway to the end of 2020.
Full ASX: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep provided an update on the development of its product candidates + its recent equity financing.
• TACTI-002 recruitment update
• 3 patients now enrolled INSIGHT-004
• Significant efti clinical data expected in coming months
More: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep has a data-heavy 6 months coming up. Hear CEO Marc Voigt talk about the clinical data on the horizon and what it could mean for Immutep, in our latest update video. youtu.be/boD8SDuzxgc via @YouTube
-
Immutep
@Immutep
Join us for a Key Opinion Leader call this week!
'Novel immuno-oncology therapy (eftilagimod alpha) for metastatic breast cancer and other settings.'
Wed 26 June at 11.00am US EDT / 8.00am US PDT (Thurs 27 June at 1.00am AEST).
Register & replay : www.immutep.com -
Immutep
@Immutep
@Immutep has completed patient enrolment of its Phase IIb AIPAC study in breast cancer, with 226 patients participating.
“This is an important milestone for Immutep as this is our largest and most advanced clinical trial," said CEO Marc Voigt.
ASX: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep has been granted a new patent entitled by the Australian Patent Office, highlighting the broad potential of efti as an immunostimulant.
ASX: www.immutep.com/files/content/investor/press-release/2019…
Protects for a range of novel & highly relevant chemo-immunotherapies featuring efti.
#immunooncology -
Immutep
@Immutep
@Immutep completes recruitment of initial cohort in 1st line non-small cell lung cancer patients for Phase II TACTI-002 trial, marking good progress for the study.
Initial data expected in mid-2019.
ASX: www.immutep.com/files/content/investor/press-release/2019…
#immunooncology -
Immutep
@Immutep
@Immutep announces the first patient in the INSIGHT-004 Phase I clinical trial has been enrolled in Germany and has received the first dose of treatment.
ASX: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep was involved in two poster presentations at #asco19 in Chicago, Illinois taking place from May 31st – June 4, 2019.
Both posters related to Immutep’s lead product candidate efti.
View: www.immutep.com/investors-media/presentations.html -
Immutep
@Immutep
@Immutep has been granted a new patent entitled “Combined Preparations for the Treatment of Cancer” by the @EPOorg.
ASX announcement: www.immutep.com/files/content/investor/press-release/2019…
#immunotherapy #chemo #biotech -
Immutep
@Immutep
@immutep's CMO & CSO, Dr Frederic Triebel participated in a panel discussion @WATRMC w industry leaders from @GenomicsEngland, Infinity Pharmaceuticals, Children's Hospital of Philadelphia & @Merck Sharp and Dohme (MSD)
Congress presentation: www.immutep.com/files/content/investor/presentation/2019/…
#watrmc19 -
Immutep
@Immutep
@Immutep: consistent with previous data, melanoma patients in Part B of PhI TACTI-mel trial continue to report positive results in terms of tumour reductions after 9 months of combination treatment with efti.
ASX: www.immutep.com/files/content/investor/press-release/2019…
#immunooncology -
Immutep
@Immutep
@Immutep was delighted to have a paper published in the scientific peer-reviewed journal, Future Oncology.
The paper talks about the rationale for and design of our ongoing Phase IIb AIPAC clinical trial in breast cancer.
Abstract: www.tandfonline.com/doi/10.2217/fon-2018-0807
#immunooncology -
Immutep
@Immutep
@Immutep is looking forward to #watrmc19!
AdTherapiesCongress
@AdTherapiesConf
Industry leaders from over 65 countries have their tickets already for #watrmc19. Meet our newest speakers from companies such as @SocietyofMSKCC, @CHOP_Research, @JunoThera, @MSDintheUK, @TCBioPharm, @INFIPharma and @Immutep. Book now! terrapinn.com/watrmc/book-now
-
Immutep
@Immutep
@Immutep update on the ongoing development of its product candidates, including:
•Recruitment for the AIPAC study expected to be completed in Q2 2019
•15 patients enrolled in TACTI-002 Phase II collaboration study with MSD
ASX: www.immutep.com/files/content/investor/press-release/2019…
#immunotherapy #biotech -
Immutep
@Immutep
Join us to hear about the latest data from our phase I TACTI-mel trial and the clinical development of our lead product candidate, efti, on a global webcast next week.
Wednesday, April 3, 2019, 7:45am AEST
Tuesday, April 2, 2019, 4:45pm US EDT
Register: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep has been granted another US patent for efti.
This new patent provides IP protection for its method of treating cancer by the administration of a chemotherapy agent, and a plurality of doses of efti.
#immunooncology
ASX announcement: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
Join us for a global webcast to discuss IMP761 preclinical results in #autoimmunedisease on:
Tuesday, March 26, 2019, 7:45 am Australian Eastern Daylight Time, or
Monday, March 25, 2019, 4:45 pm US Eastern Daylight Time
Register now: fnn.webex.com/fnn/onstage/g.php?MTID=e3a09aba7876417a76f9… -
Immutep
@Immutep
CEO Marc Voigt spoke with @Finnewsnetwork about @Immutep's recent progress and exciting news flow ahead.
youtu.be/62Mc2J_tgDI via @YouTube -
Immutep
@Immutep
Late last week, @Immutep received a A$872,351 cash rebate from the Australian Federal Government’s R&D tax incentive program.
The funds will help support our active clinical trial programs for our lead product, IMP321, known as efti.
ASX: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep announced positive results from its preclinical study of IMP761, a novel LAG3 agonist antibody being developed for the treatment of #autoimmunediseases
CEO Marc Voigt: “Our IMP761 preclinical study results are very encouraging."
ASX: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep is pleased to announce that it has dosed the first patient with the combination of Keytruda® and efti for its TACTI-002, a Phase II clinical study.
The First Patient has been dosed at “START Madrid- FJD” in Spain.
ASX announcement: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep today announced positive, more mature data from its ongoing TACTI-mel PhI study of lead product candidate, efti. Data will be presented at the World Immunotherapy Congress 2019 in San Diego USA, by Dr. Frederic Triebel, CSO & CMO
ASX: www.immutep.com/files/content/investor/press-release/2019… -
Immutep
@Immutep
@Immutep will be participating in Oppenheimer’s 29th Annual Healthcare Conference in New York on 19 March 2019.
Presentation: Marc Voigt, CEO at 9.10am EST
Live webcast link can be accessed via: www.immutep.com -
Immutep
@Immutep
@Immutep has published its half year report, for the period ended 31 December 2018, on Immutep Ltd and its subsidiaries.
Click the link for the Half Year Report - announcements.asx.com.au/asxpdf/20190227/pdf/4431625kymgj… -
Immutep
@Immutep
@Immutep will be presenting updated clinical data from TACTI-mel at World Immunotherapy Congress USA 2019 - 3-5 Mar 19.
Also, presenting new data relating to its pre-clinical product candidate, IMP761, at 14th Congress of ECCO - 6-9 Mar 19.
ASX: www.immutep.com/files/content/investor/press-release/2018… -
Immutep
@Immutep
Read Immutep Ltd's January 2019 Investor Update, published today: www.immutep.com/files/content/investor/investor-update/20…
In his CEO Message, Marc Voigt reflects on the achievements of 2018 and the Company's expectation for a very data heavy 2019, with multiple value enhancing clinical data sets expected. -
Immutep
@Immutep
@Immutep has entered into a clinical trial collaboration agreement, a supply agreement and a service agreement with CYTLIMIC Inc. for its lead product candidate eftilagimod alpha as part of a cancer vaccine.
Full ASX announcement: www.immutep.com/files/content/investor/press-release/2018… -
Immutep
@Immutep
@Immutep announces US$5.2 million financing led by U.S. specialist healthcare investor, Altium Capital
ASX announcement: announcements.asx.com.au/asxpdf/20181219/pdf/441cnzytxs3l… -
Immutep
@Immutep
Read all about @Immutep's recent news, including two new EU patents and further TACTI-mel clinical trial data, in @SmallCapsASX. smallcaps.com.au/immutep-granted-patent-lead-cancer-drug-… via @SmallCapsASX
-
Immutep
@Immutep
@Immutep has been granted another new patent, entitled “Compositions comprising LAG-3 and therapeutic antibodies and their uses in treating cancer” by the European Patent Office.
ASX: www.immutep.com/files/content/investor/press-release/2018… -
Immutep
@Immutep
@Immutep granted a new EU patent protecting combined preparations comprising its lead product candidate efti and a PD-1 or PD-L1 inhibitor, and also the use of the combined preparations for the treatment of cancer or infection.
ASK: www.immutep.com/files/content/investor/press-release/2018… -
Immutep
@Immutep
Immutep announces new data from its ongoing TACTI-mel Phase I clinical trial.
Dr. Frédéric Triebel, Immutep’s CSO/CMO, will present the data @ici_checkpoint ICI Europe Summit
ASX: www.immutep.com/files/content/investor/press-release/2018…
#immunecheckpoint #icieurope -
Immutep
@Immutep
@Immutep CEO Marc Voigt spoke with FNN about the Company's recent progress, its new partnerships and what's coming up next in terms of meaningful clinical work.
#immunotherapy
youtu.be/S01-fzPAYZ8 via @YouTube -
Immutep
@Immutep
At Friday's 2018 AGM @Immutep CEO, Marc Voigt presented to shareholders & Chairman Russell Howard set @Immutep's achievements in the context of the wider biotech landscape.
Chairman's address: www.immutep.com/files/content/investor/press-release/2018…
Presentation: www.immutep.com/files/content/investor/press-release/2018… -
Immutep
@Immutep
@Immutep's partner CYTLIMIC recently presented the results of its YNP001 study at @sitcancer '18: www.cytlimic.com/news/20181012_en.html
YNP001: First-in-Human study of cancer peptide vaccine CYT001, a combination immunotherapy with Immutep's IMP321 for 17 patients with solid cancers.
#sitc18 -
Immutep
@Immutep
@Immutep: new positive interim data from TACTI-mel PhI trial at @sitcancer ASX: www.immutep.com/files/content/investor/press-release/2018…
Dr. Triebel, CMO: “...the data further supports our hypothesis that combining efti with a checkpoint inhibitor results in a combinatory therapeutic benefit to patients" #sitc18 -
Immutep
@Immutep
@Immutep CEO Marc Voigt recently spoke with Your Money's Ingrid Willinge about the Company's growing trial and partnership momentum, and what it means for Immutep.
#biotech #immunotherapy youtu.be/jsXywL_fX24 via @YouTube -
Immutep
@Immutep
@Immutep Op Update:
•TACTI-002 PhII trial to include up to 110 patients
•AIPAC PhIIb recruitment: 155 patients, >68%
•New PhI trial with Merck KGaA & Pfizer to include 12 patients
•EOC doses first patient in PhI trial in China
ASX announcement: www.immutep.com/files/content/investor/press-release/2018… -
Immutep
@Immutep
This @washingtonpost video (via the article) explains how Nobel Laureates James P. Allison and Tasuku Honjo revolutionised cancer treatment by determining how to disengage the “brakes” that prevent the immune system from attacking cancer.
www.washingtonpost.com/national/health-science/nobel-priz… -
Immutep
@Immutep
@Immutep CEO Marc Voigt will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tues 2 Oct 2018 in New York City.
Live webcast: wsw.com/webcast/ladenburg4/register.aspx?conf=ladenburg4&…
A replay will also be available via Immutep's website following the event.
ASX: www.immutep.com/files/content/investor/press-release/2018… -
Immutep
@Immutep
@Immutep's new collaboration with @MerckGroup and @Pfizer includes a new Phase I clinical trial to evaluate the clinical benefits of ‘releasing the brakes’ and ‘pushing the accelerator’ of the body’s immune system.
#immunooncology
www.theaustralian.com.au/news/latest-news/big-pharma-back… -
Immutep
@Immutep
Great to see @Immutep's new collaboration with @MerckGroup and @Pfizer in today's The Australian Financial Review.
Immutep inks agreement with pharma heavyweights
www.afr.com/street-talk/immutep-inks-agreement-with-pharm… via @FinancialReview -
Immutep
@Immutep
@Immutep enters a new clinical trial collaboration with @merckgroup and @pfizer to evaluate the combination of Immutep’s efti with avelumab, a human anti-PD-L1 antibody, in patients with advanced solid malignancies.
ASX announcement: www.immutep.com/files/content/investor/press-release/2018… -
Immutep
@Immutep
@Immutep CEO Marc Voigt will present at the BioCentury NewsMakers Conference in New York City at 11:30 am US Eastern Time on Fri 7 Sept 2018 (today).
Webcast link: media.rampard.com/newsmakers/immutep/index.jsp
An archive of the webcast will be available for six months, via the same link. -
Immutep
@Immutep
@Immutep CEO Marc Voigt speaks with FNN about the Company's progress in FY18 and looks ahead to a data-heavy year 2019, as well as the remainder of 2018. Watch the video: www.finnewsnetwork.com.au/archives/finance_news_network19…
-
Immutep
@Immutep
@Immutep to start IMP761 cell line development & manufacturing.
Signals advancement of IMP761 towards GMP manufacturing and clinical development for autoimmune diseases, following encouraging preclinical results.
ASX: www.immutep.com/files/content/investor/investor-update/20… -
Immutep
@Immutep
@immutep has received a €1,221,906 (~ A$1,910,010) cash rebate from the French Government under its Crédit d’Impôt Recherche scheme.
Funds will be used to support the ongoing and planned global clinical and preclinical development of its pipeline.
ASX: www.immutep.com/files/content/investor/investor-update/20… -
Immutep
@Immutep
@Immutep has been invited to present a corporate overview and business update at the @BioCentury 25th Annual NewsMakers in the Biotech Industry Conference on Friday 7 September 2018 in New York City.
-
Immutep
@Immutep
Stephen M. Ansell, MD, PhD, of Lymphoma Group at @MayoClinic, discusses immune evasion in patients with lymphoma in this @OncLive video.
Different cancer setting to @immutep's trials, but interesting to hear his thoughts on blocking LAG-3. shar.es/a1WIcQ via @onclive -
Immutep
@Immutep
Great to see @Immutep's latest news being covered by SmallCaps in the article below!
'Immutep recruits final patient for melanoma trial, receives Canadian patent for antibody' smallcaps.com.au/immutep-recruits-final-patient-melanoma-… via @SmallCapsASX -
Immutep
@Immutep
@Immutep is pleased to report in an operational update today that the final patient for its TACTI-mel Phase I trial has now been recruited.
Additional operational updates: www.immutep.com/files/content/investor/investor-update/20…
Plus, grant of Canadian patent for its IMP731 antibody: www.immutep.com/files/content/investor/investor-update/20… -
Immutep
@Immutep
@Immutep announces the approval of its Investigational New Drug (IND) application for efti by the @US_FDA, enabling its TACTI-002 phase II clinical trial to move forward in the US.
#immunooncology
www.immutep.com/files/content/investor/investor-update/20… -
Immutep
@Immutep
Yesterday, @GSK gave an update on GSK’781 (IMP731 licensed from @Immutep) as part of its 2018 Q2 and R&D update call.
See slide 12 & 13 of GSK’s R&D update by Hal Barron, CSO and President, R&D, and watch the recording of the webcast below.
www.youtube.com/watch?v=X62jsj-l6RI -
Immutep
@Immutep
The interaction between the immune system and cancer is explained nicely in this article from @immunooncnews.
immuno-oncologynews.com/immuno-oncology/ -
Immutep
@Immutep
How does immunotherapy help the body fight cancer? This recent animation from @theNCI (US National Cancer Institute) gives a very good, top level introduction to immunotherapy and cancer. Hope it's useful!
www.youtube.com/watch?v=jDdL2bMQXfE -
Immutep
@Immutep
@Immutep announces that it has submitted its IND application to the US FDA for efti in June 2018. ASX: www.immutep.com/files/content/investor/investor-update/20…
If granted by the FDA, it will represent an important step in the clinical trial preparations for the Company's Phase II TACTI-002 clinical trial. -
Immutep
@Immutep
@Immutep has published its June 2018 Investor Update (www.immutep.com/files/content/investor/investor-update/20…) which includes updates on: NASDAQ bell ringing, ASCO posters, TACTI-mel interim results, AIPAC trial recruitment mid point, TACTI-002 IND prep, as well as partner updates.
-
Immutep
@Immutep
@Immutep reaches mid-point in AIPAC patient enrolment
ASX announcement: www.immutep.com/files/content/investor/investor-update/20…
Dr. Frederic Triebel, Immutep’s CSO and CMO, commented: “We are very excited to have reached this important milestone.”
#immunooncology -
Immutep
@Immutep
In case you missed the live stream event of @Immutep's NASDAQ bell ringing ceremony, you can watch the short video we created here: www.youtube.com/watch?v=UzlQPrhaLT4
#rewritetomorrow #immunotherapy -
Immutep
@Immutep
Our partner @Novartis talks about “smart combinations” for cancer: www.novartis.com/stories/di...itter&utm_content=immuno-on…. It has selected LAG525, licensed from @Immutep, as one of two immunotherapies that have shown early clinical activity, and warrant further clinical investigation.
#immunooncology -
Immutep
@Immutep
@Immutep is involved in three poster presentations at the @ASCO's Annual Meeting, in Chicago, Illinois from 1 - 5 June, relating to eftilagimod alpha.
ASX announcement: www.immutep.com/files/content/investor/investor-update/20…
Posters: www.immutep.com/investors-media/presentations.html
#immunooncology #conquercancer #asco18 -
Immutep
@Immutep
What a great moment! Thanks for celebrating with us @AustradeUSA!
#rewritetomorrow -
Immutep
@Immutep
@Immutep is excited to be celebrating its listing on @Nasdaq by ringing the Closing Bell! Live stream: watch CEO Marc Voigt and the team ring the Closing Bell at 4 pm US EDT on 1 June (6 am AEST on Saturday 2 June) via facebook.com/Nasdaq
#rewritetomorrow #immunotherapy -
Immutep
@Immutep
TACTI-mel: New data shows Overall Response Rate of 61% (11/18 patients)
WEBCAST REMINDER: register fnn.webex.com/fnn/onstage/g.php?MTID=edd0388586f757aa2ea7…
“The new data is very encouraging,” said Marc Voigt, CEO of Immutep.
Results: announcements.asx.com.au/asxpdf/20180530/pdf/43vdfj6wxy44…
Slides: announcements.asx.com.au/asxpdf/20180530/pdf/43vdfl2lhpnf… -
Immutep
@Immutep
Immutep Ltd advises that it will present interim results from the three initial patient cohorts of its ongoing TACTI-mel Phase I clinical trial in a global webcast and Q&A.
Register: fnn.webex.com/fnn/onstage/g.php?MTID=edd0388586f757aa2ea7…
Announcement: www.immutep.com/files/content/investor/investor-update/20…
#immunooncology -
Immutep
@Immutep
@Immutep CEO Marc Voigt spoke recently with Financial News Network about the Company’s upcoming clinical data results and milestones, including its new planned trial with @Merck MSD, TACTI-002, and it's partnership strategy.
Interview: www.immutep.com/investors-media/video.html
#immunooncology -
Immutep
@Immutep
@Immutep CEO Marc Voigt appeared live on @skybusiness's #tradingday program last week, interviewed by Chief Business Reporter, @IngridWillinge, and #tribecainvestmentpartners Portfolio Manager, Jun Bei Liu.
Watch the interview: www.immutep.com/investors-media/video.html -
Immutep
@Immutep
@Immutep welcomes the Australian Government’s commitment to make clinical trials exempt from the R&D tax refund cap.
biotechdispatch.com.au/news/rd-tax-incentive-reform-deliv… -
Immutep
@Immutep
@Immutep CEO Marc Voigt spoke with one of Australia’s most experienced commentators, @AlanKohler, at @TCIHQ about the Company’s uniquely positioned LAG-3 technology and treating cancer, along with Immutep‘s business model and big pharma partners.
Podcast: theconstantinvestor.com/cancer-therapies-immutep/ -
Immutep
@Immutep
@Immutep is pleased to announce that it will present three posters during the 2018 American Society for Clinical Oncology (@ASCOCancer) Annual Meeting, being held 1-5, June 2018 in Chicago, Illinois. #asco18
Read more: www.immutep.com/investors-media/press-releases/detail-pre… -
Immutep
@Immutep
Immutep CEO Marc Voigt had the pleasure of speaking with @AlanKohler yesterday about the Company's recent progress. We look forward to sharing the podcast shortly. @TCIHQ #immunotherapy
Alan Kohler
@AlanKohler
And now I’m about to talk to Marc Voigt, the Berlin-based CEO of Immutep (IMM.ASX), about whether cancer will be cured before I get it.
-
Immutep
@Immutep
@Immutep has today provided an operational update on the Company’s ongoing development activities for its lead product candidates, eftilagimod alpha, and IMP761, along with partner updates. More: www.immutep.com/investors-media/whats-new.html
-
Immutep
@Immutep
@Immutep’s Dr Frédéric Triebel presented updated data from the TACTI-mel Phase I study, demonstrating continued anti-tumor activity of efti in combination with pembrolizumab, at Immuno-Oncology Summit Europe.
More: www.immutep.com/files/content/investor/press-release/2018…
Presentation: www.immutep.com/investors-media/presentations.html -
Immutep
@Immutep
@Immutep is pleased to report that this week, the first patient in the additional cohort of its TACTI-mel Phase I clinical trial received their first dose of the two drugs being evaluated in combination, Immutep’s efti and pembrolizumab (KEYTRUDA®).
More: www.immutep.com/files/content/investor/press-release/2018… -
Immutep
@Immutep
Great to see Immutep's recent fund raise and new institutional investors, Australian Ethical Investment and Platinum Asset Management Limited, highlighted in BiotechDispatch.
Immutep attracts new investment biotechdispatch.com.au/news/immutep-attracts-new-investment -
Immutep
@Immutep
Eligible @Immutep shareholders are invited to participate in Immutep’s Share Purchase Plan, on the same terms as the placement announced on 12 March, which raised $6.85m. More in Chairman, Dr Russell Howard’s letter to shareholders: www.immutep.com/files/content/investor/investor-update/20…
#immunotherapy -
Immutep
@Immutep
@Immutep is delighted that its partner CYTLIMIC has started its phase I study for adjuvant immunotherapy at Yamaguchi University Graduate School of Medicine. The study tests CYTLIMIC’s cancer peptide vaccine in combination with Immutep’s IMP321.
More: www.cytlimic.com/news/20180301_en.html -
Immutep
@Immutep
It's great to see @Immutep featured in @australian following our recent news. #immunotherapy www.theaustralian.com.au/business/companies/merck-cancer-…
-
Immutep
@Immutep
@Immutep’s new Phase II clinical trial significantly builds on the momentum it is delivering in the evaluation of efti in cancer, with two Phase I clinical trials and now two Phase II clinical trials in our program for 2018. More: www.immutep.com/files/content/investor/investor-update/20… #immunotherapy
-
Immutep
@Immutep
@Immutep is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada).
More: www.immutep.com/files/content/investor/investor-update/20… @Merck #immunotherapy -
Immutep
@Immutep
Immutep announces a successful $6.85m Placement and proposed Share Purchase Plan. It welcomes institutional investors, Platinum and Australian Ethical to our share register, plus further investment from, Lucy Turnbull. More: www.immutep.com/files/content/investor/investor-update/20…
@platassetmgmt @austethical -
Immutep
@Immutep
Strengthening the Company’s intellectual property protection, Immutep announces the grant of a US patent for its IMP701 antibody. The patent is co-owned by Immutep’s partner for this candidate product, Novartis AG and will expire in 2035. Read more: www.immutep.com/files/content/investor/investor-update/20…
-
Immutep
@Immutep
Immutep is pleased to announce that it has received a A$686,704 cash rebate from the Federal Government’s R&D tax incentive program, which it will apply towards furthering its current active clinical trial program for lead product, Efti. Read more: www.immutep.com/files/content/investor/investor-update/20…
-
Immutep
@Immutep
Immutep CEO Marc Voigt presented "The next big immune checkpoint: LAG-3" to a receptive audience of biotech and pharma industry professionals at @PharEast2018, Phar-East Asia Convention on 1 March 2018.
#phareast #immunotherapy -
Immutep
@Immutep
Immutep welcomes news of another success story building in the immuno-oncology space, with Merck proposing to acquire Viralytics (ASX:VLA) for AU$502m (US$394m). @Merck @Viralytics
Merck to buy virus-based cancer drug firm Viralytics for $394 million www.reuters.com?edition-redirect=uk -
Immutep
@Immutep
It’s encouraging to see that big pharma’s interest in the immuno-oncology space continues at an exciting pace.
Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug via @forbes www.forbes.com/sites/matthewherper/2018/02/14/bristol-mye… -
Immutep
@Immutep
@Immutep’s LAG-3 could be the next checkpoint to emerge for immuno-oncology combinations, according to Streetwise Reports citing Maxim report: www.streetwisereports.com/article/2018/02/07/immuno-oncol… via @SWReports #immuno-oncology
-
Immutep
@Immutep
DSMB confirms that the combination of Efti with pembrolizumab (KEYTRUDA) is safe and well tolerated at up to 30 mg / injection. www.immutep.com/files/content/investor/investor-update/20…
-
Immutep
@Immutep
Immutep announces million dollar milestone payment from Chinese partner, EOC Pharma (affiliate of Eddingpharm) -
www.immutep.com/files/content/investor/investor-update/20… #biotech #immunotherapy -
Immutep
@Immutep
Read here for a review of the JP Morgan Healthcare Conference in San Francisco which includes a mention of Immutep as a small company doing breakthrough work: wealthyretirement.com/healthcare-investing-ideas/ #biotech #immunotherapy
-
Immutep
@Immutep
Immutep listed as one of 4 Promising Biotechs for 2018 – the article reports on the “pivotal” clinical trial in Europe as being the most advanced for a prospective #immunotherapy drug www.nabtrade.com.au/investor/insights/latest-news/news/20…
-
Immutep
@Immutep
Immutep's latest Investor Update is now available via the website: www.immutep.com/files/content/investor/investor-update/20… #biotech #immunotherapy
-
Immutep
@Immutep
The brand new Immutep website is now live - www.immutep.com
-
Immutep reposted
EdisonHealthcare
@EdisonHealth
.@Primabio changes name to @Immutep. Presents encouraging LAG-3 combo data at #sitc17 www.edisoninvestmentresearch.com/research/report/immutep/… $IMM
-
Immutep
@Immutep
Immutep releases operational update on its two clinical trials, partnerships, and new product candidate - www.immutep.com #immunotherapy
-
Immutep
@Immutep
Dr Triebel showing IMP321 or “Efti” in this chart induces better CD8 Tc1 differentiation than other agonists #science #immunology
-
Immutep
@Immutep
Chief Science Officer Dr Frederic Triebel presenting to members of the Garvan Institute @ Kinghorn Cancer Centre on LAG-3 #immunotherapy
-
Immutep
@Immutep
Prima announces the grant of a new European #patent, geared toward the use of lead candidate IMP321 and its application in the AIPAC clinical trial in metastatic breast #cancer in Europe. www.immutep.com
-
Immutep
@Immutep
Prima to change its name to Immutep following shareholder approval, effective Dec 1. View full ASX announcement: announcements.asx.com.au/asxpdf/20171120/pdf/43pdbsdv7yt2…
-
Immutep
@Immutep
CEO Marc Voigt at today’s AGM in Sydney revealing the new logo for Immutep. #immunotherapy #biotech
-
Immutep
@Immutep
Prima in pre-IND talks with the FDA to discuss the regulatory pathway for the development of Eftilagimod Alpha (LAG-3Ig or IMP321) in the United States
www.immutep.com -
Immutep
@Immutep
Prima releases new encouraging clinical data from its Australian TACTI-mel Phase I melanoma trial, studying IMP321 in combo w/ Keytruda. 58% exp. reduction in tumour: www.immutep.com
-
Immutep
@Immutep
Prima's Dr. Frédéric Triebel presented @ The World Immunotherapy Congress '17.See overview of his presentation here: goo.gl/m5s6oe
-
Immutep
@Immutep
Dr. Frederic Triebel to present @ the World Immunotherapy Congress 2017 in Switzerland on Australian TACTI-mel trial announcements.asx.com.au/asxpdf/20171020/pdf/43ndrqk0l9r9…
-
Immutep
@Immutep
New data from IMP321 accepted for presentation @ the Society for Immunotherapy of Cancer Conf. in USA @sitcancer announcements.asx.com.au/asxpdf/20171017/pdf/43n9fzf4kv4f…
-
Immutep
@Immutep
The latest Investor Update covering recent Company news has been released via the ASX and is available at: www.immutep.com #ausbiz
-
Immutep reposted
EdisonHealthcare
@EdisonHealth
.@PrimaBioMed: #esmo17 data support APC-activator combos. $BMY results validate anti-LAG-3 strategy in cancer www.edisoninvestmentresearch.com/research/report/prima-bi… $PRR
-
Immutep
@Immutep
LAG-3 & combination therapies (or in combo w/ a PD-1 antagonist) garnering traction @myESMO Conf, where PRR present www.fiercebiotech.com/biotech/bristol-myers-advances-new-…
-
Immutep reposted
David Langsam
@biotech_daily
.@PrimaBioMed Japan Patent For IMP321 For Infectious Diseases - subscribe to Biotech Daily www.biotechdaily.com.au
-
Immutep reposted
Melanoma Institute Australia
@MelanomaAus
New #research: Australian researchers stopping #melanoma in its tracks with adjuvant combo therapy. melanoma.org.au/news-events/news/australian-researchers-s… #esmo17 @NEJM
-
Immutep
@Immutep
Bristol-Myers Squibb is at @myESMO 2017 and will present on Opdivo plus anti-LAG-3 antibody @bmsnews #biotech news.bms.com/press-release/bmy/bristol-myers-squibb-data-…
-
Immutep
@Immutep
Prima $PRR secures Japanese Patent Grant for IMP731 Antibody. See ann: www.immutep.com #biotech #immunotherapy #ausbiz
-
Immutep
@Immutep
Prima Secures Japanese Patent Grant for IMP321 in the treatment of infectious disease www.immutep.com
-
Immutep
@Immutep
Prima announces research collab w/ @MonashUni @RossjohnLab and funding grant of A$360k from Aust Research Council: www.immutep.com
-
Immutep
@Immutep
Prima announces NED appointment of ex-BAML banker Grant Chamberlain to its Board, as mentioned in @FinancialReview www.afr.com/street-talk/mercury-rises-on-interactive-stak…
-
Immutep
@Immutep
Prima receives A$1.3m tax refund from French Govt which will support further development of clinical trials www.immutep.com #biotech
-
Immutep reposted
IB Communications Ltd
@IBcommsagency
Great to work with Frederic Triebel, CSO, @PrimaBioMed, LAG-3 gene discoverer on #immunooncology article in @MedNous www.mednous.com/sites/default/files/Triebel LAG-3 JulAug2…
-
Immutep
@Immutep
Prima BioMed releases Investor Update on @ASCO 2017, recent clinical developments & upcoming events. #immunotherapy www.immutep.com
-
Immutep
@Immutep
Prima's Chief Scientist Frederic Triebel writes for @MedNous on the rise of immuno-oncology & the recent @ASCO conf: www.mednous.com/sites/default/files/Triebel LAG-3 JulAug2…
-
Immutep reposted
David Langsam
@biotech_daily
.@Novartis Pays @PrimaBioMed ‘Undisclosed Significant’ Milestone - subscribe to Biotech Daily www.biotechdaily.com.au
-
Immutep
@Immutep
Prima provides the market with a #financial update for 2H17 disclosing the Novartis milestone payment of ~A$1.3m www.immutep.com
-
Immutep
@Immutep
Prima to receive 2nd significant clinical milestone payment from Novartis relating to Prima’s IMP701 LAG-3 antibody announcements.asx.com.au/asxpdf/20170717/pdf/43kp048h48mx…
-
Immutep
@Immutep
Prima receives regulatory/ethical approvals to initiate new clinical trial ‘INSIGHT’ for IMP321 in solid tumours www.immutep.com
-
Immutep
@Immutep
Prima raises US$5 million with healthcare specialist U.S. institutional investors - the first ever US raise $PRR announcements.asx.com.au/asxpdf/20170630/pdf/43k9cq94s424…
-
Immutep
@Immutep
Prima's TACTI-mel trial has started recruitment for the 3rd cohort of Aussie patients; AIPAC is now recruiting patients in Poland & Hungary
-
Immutep
@Immutep
Prima releases positive operational update on its 2 active #clinical trials in IMP321 for melanoma & breast #cancer www.immutep.com
-
Immutep reposted
David Langsam
@biotech_daily
.@Primabiomed : ‘Imp321 Immune Response For #breast #cancer’ - subscribe to Biotech Daily www.biotechdaily.com.au
-
Immutep reposted
Small Caps
@SmallCapsASX
PrimaBioMed's breast #cancer drug achieves safety milestone
smallcaps.com.au/prima-biomed-breast-cancer-drug-safety-m… $PRR #asx @PrimaBioMed -
Immutep reposted
Sarah-Jane Tasker
@SarahJaneTasker
Lucy Turnbull-chaired biotech reveals its breast cancer drug is safe in patients #cancer #ausbiz www.theaustralian.com.au/business/primas-trial-backs-safe…
-
Immutep reposted
Business Review
@aus_business
BUSINESSNOW: Nothing like a dose of success to send this small med stock skyward www.theaustralian.com.au/business/businessnow/business-ma… #ausbiz
-
Immutep reposted
EdisonHealthcare
@EdisonHealth
Paclitaxel + IMP321 (LAG3 Ig) from @PrimaBioMed: 47% PR; 87% DCR (n=15). Note that expected hist. PR w/ pacl alone is ~20%. #asco17 $PRR
-
Immutep
@Immutep
"Prima Biomed has revealed new data that backs the safety of its metastatic breast cancer drug" via @SarahJaneTasker
www.theaustralian.com.au/business/primas-trial-backs-safe… -
Immutep
@Immutep
A photo of Prima's poster presentation at today's @ASCO conference. Click link to view the presentation online: www.immutep.com
-
Immutep
@Immutep
Prima $PRR releases new clinical data at @ASCO conference, demonstrating IMP321 w/ chemo is safe and well tolerated: www.immutep.com
-
Immutep
@Immutep
Prima announces new international Clinical Advisory Board to oversee drug IMP321 in breast #cancer #clinical trials announcements.asx.com.au/asxpdf/20170601/pdf/43jnjrgb7kcq…
-
Immutep
@Immutep
A Prima abstract & poster have been accepted for presentation
at the 53rd @ASCO annual meeting in Chicago next month www.immutep.com -
Immutep
@Immutep
Prima receives approval for 3rd cohort of its phase I Australian #melanoma trial for IMP321 and #keytruda. See ann: announcements.asx.com.au/asxpdf/20170419/pdf/43hlmxbygv6l…
-
Immutep
@Immutep
Prima's CMO Frédéric Triebel is published in latest issue of The Medicine Maker: Chasing Checkpoints.View: themedicinemaker.com/issues/0217/chasing-checkpoints/ #biotech
-
Immutep
@Immutep
Prima's 2nd cohort of patients has been recruited for its melanoma clinical trial being conducted in Australia. See: www.immutep.com
-
Immutep
@Immutep
Read about our development activities & newest employee in our latest March 2017 Investor Update, here: www.immutep.com #biotech
-
Immutep
@Immutep
Prima BioMed granted #patent for lead product IMP321 by the United States Patent Office: www.immutep.com #biotech #ip $PBMD $PRR
-
Immutep
@Immutep
Prima releases 1H17 operational update:extension of cash reach & positive recruitment rates for both clinical trials announcements.asx.com.au/asxpdf/20170224/pdf/43g9hhmw3qr9…
-
Immutep
@Immutep
Prima BioMed Receives ~A$860,000 Tax Credit Payment from French Government www.immutep.com
-
Immutep
@Immutep
Prima CEO Marc Voigt interviewed by The Wall Street Analyzer on immuno-oncology + IMP321 #clinical development $PBMD wallstreetanalyzer.com/2017/01/24/prima-biomed-ltd-asx-pr…
-
Immutep reposted
medify
@medifydaily
$PRR/@PrimaBioMed: CSO Dr Frédéric Triebel to present at 2nd Annual Cancer Immunotherapy Conference, San Francisco, Feb 20.
-
Immutep
@Immutep
[VIDEO] Prima’s CEO + CMO were recently interviewed on PRR's leading position in immuno-oncology. View full video: www.youtube.com/watch?v=vbABC4_qqJ0&t=308s
-
Immutep
@Immutep
Prima $PRR commences enlarged randomisation phase of breast #cancer #clinical trial involving 226 patients www.immutep.com #biotech
-
Immutep
@Immutep
Prima BioMed - first patient dosed for 2nd cohort of its #melanoma clinical trial for IMP321 in combo w/ KEYTRUDA www.immutep.com
-
Immutep
@Immutep
Prima BioMed $PRR enters New Material Transfer Agreement with Japan’s Cytlimic. #biotech #ausbiz See announcement: www.immutep.com
-
Immutep
@Immutep
Stay up to date with our updated product pipeline graphic on our website #biotech #development www.primabiomed.com.au/products/
-
Immutep
@Immutep
In December Prima announced positive clinical data results from its combinaion of IMP321 w/ ANTI-PD1. See details: www.immutep.com
-
Immutep
@Immutep
Prima announces it has developed a new early stage product candidate to be known as IMP761: a LAG-3 Agonist Antibody www.immutep.com
-
Immutep
@Immutep
Prima $PRR announces positive interim safety data results from IMP321 AIPAC #clinical trial in breast #cancer. More: www.immutep.com
-
Immutep
@Immutep
So hot right now: current deal activity in Immuno-Oncology technologies is significant for #biotech industry. Read: www.locustwalk.com/immuno-oncology-deals-why-are-they-so-hot
-
Immutep
@Immutep
More news from SITC: LAG-3 recognised for checkpoint antibodies in clinical results via @lymphomanews
bionews.com/this-site-is-on-hiatus/ -
Immutep
@Immutep
Prima BioMed $PRR CEO Marc Voigt interviewed by CNBC on the current global #biotech landscape. #biologic #ausbiz cnb.cx/2gm1bqf
-
Immutep
@Immutep
Prima's Marc Voigt in @aus_business - "As a small Australian company we are spearheading #chinese #development" via www.theaustralian.com.au/business/companies/prima-biomed-…
-
Immutep
@Immutep
The Australian reports on the back of today's WuXi partnership deal, $PRR shares up more than 8% #biologics #ausbiz
www.theaustralian.com.au/business/companies/lucy-turnbull… -
Immutep
@Immutep
Prima $PRR signs MOU and announces strategic manufacturing partnership with Chinese-based WuXi biologics for IMP321 announcements.asx.com.au/asxpdf/20161123/pdf/43d3ysh5gsp7…
-
Immutep
@Immutep
Prima's Chief Scientist Frederic Triebel's presentation on IMP321 for SITC Conference now available on ASX announcements.asx.com.au/asxpdf/20161111/pdf/43ctfw25jh67…
-
Immutep
@Immutep
Prima's latest lnvestor Update (Edition 18) now available via ASX $PRR #biotech #ausbiz #investor
announcements.asx.com.au/asxpdf/20161111/pdf/43cth9wjgcj0… -
Immutep reposted
IB Communications Ltd
@IBcommsagency
Great Jacob Plieth @EPVantage article on LAG-3 after fascinating conversation with @PrimaBioMed, getting focus above GSK, Roche, BMS, etc.
-
Immutep
@Immutep
Prima’s Dr Frederic Triebel interviewed on LAG-3 treatments including IMP321 ahead of @sitcancer conference
www.evaluate.com/universal/view.aspx?type=Story&id=669900… -
Immutep
@Immutep
Prima to present at 2016 Society for #immunotherapy of Cancer Conference in November. See ASX ann: announcements.asx.com.au/asxpdf/20161013/pdf/43byjpqwr312… #biotech
-
Immutep
@Immutep
Abstracts from Prima IMP321 trials to be displayed @myESMO Symposium on Immuno-Oncology, Nov 4-5, Switzerland. Ann: www.immutep.com
-
Immutep
@Immutep
.@Novartis emphasises immuno-oncology as core to its overall oncology business strategy. Story via @FierceBiotech www.fiercebiotech.com/biotech/as-novartis-looks-to-play-c…
-
Immutep
@Immutep
Prima BioMed $PRR announces the granting of a #patent relating to its IMP731 #antibody by the European Patent Office announcements.asx.com.au/asxpdf/20160825/pdf/439m8hg6f2z9…
-
Immutep
@Immutep
#immunotherapy treatment labelled a genuine game-changer in article celebrating some of Keytruda’s successes: www.theage.com.au/interactive/2016/fight-club/ #merck
-
Immutep
@Immutep
Prima provides market update on cash position & the recruitment progress in its 2 active #clinical trials in IMP321: www.immutep.com
-
Immutep
@Immutep
Prima $PRR announces new collaborative (upto 40-patient) study investigating the intra-tumoural injection of IMP321 announcements.asx.com.au/asxpdf/20160712/pdf/438j8y6l23vg…
-
Immutep
@Immutep
Prima $PRR CEO Marc Voigt: initial data significantly de-risks remainder of AIPAC trial in metastatic breast cancer announcements.asx.com.au/asxpdf/20160622/pdf/4381fqr5z12p…
-
Immutep
@Immutep
Data from first six patients confirms IMP321 safe+well tolerated in Prima metastatic breast #cancer trial announcements.asx.com.au/asxpdf/20160622/pdf/4381fqr5z12p… #biotech
-
Immutep
@Immutep
Nasdaq confirms @PrimaBiomed $PBMD to retain ADS listing announcements.asx.com.au/asxpdf/20160607/pdf/437qvk4sb05s… #biotech #nasdaq
-
Immutep
@Immutep
Investor Update: Edition 17 of Prima’s newsletter is now available. View it from our website: www.immutep.com
-
Immutep
@Immutep
Prima CEO Marc Voigt: we believe it best positions CVac for clinical success & hopefully, commercialization announcements.asx.com.au/asxpdf/20160512/pdf/4376mp8rsjk7… #biotech
-
Immutep
@Immutep
.@PrimaBioMed $PRR enters into Sale + Licensing Agreement with SYDYS Corp to Advance CVac Program. See Ann: announcements.asx.com.au/asxpdf/20160512/pdf/4376mp8rsjk7… #biotech
-
Immutep
@Immutep
Prima granted Japanese #patent for the use of recombinant LAG-3 for eliciting monocyte immune response- See ASX ann: announcements.asx.com.au/asxpdf/20160502/pdf/436y6g0hyklt…
-
Immutep
@Immutep
Bristol-Myers’ LAG3 Antibody advances into a large Phase 2 study: www.franklinindependent.com/leerink-bmys-lag3-antibody-mo… #biotech #immunotherapy #antibody
-
Immutep
@Immutep
IMP321 shows potential in vaccine settings: first public data from collaboration with Japan’s @NEC + @Yamaguchi Uni onlinelibrary.wiley.com/doi/10.1111/cas.12861/abstract
-
Immutep
@Immutep
Results from study of vaccine + IMP321 as adjuvant in solid cancers by @NEC + @Yamaguchi featured in Cancer Science: onlinelibrary.wiley.com/doi/10.1111/cas.12861/abstract
-
Immutep
@Immutep
[VIDEO] watch #animation of how the mode of action of IMP321 works (currently undergoing #clinical trials in Aus)
www.immutep.com -
Immutep
@Immutep
Our positive safety/immune monitoring data from investigator-led clinical trial in #melanoma using IMP321 published: www.immutep.com
-
Immutep
@Immutep
.@Prima BioMed CMO Dr Frederick Triebel co-author of IMP321 study published in @Clinical Cancer Research journal www.immutep.com
-
Immutep reposted
medify
@medifydaily
$PRR/@PrimaBioMed: Safety/immune monitoring data from trial of IMP321 in #melanoma features in current Clinical Cancer Research journal.
-
Immutep
@Immutep
H.C.Wainwright reaffirms "buy" rating on $PBMD Prima stock www.americanbankingnews.com #biotech
-
Immutep
@Immutep
Prima $PRR and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial. See Ann: www.immutep.com
-
Immutep
@Immutep
Investor Update: Prima BioMed's latest newsletter [Edition 16] is now availabe on our website:
www.immutep.com -
Immutep
@Immutep
The US patent for IMP731 provides protection for specific sequences of the antibody and its use in depleting LAG-3+ T cells
-
Immutep
@Immutep
@PrimaBioMed receives first ever patent for LAG-3 depleting antibodies by US Patent and Trademark Office @USPTO announcements.asx.com.au/asxpdf/20160128/pdf/434m0nhwjk1j…
-
Immutep
@Immutep
Prima Biomed initiates first clinical trial site for TACTI-mel in QLD: first patients expected to be dosed 1Q 2016. announcements.asx.com.au/asxpdf/20160127/pdf/434l4dwdgbyp…
-
Immutep
@Immutep
ROTH Capital initiates coverage on Prima $PBMD with a Buy rating and $6 price target. View the analyst report here: www.immutep.com
-
Immutep
@Immutep
ASX: Prima Initiates Phase IIB Study in Metastatic Breast Cancer at first clinical site in Belgium www.asx.com.au/asx/statistics/displayAnnouncement.do?disp…
-
Immutep
@Immutep
Prima $PRR announces progress w IMP321 in pre-clinical work: collab w NEC Corporation + Yamaguchi Uni in Japan #asx announcements.asx.com.au/asxpdf/20151211/pdf/433qy1g76vs8…
-
Immutep
@Immutep
Our Chairman Lucy Turnbull interviewed by @afrmag out today
www.afr.com/life-and-luxury/theres-something-about-lucy-2… -
Immutep
@Immutep
FBR&Co. initiates coverage on Prima BioMed PBMD with an Outperform rating and price target of $6 per share. Report: www.immutep.com
-
Immutep
@Immutep
FBR & Co. says current value of Prima BioMed doesn’t reflect significant value in advancing clinical stage product pipeline #immunotherapy
-
Immutep
@Immutep
[VIDEO] view CEO Marc Voigt's interview with @SkyBusiness - now posted on our website:
www.primabiomed.com.au/media/ -
Immutep
@Immutep
Prima CEO Marc Voigt's interview w/ @SkyBusiness following last week's AGM. Link to footage available soon #biotech
-
Immutep
@Immutep
Results of Prima BioMed AGM yesterday: all resolutions unanimously passed. See ASX announcement: announcements.asx.com.au/asxpdf/20151125/pdf/43391mp72qf1… #biotech #agm
-
Immutep
@Immutep
Prima BioMed AGM y'day saw all resolutions approved by shareholders, inc. the re-election of Lucy Turnbull as Chair www.theaustralian.com.au/business/companies/lucy-turnbull…
-
Immutep
@Immutep
UPDATE: Prima BioMed November Newsletter available here: announcements.asx.com.au/asxpdf/20151123/pdf/433674jd70yf… #biotech
-
Immutep
@Immutep
Prima $PRR to run Phase I combination study of IMP321 + checkpoint inhibitor in metastatic #melanoma in Aus #biotech announcements.asx.com.au/asxpdf/20151118/pdf/4332v4bbmb74…
-
Immutep
@Immutep
Prima’s Chief Scientist Dr. Frédéric Triebel to present at Immune Checkpoint Inhibitors Europe meeting, Nov #biotech announcements.asx.com.au/asxpdf/20151105/pdf/432rmvq0p8kf…
-
Immutep
@Immutep
Prima BioMed Receives a Research Tax Credit Cash Rebate in France. pcgadvisory.com/news/prima-biomed-receives-a-research-tax…
-
Immutep
@Immutep
CVac Shows Clear Trend for Overall Survival Benefit in Second Remission Ovarian Cancer in Phase II Study. pcgadvisory.com/news/cvac-shows-clear-trend-for-overall-s…
-
Immutep
@Immutep
CVac Shows Clear Trend for Overall Survival Benefit in Second Remission Ovarian Cancer in Phase II Study. pcgadvisory.com/news/cvac-shows-clear-trend-for-overall-s…
-
Immutep
@Immutep
Prima BioMed Announces Japanese Collaboration. pcgadvisory.com/news/prima-biomed-announces-japanese-coll…
-
Immutep
@Immutep
Do I Have Ovarian Cancer? 6 Symptoms Women Should Never Ignore.www.newsmax.com/fastfeatures/ovarian-cancer-symptoms-heal…
-
Immutep
@Immutep
Precision Medicine in Cancer: Targeted Drugs and Immunotherapy. www.medscape.com/viewarticle/838912
-
Immutep
@Immutep
Prima Biomed to Prioritize Immuno-Oncology Programs Targeting Immune Checkpoint LAG-3 pcgadvisory.com/news/prima-biomed-to-prioritize-immuno-on…
-
Immutep
@Immutep
Prima BioMed to Receive Financial Milestone Payment From GSK. pcgadvisory.com/news/prima-biomed-to-receive-financial-mi…
-
Immutep
@Immutep
Prima BioMed Receives $777K R&D Tax Incentive Refund. pcgadvisory.com/news/prima-biomed-receives-777k-rd-tax-in…
-
Immutep
@Immutep
Prima BioMed Announces Immutep’s IMP321 Patent Application Receives Canadian Patent Office Notice of Grant. pcgadvisory.com/news/prima-biomed-announces-immuteps-imp3…
-
Immutep
@Immutep
Prima BioMed Completes Immutep Acquisition. pcgadvisory.com/news/prima-biomed-completes-immutep-acqui…
-
Immutep
@Immutep
Prima Biomed Enhances CVac Manufacturing and Logistics Capability. pcgadvisory.com/news/prima-biomed-enhances-cvac-manufactu…
-
Immutep
@Immutep
Our CVac Demonstrates Overall Survival Benefit in Second Remission Ovarian Cancer $PBMD $PRR pcgadvisory.com/news/cvac-demonstrates-overall-survival-b…
-
Immutep
@Immutep
We Will Host Conference Call& Webcast to Discuss Acquisition of Immutep Today at 5PM ET/ Friday 8AM AU EST $PBMD $PRR finance.yahoo.com/news/prima-biomed-host-conference-call-…
-
Immutep
@Immutep
UConn Researchers Develop Personalized #ovariancancer Vaccines today.uconn.edu/blog/2014/10/uconn-researchers-develop-pe…
-
Immutep
@Immutep
Our Company Has Announced Immutep's IMP321 Patent Application Receives Australian Notice of Allowance $PBMD $PRR pcgadvisory.com/news/prima-announces-immuteps-imp321-pate…
-
Immutep reposted
PRIME Management
@PRIME_Mgmt_Ptnr
Join #rocknrun this weekend to #fight #breastcancer and #ovariancancer communitynewspapers.com/pinecrest-tribune/rock-n-run-brea… #florida @PrimaBioMed
-
Immutep
@Immutep
We Have Announced Strategic Acquisition of Immutep SA $PBMD $PRR pcgadvisory.com/news/prima-biomed-announces-strategic-acq…
-
Immutep
@Immutep
Our Company Has Secured US$37.4M Investment Agreement With US Institutional Investor Bergen $PBMD $PRR pcgadvisory.com/news/prima-secures-us37-4m-investment-agr…
-
Immutep reposted
National Ovarian Cancer Coalition
@NOCCNational
September is Ovarian Cancer Awareness Month! www.whyteal.org/september-ovarian-cancer-awareness-month/
-
Immutep reposted
-
Immutep
@Immutep
CVac™ CAN-003 Abstract Accepted For Poster Presentation At @sitcancer Annual Meeting $PBMD $PRR proactivecapital.com/cvac-can-003-abstract-accepted-for-p…
-
Immutep
@Immutep
We have issued our latest shareholder newsletter to the ASX $PBMD $PRR www.immutep.com
-
Immutep
@Immutep
We've Received A US Patent Grant for CVac $PBMD $PRR proactivecapital.com/prima-receives-us-patent-grant-for-c…
-
Immutep
@Immutep
We Have Appointed Marc Voigt as New Chief Executive Officer $PBMD $PRR proactivecapital.com/prima-biomed-pbmd-appoints-new-chief…
-
Immutep
@Immutep
CAN-002 CVac(TM) Trial Published in Journal for ImmunoTherapy of Cancer finance.yahoo.com/news/prima-biomeds-002-cvac-tm-12513274… $PBMD $PRR
-
Immutep
@Immutep
Dr. Heidi Gray to Present at 2014 WAGO Annual Meeting $PBMD $PRR finance.yahoo.com/news/prima-biomed-present-2014-wago-121…
-
Immutep
@Immutep
Dr. Monk and Dr. Gray to Discuss Abstract Presented at ASCO At Call TODAY 9 PM EST/ 11AM AEST $PBMD $PRR #asco14 www.media-server.com/m/go/primabiomed-june-2014
-
Immutep
@Immutep
We have demonstrated positive trend in overall survival in second remission ovarian cancer $PBMD #cvac #cancer finance.yahoo.com/news/inplay-briefing-com-055139997.html
-
Immutep
@Immutep
We Are Hosting a Conference Call Today at 11AM AEST (9 PM EST) to Discuss Abstract Presented at ASCO $PBMD #asco14 finance.yahoo.com/news/prima-biomed-host-conference-call-…
-
Immutep
@Immutep
A Conference Call on to Discuss Abstract Presented at ASCO Will Be Held June 3 11AM AEST (9 PM EST) $PBMD #asco14 finance.yahoo.com/news/prima-biomed-host-conference-call-…
-
Immutep reposted
ASCO
@ASCO
Celebrate 50 years of progress against cancer with ASCO Daily News anniversary issue read.uberflip.com/i/320982-am-2014-daily-news-anniversary… #asco14
-
Immutep
@Immutep
We Will Host a Conference Call on June 3 11AM AEST (9 PM EST) to Discuss Abstract Presented at ASCO $PBMD #asco14 finance.yahoo.com/news/prima-biomed-host-conference-call-…
-
Immutep
@Immutep
We Are Hosting a Conference Call on June 3 11AM AEST (9 PM EST) to Discuss Abstract Presented at @ASCO $PBMD #asco14 finance.yahoo.com/news/prima-biomed-host-conference-call-…
-
Immutep
@Immutep
"The field of immuno-oncology has attracted tremendous scientific & investor interest as of late." - CEO Matt Lehman pharmaphorum.com/articles/cancer-vaccines-renewed-role-in…
-
Post not available here, view on X
Immutep
@Immutep
CEO Matt Lehman discusses “@pharmaphorum: Immuno-oncology: pharma's next big thing
pharmaphorum.com/articles/cancer-vaccines-renewed-role-in…” -
Immutep
@Immutep
"Cancer vaccines: renewed role in immuno-oncology combinations" by Matt Lehman, CEO in @pharmaphorum $PBMD $PRR pharmaphorum.com/articles/cancer-vaccines-renewed-role-in…
-
Immutep
@Immutep
Prima BioMed's therapy improves survival rates in ovarian cancer via @ReutersHealth finance.yahoo.com/news/prima-biomeds-therapy-improves-sur… $PBMD $PRR
-
Immutep reposted
ASCO
@ASCO
In case you missed it, #asco14 abstracts are now live: meetings.asco.org/abstracts-presentations
-
Post not available here, view on X
Immutep
@Immutep
@DiamondBurlesqu thank you for the shoutout!
-
Immutep reposted
BioWorld
@BioWorld
Immuno-oncology is the word as #asco14 abstracts go public. Highlights, here: www.bioworld.com/content/immuno-oncology-word-asco-abstra…
-
Immutep
@Immutep
Dr Heidi Gray will deliver the final CAN-003 PFS data oral presentation (Abstract #5504) at #asco14 finance.yahoo.com/news/prima-biomeds-cvac-demonstrates-im… $PBMD $PRR
-
Immutep
@Immutep
CVac Demonstrates Improvement in Progression-Free Survival in Second Remission Ovarian Cancer $PBMD $PRR finance.yahoo.com/news/prima-biomeds-cvac-demonstrates-im…
-
Immutep reposted
Alliance for Regenerative Medicine (ARM)
@alliancerm
@PrimaBioMed receives @US_FDA Fast Track Status for the co.'s CVac development program www.immutep.com
-
Immutep reposted
Singhzz
@iam_mnjt
Proud to be a shareholder in @PrimaBioMed ..doing great things in the fight against ovarian cancer
-
Immutep
@Immutep
The US FDA has granted us Fast Track Designation to the CVac clinical development program $PBMD $PRR Read more:finance.yahoo.com/news/prima-biomeds-cvac-tm-granted-1100… @usfda
-
Immutep
@Immutep
Persistent abdominal/pelvic pain are common symptoms of ovarian cancer. Spread the word about #worldovariancancerday
-
Immutep
@Immutep
Every woman in the world is at risk of developing ovarian cancer. Spread awareness about #worldovariancancerday
-
Immutep
@Immutep
Today is #worldovariancancerday, dedicated to raise the profile of a disease that kills 140,000 women every year.
-
Immutep
@Immutep
Our Third Quarter Conference Call will begin at 7:00 PM EST, Detail here: finance.yahoo.com/news/prima-biomed-third-quarter-confere… $PBMD
-
Immutep
@Immutep
The May Investor Update newsletter is now available! $PBMD $PRR www.immutep.com
-
Immutep
@Immutep
Prima Biomed 3rd Quarter Conference Call will be held on Monday, May 5th at 7:00 PM EST Click here for details: finance.yahoo.com/news/prima-biomed-third-quarter-confere…
-
Immutep
@Immutep
Prima Biomed 3rd Quarter Conference Call will be held on Monday, May 5th at 7:00 PM EST $PBMD Click here for details: finance.yahoo.com/news/prima-biomed-third-quarter-confere…
-
Immutep
@Immutep
Enrollment has commenced for our amended phase 2 CAN-004 clinical trial in EU for treatment of ovarian cancer finance.yahoo.com/news/prima-biomeds-004-phase-2-13315332… $PBMD
-
Immutep
@Immutep
5 Key Facts About Ovarian Cancer
-
Immutep reposted
World Ovarian Cancer Coalition
@WOCCnews
What are you going to do to help spread awareness #worldovariancancerday? Tell us on FB: www.facebook.com/WorldOvarianCancerDay
-
Immutep reposted
World Ovarian Cancer Coalition
@WOCCnews
Sign the pledge to build one voice for every woman and help spread awareness about ovarian cancer. worldovariancancercoalition.org
-
Immutep
@Immutep
Nature Video explains immunotherapy m.youtube.com/watch?v=Q2VrWdLFu-M&a=
-
Immutep
@Immutep
Did you know that May 8, 2014 is #worldovariancancerday?
-
Immutep
@Immutep
CEO Matt Lehman is now presenting at the 13th Annual Needham Healthcare Conference wsw.com/webcast/needham65/register.aspx?conf=needham65&pa… $PBMD

















































































































































































































































































































































































































































